Utilizing NMR Spectroscopy and Molecular Docking as Tools for the Structural Determination and Functional Annotation of Proteins by Stark, Jaime
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Student Research Projects, Dissertations, and 
Theses - Chemistry Department Chemistry, Department of 
2-2013 
Utilizing NMR Spectroscopy and Molecular Docking as Tools for 
the Structural Determination and Functional Annotation of 
Proteins 
Jaime Stark 
University of Nebraska-Lincoln, jaime.stark@huskers.unl.edu 
Follow this and additional works at: https://digitalcommons.unl.edu/chemistrydiss 
 Part of the Analytical Chemistry Commons, Biochemistry Commons, Bioinformatics Commons, and 
the Structural Biology Commons 
Stark, Jaime, "Utilizing NMR Spectroscopy and Molecular Docking as Tools for the Structural 
Determination and Functional Annotation of Proteins" (2013). Student Research Projects, Dissertations, 
and Theses - Chemistry Department. 40. 
https://digitalcommons.unl.edu/chemistrydiss/40 
This Article is brought to you for free and open access by the Chemistry, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Student Research Projects, 
Dissertations, and Theses - Chemistry Department by an authorized administrator of DigitalCommons@University of 
Nebraska - Lincoln. 
UTILIZING NMR SPECTROSCOPY AND MOLECULAR DOCKING AS TOOLS 
FOR THE STRUCTURAL DETERMINATION AND FUNCTIONAL ANNOTATION 
OF PROTEINS 
By 
Jaime L. Stark 
  
A DISSERTATION 
  
Presented to the Faculty of 
The Graduate College at the University of Nebraska 
In Partial Fulfillment of Requirements 
For the Degree of Doctor of Philosophy 
  
Major: Chemistry 
  
Under the Supervision of Professor Robert Powers 
Lincoln, Nebraska 
  
February, 2013
UTILIZING NMR SPECTROSCOPY AND MOLECULAR DOCKING AS TOOLS 
FOR THE STRUCTURAL DETERMINATION AND FUNCTIONAL ANNOTATION 
OF PROTEINS 
Jaime L. Stark, Ph.D. 
University of Nebraska, 2013 
  
Advisor: Robert Powers 
With the completion of the Human Genome Project in 2001 and the subsequent 
explosion of organisms with sequenced genomes, we are now aware of nearly 28 million 
proteins. Determining the role of each of these proteins is essential to our understanding 
of biology and the development of medical advances. Unfortunately, the experimental 
approaches to determine protein function are too slow to investigate every protein. 
Bioinformatics approaches, such as sequence and structure homology, have helped to 
annotate the functions of many similar proteins. However, despite these computational 
approaches, approximately 40% of proteins still have no known function. Alleviating this 
deficit will require high-throughput methods that combine experimental and 
computational approaches. 
Nuclear magnetic resonance (NMR) ligand affinity screens are an experimental 
approach that can detect protein-ligand interactions, measure a corresponding 
dissociation constant, and reliably identify the ligand binding site. Correspondingly, 
molecular docking is a computational tool that can be used predict the location of the 
binding site and conformation of a compound when bound to a protein using only the 
structures of both the protein and the compound. Molecular docking provides an 
rapid way to generate protein-ligand costructures and evaluate numerous compounds in a 
large chemical library. Together, molecular docking and NMR ligand affinity screens 
provide valuable information for determining the function of a protein. 
 This dissertation describes the high-throughput application of the Functional 
Annotation Screening Technology by NMR (FAST-NMR), which combines NMR ligand 
affinity screens, molecular docking, and bioinformatics to help determine the function of 
20 previously uncharacterized proteins. Additionally, new tools were developed to utilize 
2D 1H, 15N-HSQC (heteronuclear single quantum coherence) chemical shift perturbations 
(CSPs) and molecular docking to generate consensus binding sites (CSP-Consensus) and 
protein-ligand costructures (AutoDockFilter). Virtual screening was also successful 
utilized to identify a potential natural ligand and propose a function for the YndB protein 
from Bacillus subtilis. Finally, the solution structure of human protein DNAJA1 was 
determined and its potential role in pancreatic cancer investigated. 
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"Nature uses only the longest threads to weave her patterns, so that each small piece of 
her fabric reveals the organization of the entire tapestry." 
- Richard Feynman 
 
"Careful. We don't want to learn anything from this." 
- Bill Watterson, "Calvin and Hobbes" 
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CHAPTER 1 
INTRODUCTION† 
  
1.1 STRUCTURAL AND FUNCTIONAL GENOMICS 
The completion of the Human Genome Project1,2 in 2001 and the technology 
associated with it has led to an explosion in the number of organisms with sequenced 
genomes. As of September 2012, the Genomes OnLine Database (GOLD) indicates that 
3,738 genomes have been completely sequenced, with another 11,605 genome projects in 
progress.3 As a result of these sequencing projects, the DNA sequence of every gene in 
the genome in a particular organism could be determined. Because each gene carries the 
blueprint for the production of a protein, knowledge of the sequence of gene also 
provides knowledge of the amino acid sequence of the resulting protein. While genes are 
the basic unit of heredity from parent to offspring, proteins are responsible for most of the 
structural and biochemical functions in an organism, which makes determining the role of 
each protein essential to our understanding of biology and the development of medical 
advances. 
1.1.1 Defining protein function. Protein function can be described in several 
ways that make it difficult to define and compare to other proteins.4 The function of a 
protein could be described in terms of the cellular process with which the protein is 
involved, the specific enzymatic reaction the protein catalyzes, or a physiological role 
that the protein plays. In order to address this problem of definition, several projects were 
developed to provide a classification or ontology to protein function. 
                                                
† Chapter 1, Section 2 and 3 were adapted from Stark, J. L. and Powers, R. Application of NMR and 
molecular docking in structure-based drug discovery. Top Curr Chem 326, 1-34 (2012). Reprinted with 
permission, copyright 2012 by Springer. 
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The Enzyme Commission (E.C.) classification5 is a hierarchical approach to 
define the function of enzymes, where each protein is assigned a four-numbered code, or 
E.C. number. Each number, from left to right, represents a more specific classification of 
the catalyzed reaction. While this approach works well for enzymes, non-enzymatic 
protein functions are not included. On the other hand, Gene Ontology (GO)6 annotations 
create a well-defined vocabulary to represent the functions of a protein. Additionally, 
these GO terms can be divided into three categories: molecular function (i.e., the specific 
reaction or binding interaction the protein is involved in), cellular component (i.e., where 
in the organism the protein performs its function), and biological process (i.e., the higher 
level process that the protein function helps to accomplish). 
There are several experimental methods that can be used to determine the function 
of a protein: genotype to phenotype studies,7 monitoring gene expression levels,8,9 
protein-protein interaction assays,10,11 ChIP-seq and RNA-seq transcription analysis,12,13 
enzymatic assays,14 and RNA interference.15,16 While many of these approaches are high-
throughput, the results of these experiments often do not provide definitive evidence of 
the function of a protein.17-20 Therefore, additional experimentation often requires even 
more time and resources. 
Because of the success of the various genome projects, there are currently 
27,661,073 protein sequences in the UniProtKB database (October 2012), which is 
continually growing.21,22 Of these, 10,401,675 (37.6%) have no known function and have 
been assigned as “putative”, “uncharacterized”, or “unknown” proteins.  Determining the 
function of each of these proteins is clearly not feasible using only an experimental 
approach. Due to these restraints, computational approaches are often utilized to annotate 
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the function of a protein by comparing it to the sequences/structures of homologous 
proteins with an experimentally determined function. Thus, only a small number of 
protein annotations are actually generated from experimental data. 
1.1.2 Protein sequence to function. With over 27 million protein sequences 
available, determining sequence similarity between proteins is one of the most common 
approaches to identifying homology between proteins.4 Two proteins that have very 
similar amino acid sequences have a common evolutionary origin and likely the same 
function. There are several tools available that align amino acid sequences using various 
alignment algorithms, which include BLAST,23,24 HMMER,25 SAM,26,27 and 
ClustalW.28,29 The results of these tools are typically a representation of the aligned 
sequences and a score that indicates the number of aligned residues as well as a 
probability that the alignment is correct. 
 As protein sequences diverge, the assumption is that the proteins are less 
homologous and it becomes more difficult to infer functional similarity.4,30 However, 
sequence similarity does not directly indicate functional similarity since homologous 
proteins can be orthologs or paralogs. Orthologs are proteins that originated from a 
common ancestor, while paralogs are the result of gene duplication in the same genome; 
thus, orthologs tend to have more conserved protein function relative to paralogs.31 
Additionally, there is no definitive cutoff for sequence similarity that will guarantee a 
similar function. There are several cases of proteins, such as duck eye lens proteins32 or 
phosphoglucose isomerase,33,34 that have the same sequence yet have completely 
unrelated functions. Because a small number of changes in amino acid sequence can lead 
to large changes in the function, sequence similarity is not safe to definitively annotate 
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proteins. However, most of the “annotated” proteins in the UniProtKB have functions 
based primarily on global sequence similarity to other proteins.35 This is troubling 
because only 538,259 (1.9%) of the total protein sequences have actually been manually 
reviewed and verified. 
1.1.3 Protein structure to function. Proteins are composed of a string of amino 
acids with various structural and chemical properties (i.e. charge, polarity, size, etc.). The 
sequence or arrangement of these amino acids determines the specific three-dimensional 
structure of a protein. Unfortunately, experimentally determining the structure of a 
protein using X-ray crystallography or NMR spectroscopy is much more time intensive 
than determining the sequence.36,37 The RCSB Protein Data Bank (PDB; 
www.rcsb.org)38,39 has 85,848 protein structures deposited, however, this only represents 
the structures of 28,806 unique proteins. Compared to 27 million protein sequences, 
structural efforts are understandably far behind. 
Structural genomics efforts, such as the Protein Structure Initiative (PSI),40 have 
focused structure determination on protein sequences that have little amino acid sequence 
identity to proteins with known structures. The structure and sequence of that protein can 
be used to predict the structure of proteins with similar sequences.41 This approach allows 
for the more efficient investigation of protein structure space and has resulted in 5,107 
new protein structures deposited in the PDB (October 2012), many of which have unique 
structural architectures or folds. 
Ideally, proteins that have the same chemical composition and the same structure 
should have the same molecular function. Sequence similarity approaches attempt to 
leverage this relationship by only comparing amino acid sequences, which is a primary 
 5 
factor in the resulting protein structure. However, even small changes in sequence can 
have significant changes in the structure of a protein, which may also change the 
function. Therefore, directly comparing the structures of proteins should provide 
additional evidence for homology between proteins even in the absence of high sequence 
similarity.42,43 
The most common methods/programs to compare the structures of proteins are 
DALI,44,45 SSM,46 FATCAT,47 CATHEDRAL,48 and MAMMOTH.49 These programs 
typically attempt to find the best match between protein backbone atoms or protein 
secondary structure elements. The result is typically a structure file of the aligned 
residues and a score that indicates the root mean square difference (RMSD) between the 
aligned regions as well as the proportion of the protein that was aligned.  
However, having a similar overall structure does not necessarily correlate directly 
to function. As with sequences, proteins can have the same fold yet perform completely 
different functions.50 This is not too surprising since only ~8,000 distinct protein folds are 
predicted to exist. 51,52 On the other hand, proteins with completely different structures 
can have the same function.53 
1.1.4 Protein active-site to function. Inferring a protein function from global 
sequence and structure comparisons has significant drawbacks. The molecular function of 
a protein primarily depends on the structural arrangement and chemical properties of the 
amino acids exposed on the surface of the protein and the resulting non-covalent 
interactions (binding) with other molecules, such as proteins, DNA/RNA, and small 
molecules. While a protein may experience numerous weak interactions with many 
different molecules, typically the molecule (often called a ligand) that maximizes the 
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number of interactions by having complementary chemistry and structure often defines 
the function of a protein. The region of the protein where the ligand binds is called the 
binding site or active-site and is often a cavity in the surface of the protein. Because the 
active-site of a protein is directly related to the function of the protein, the active-site is 
more evolutionarily stable than the rest of the protein sequence, which explains the 
difficulties of assigning function from global sequence or structure similarities.54  
Several computational tools exist that attempt to locate and compare protein 
active-sites using various approaches: identifying common sequence motifs,55,56 
computational calculation of ligand “hot-spots”,57 locating structural cavities/clefts, 58-60 
or using evolutionary conservation.61-64 These approaches typically work by using the 
information of known binding sites, which may be problematic when dealing with 
proteins that have unique functions that haven’t been characterized previously. 
One approach to minimize ambiguity in locating the active-site is to identify a 
ligand that binds to the protein at the active-site. 65-68 Searching the entirety of chemical 
space (~1060 compounds)69 for a ligand that binds to the protein is obviously not feasible. 
Therefore, using a chemical library that is focused on functionally relevant compounds is 
important for this approach. 68,70 Despite a focused compound library, a significant 
number of compounds still need to be evaluated for binding activity. Two high-
throughput screening approaches are commonly used in this situation: ligand affinity 
screens by nuclear magnetic resonance (NMR) spectroscopy and molecular 
docking/virtual screening. Analysis of the experimentally determined ligand binding site 
can then be utilized to infer a function based on sequence and structural similarities to 
other ligand binding sites.71,72 
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1.2 HIGH-THROUGHPUT SCREENING BY NMR 
Nuclear magnetic resonance (NMR) spectroscopy is uniquely qualified to assist in 
the high-throughput functional annotation of proteins.73 High-throughput screening by 
NMR is useful for several reasons: (1) it can directly detect the interaction between the 
ligand and protein using a variety of techniques; (2) samples are typically analyzed under 
native or near-native conditions; (3) hundreds of samples can be analyzed per day; and 
(4) information on the binding site and binding affinity can be readily obtained. 
In high-throughput screening by NMR, a binding event is detected by the relative 
differences between the protein or ligand NMR spectrum in the bound and unbound 
states.74 However, the specific type of information obtained about the binding process 
depends on whether a ligand-based or target-based NMR experiment is used. 
1.2.1 Ligand-based NMR screens. Ligand-based NMR screens typically monitor 
the NMR spectrum of a ligand under free and bound conditions. Distinguishing between 
a free ligand and a protein-ligand costructure is generally based on the large molecular 
weight difference that affects several NMR parameters. Small molecular weight 
molecules have slow relaxation rates (R2), negative nuclear Overhauser effect (NOE) 
cross-peaks, and large translational diffusion coefficients (Dt). If a protein-ligand binding 
event occurs, the ligand adopts the properties of the larger molecular-weight protein, 
increasing R2, producing positive NOE cross-peaks, and decreasing D2, all of which can 
be observed by NMR.75 Most ligand-based NMR screens use one-dimensional (1D) 1H-
NMR experiments to monitor these changes, which provide significant benefits for a 
high-throughput screen. 1D NMR experiments are typically fast (2-5 min) and routinely 
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use mixtures without the need to deconvolute.76 The deconvolution of mixtures is 
avoided by ensuring the NMR ligand peaks do not overlap in the NMR spectrum [Figure 
1.1]. The application of mixtures allows for hundreds to thousands of compounds to be 
screened in a single day. Another advantage of ligand-based NMR methods is the 
minimal amount of protein required (<10 µM) for each experiment. Additionally, 
isotopically labeled proteins are not needed for the NMR ligand affinity screen and 
protein molecular weight is not a limiting factor.77 In fact, higher molecular-weight 
proteins enhance the observation of a binding event in a ligand-based NMR screen. All of 
these characteristics make ligand-based NMR screens a routinely used high-throughput 
screening technique. 
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Figure 1.1 An example of the use of a ligand-detect NMR experiment to observe the line 
broadening (increase R2) that occurs when on compound, in a mixture of two compounds, 
binds a protein target. The 1H-NOESY spectra of nicotinic acid (left structure) and 2-
phenoxybenzoic acid (right structure) in a mixture without protein (top spectrum) and 
with the protein, p38 MAP kinase, added (bottom spectrum). The solid and dashed 
arrows represent the resonances of nicotinic acid and 2-phenoxybenzoic acid, 
respectively. In this case, the resonances corresponding to 2-phenoxybenzoic acid are 
broadened, indicating binding of this compound to the protein. (Reprinted with 
permission, copyright 2001 by Academic Press)78 
 
There are several screening techniques created from ligand-based NMR 
experiments: line broadening,79 STD NMR,80 WaterLOGSY,81 SLAPSTIC,82 TINS,83 
transferred NOEs,84 FAXS,85,86 FABS,87,88 and diffusion measurements.89,90 Each of these 
methods utilizes a specific NMR parameter that indicates ligand-binding, such as a 
 10 
change in ligand NMR peak width or diffusion, a saturation transfer from the protein or 
solvent to the ligand, an NOE transfer between the free and bound ligand, a spin-label 
induced paramagnetic relaxation, or fluorine chemical shift anisotropy. The choice of 
which method to use typically depends upon the protein target and the compound library 
being screened. In addition, line broadening and STD, among other techniques, can be 
used to measure dissociation constants (KD).91,92 On the other hand, ligand-based NMR 
screens don’t provide any structural information about the protein-ligand complex. 
1.2.2 Target-based NMR screens. A target-based screen focuses on changes in 
the protein (or other target) NMR spectrum to identify a binding event. Typically, 
chemical shift perturbations (CSPs) occur in the protein NMR spectrum upon ligand 
binding. The complexity and severe peak overlap in a protein 1D 1H NMR spectrum 
makes it impractical to observe subtle CSPs for weak binding ligands. Instead, two-
dimensional (2D) heteronuclear NMR93-95 experiments are typically used for target-based 
NMR ligand affinity screens.74 2D 1H-13C/15N HSQC/TROSY NMR experiments require 
a significant increase in experiment time (>10 min) due to the additional dimension and 
the need to collect a reference spectrum for the ligand-free protein. Also, the protein 
needs to be 15N and/or 13C isotopically labeled. However, 2D 1H-13C/15N HSQC/TROSY 
NMR experiments are useful because they provide additional information about the 
ligand binding site. 
A binding ligand often results in the observation of CSPs of the resonances in a 
2D 1H-15N- or 1H-13C-HSQC spectrum [Figure 1.2]. These CSPs are usually caused by a 
change in the chemical environment for residues proximal to the bound ligand or residues 
undergoing ligand-induced conformational changes. The availability of the protein 
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structure and the NMR sequence assignments (correlation of an NMR resonance with a 
specific amino acid residue) allows for the CSPs to be mapped onto a three-dimensional 
(3D) representation of the protein’s surface. A cluster of residues on the protein surface 
with observed CSPs often identifies the ligand-binding site. 
 
 
Figure 1.2 An overlay of the 2D 1H-15N HSQC spectra for the protein YndB titrated with 
increasing amounts of chalcone. The perturbed residues can be used to identify a 
consensus binding site. (Reprinted with permission, copyright 2010 by John Wiley and 
Sons)68 
 
The ligand binding affinity (KD) is also routinely determined from CSPs measured 
from a series of 2D 1H, 13C/15N-HSQC/TROSY NMR experiments. The magnitude of the 
CSPs at varying ligand concentrations is correlated to the KD for the protein-ligand 
costructure using the following equation:96,97 
CSP!"# = CSP!"# 𝐾! + 𝐿 + 𝑃 − (𝐾! + 𝐿 + 𝑃 )! − 4( 𝐿 𝑃 )2[𝑃]                         (1.1) 
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where [P] is the protein concentration, [L] is the ligand concentration, CSPmax is the 
maximum CSP observed for a fully bound protein, and CSPobs is the observed CSP at a 
particular ligand concentration. A least squares fit of Equation 1 to the experimental CSP 
data is used to calculate a KD [Figure 1.3]. 
 
 
Figure 1.3 NMR titration data for YndB bound to chalcone (blue), flavanone (green), 
flavone (purple), and flavanol (orange). The magnitude of the chemical shift perturbation 
can be used to calculate the dissociation constants for each compound. (Reprinted with 
permission, copyright 2010 John Wiley and Sons)68 
 
 As previously mentioned, because target-based screens require the use of 
multidimensional NMR experiments, data collection is significantly longer relative to 
ligand-based NMR screens. Also, target-based screens require higher protein 
concentrations (>50 µM compared to < 10 µM). This severely limits the utility of target-
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based NMR screens for the high-throughput analysis of large compound libraries. 
Instead, the approach is typically used to validate hits from a high-throughput screen or 
the analysis of relatively small fragment-based libraries.98-100 A fragment-based library 
consists of low molecular-weight compounds (<250-350 Da) that are fragments of known 
drugs or have drug-like properties.101 Recent advances like the SOFAST-HMQC 
experiment102,103 and the Fast-HSQC experiment104 have decreased the time and amount 
of protein necessary for a target-based screen. Nevertheless, the combination of ligand-
based and target-based NMR screens are still very resource intensive, requiring a 
significant amount of time and material. Also, because any high-throughput screen 
produces a significant amount of negative data (most ligands don’t bind or inhibit a 
protein),105 a more efficient approach is to screen a library of compounds with a higher 
probability of binding the protein target. In effect, a virtual or in silico screen can be used 
to enrich a library with likely binders. 
  
1.3 MOLECULAR DOCKING AND VIRTUAL SCREENING 
Molecular docking is a computational tool that predicts the binding site location 
and conformation of a compound when bound to a protein using only the knowledge of 
the structures of the protein and ligand.106-113 This approach has been found to be fairly 
successful in redocking compounds into previously solved protein-ligand costructures,114 
where more than 70% of the redocked ligands reside within 2 Å RMSD of the actual 
ligand pose. During the prediction of protein-ligand costructures, molecular docking 
programs calculate a binding score that allows for the selection of the best ligand pose. 
The binding score is typically based on a combination of geometric and energetic 
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functions (bond lengths, dihedral angles, van der Waals forces, Lennard-Jones and 
electrostatic interactions, etc.) in conjunction with empirical functions unique to each 
specific docking program.115-120 
These binding scores are also routinely used to rank different ligands from a 
compound library after being docked to a protein target. The virtual or in silico screening 
of a library composed of thousands of theoretical compounds can be accomplished in a 
day with minimal cost.121-123 Thus, a virtual screen can significantly accelerate the hit 
identification and optimization process while reducing the amount of experimental effort. 
However, a virtual screen does have significant limitations that prevent it from 
completely replacing experimental high-throughput screening.108,124-126 These limitations 
include inaccurate scoring functions, use of rigid proteins, and simplified solvation 
models. In essence, a virtual screen only increases the likelihood that a predicted ligand 
actually binds the protein target; experimental verification is still essential. 
An accurate prediction of the interactions between two molecules requires an in-
depth understanding of the energetics that led to a stable biomolecular complex. 
Unfortunately, a model that correctly accounts for all the factors involved in a productive 
protein-ligand interaction is currently unknown. Furthermore, the problem is 
exponentially more complex than just modeling the specifics of a protein-ligand 
interaction. A protein contains thousands of atoms that have specific interactions with 
each other, with the solvent, and with other ions in addition to the bound ligand. Because 
of this complexity, computational efforts that attempt to model protein-ligand interactions 
require significant amounts of processing power and time. Many efforts that utilize 
molecular dynamics and distributed computing127,128 are generally limited to a detailed 
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analysis of a single system. These methods are generally not practical for the majority of 
researchers interested in conducting a virtual screen of a library containing upwards of 
millions of compounds. To make molecular docking computationally feasible and easily 
accessible, many simplifications and trade-offs in the process are necessary. 
Many computer programs are available to perform or assist with molecular 
docking, such as: AutoDock,129 DOCK,130 FlexX,131 Glide,132 HADDOCK,133 and 
LUDI.134,135 Each docking program does have some unique features that make them 
particularly useful for a given situation or problem. However, nearly all the docking 
programs consist of two primary components: docking (or searching) and scoring.106,107 
Docking refers to the sampling of the ligand’s conformation space and its orientation 
relative to a receptor. Scoring is used to evaluate and rank the current pose of the ligand. 
1.3.1 Docking. The docking process requires, at a minimum, two inputs: the 
three-dimensional structures of the receptor (protein) and the ligand. The most common 
simplification to the docking process is to keep the structure of the receptor rigid and 
stationary. Only the ligand is typically allowed to be flexible as it is docked to the 
protein. Keeping the protein rigid significantly minimizes the complexity of the 
calculation. Sampling the conformations and orientations of the ligand is done using 
systematic or stochastic methods.106,107 
Systematic search methods attempt to sample all of the possible conformations of 
a ligand by incrementing the torsional angles of each rotatable bond. Unfortunately, this 
technique is computationally expensive due to the exponential increase in the number of 
possible conformations (Nconf) as the number of rotatable bonds increases:106 
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where N represents the number of rotatable bonds, ninc is the number of incremental 
rotations for each rotatable bond, and θi,j is the size of the incremental rotation for each 
rotatable bond. As a result, purely brute force systematic approaches are generally not 
used. Instead, most systematic searches require the use of efficient shortcuts. 
 Perhaps the most commonly utilized systematic search method is incremental 
construction, which is used by DOCK,130 FlexX,131 E-Novo,136 LUDI,134,135 ADAM,137 
and TrixX.138 In this particular method, the ligand is split into fragments. The most rigid 
fragments are often used as the core or anchor and are docked first into the receptor 
binding pocket. The remaining fragments are incrementally added back onto the core 
fragment, where each addition is systematically rotated to evaluate the most optimal 
conformation. Thus, incremental construction drastically reduces the number of possible 
conformations that need to be searched in order to identify the optimal pose. 
 Another systematic approach uses rigid docking in combination with a predefined 
library of ligand conformations, which is implemented in OMEGA,139 FLOG,140 Glide,132 
and the TrixX Conformer Generator.141 This technique generates several low energy 
conformers for a ligand that are clustered by RMSD. A representative conformer from 
each cluster is then docked into the receptor. The approach is very fast because the 
docking process keeps the ligand rigid, eliminating the need to spend computation time 
on searching torsional space. A tradeoff for this increase in speed is a potential loss in 
accuracy, because the binding potential for all possible conformers may not be explored. 
However, a major benefit of the technique is the fact that the library of structural 
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conformers only needs to be generated once. This is a significant savings in time for the 
pharmaceutical industry, where screening libraries may consist of millions of compounds. 
 Unlike systematic approaches that attempt to sample all possible ligand 
conformations, stochastic searches explore conformational space by making random 
torsional changes to a single ligand or a population of ligands. The structural changes are 
then evaluated using a probability function. There are three types of stochastic searches: 
Monte Carlo algorithms,142 genetic algorithms,143 and tabu search algorithms.144 The 
most basic stochastic method is the Monte Carlo algorithm, which utilizes a Boltzmann 
probability function to determine whether to accept a particular ligand pose:145 
 𝑃~ exp ! !!!!!!!!                                                                                                               (1.3) 
where P is the probability the conformation is accepted, E0 and E1 are the ligand’s energy 
before and after the conformational change, KB is the Boltzmann constant, and T is the 
absolute temperature. The simple scoring function used by the Monte Carlo algorithms is 
more effective than molecular dynamics in avoiding local minima and finding the global 
minimum.145 Alternatively, genetic algorithms utilize the theory of evolution and natural 
selection to search ligand conformation space. In this case, the conformations, 
orientations, and coordinates of a ligand are encoded into variables representing a 
“genetic code.” A population of ligands with random genetic codes is allowed to evolve 
using mutations, crossovers, and migrations. The new population is evaluated using a 
fitness function that eliminates unfavorable ligand poses. Eventually, a final population 
converges to ligands with the most favorable “genes” or conformations [Figure 1.4]. 
Tabu searches, like other stochastic methods, randomly modify the conformation and 
coordinates of a ligand, score the conformer, and then repeat the process for a new 
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conformation. Tabu searches utilize a tabu list to remember previous ligand states. A 
pose is immediately rejected if it is close to a prior conformation. The tabu list 
encourages the search to progress to unexplored regions of conformational space.  
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Figure 1.4 An illustration of the genetic algorithm approach, where the states of the 
ligand (translation, orientation, and conformation relative to the protein) are interpreted 
as the ligand genotype and the atomic coordinates represent the phenotype. A plot of the 
change in the fitness function (f(x)) as the ligand population is allowed to mutate, 
crossover, and migrate. The genetic evolution of the ligand effectively samples 
conformational space where the best conformer is identified by a minimum in the fitness 
function. (Reprinted with permission, copyright 1998 by John Wiley and Sons)146 
 
1.3.2 Scoring. While docking algorithms are generally efficient at generating the 
correct ligand pose, it is important for the docking program to actually select the correct 
ligand conformation from an ensemble of similar conformers. In essence, the scoring 
function should be able to distinguish between the true or optimal binding conformation 
and all the other poses. The scoring function is also used to rank the relative binding 
affinities for each compound in the library. Ideally, the scoring function should be able to 
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calculate the free energy (ΔGbinding) of the protein-ligand binding interaction,which is 
directly related to the dissociation constant (KD):96,106,147 
∆𝐺!"#$"#% = −𝑅𝑇ln 1𝐾!                                                                                                         (1.4) 
Unfortunately, accurately calculating the binding free energy is challenging due to 
the many forces that influence binding. In molecular docking, there are five primary 
types of scoring functions: force field-based, empirical, knowledge-based, shape-based, 
and consensus.148-150 
Force field-based scoring functions106,107 are used to calculate the free energy of 
binding by combining the receptor-ligand interaction energy and the change in internal 
energies of the ligand based on its bound conformation [Figure 1.5] The internal energy 
of the receptor is usually ignored because the receptor is kept rigid for most docking 
programs. The protein-ligand binding energies are typically defined by van der Waal 
forces, hydrogen bonding energies, and electrostatic energy terms. The van der Waals 
and hydrogen bonding terms often utilize a Lennard-Jones potential function, while the 
electrostatic terms are described by a coulombic function. Unfortunately, these 
interaction energies were originally derived from measuring enthalpic interactions in the 
gas phase.106 Of course, protein-ligand binding interactions typically occur in an aqueous 
solution, which introduces additional interactions between the solvent molecules, the 
receptor, and the ligand. Protein-ligand binding energies are also dependent on the 
entropic changes that occur upon binding, which include torsional, vibrational, rotational, 
and translational entropies. Most entropy and solvation-based energy terms can’t be 
calculated using force field-based scoring functions. As a result, force field-based scoring 
functions are incomplete and inaccurate. 
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Figure 1.5 (a) A representation of p38 mitogen-activated protein kinase structure bound 
to BIRB796 and (b) an expanded view of the binding site. (c) A representation of the 
hydrogen-bonding (red) and electrostatic interactions (green) between the atoms of the 
protein and the atoms of the ligand. (d) A representation of three force-field energy terms 
(van der Waals, hydrogen-bonding, and electrostatic) as distance between the interacting 
atom pairs change. (Reprinted with permission, copyright 2004 by the Nature Publishing 
Group)106 
 
Empirical scoring functions151-153 are similar to force field-based scoring 
functions because they use a summation of individual energy terms. But empirical 
scoring functions also attempt to include solvation and entropic terms. This is typically 
achieved by using experimentally determined binding energies of known ligand-receptor 
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interactions to train the scoring system using regression analysis. Empirical scoring 
functions are fast, but the accuracy is completely dependent upon the experimental data 
set used to train the scoring function. In general, empirical scoring functions are reliable 
for ligand-receptor complexes that are similar to the training set. 
Knowledge-based scoring functions154-156 are fundamentally different from force 
field-based and empirical scoring functions. Knowledge-based scoring functions don’t 
attempt to calculate the free energy of binding. Instead, these scoring functions utilize a 
sum of protein-ligand atom pair interaction potentials to calculate a binding affinity. The 
atom pair interaction potentials are generated based upon a probability distribution of 
interatomic distances found in known protein-ligand structures. The probability 
distributions are then converted into distance-dependent interaction energies. In this 
manner, knowledge-based scoring functions allow for the modeling of binding 
interactions that are not well understood. The approach is also simple, which is useful for 
screening large compound libraries. Unfortunately, knowledge-based scoring functions 
are designed to reproduce known experimental structures, and the binding score 
generated has little relevance to an actual binding affinity. This is an issue similar to 
empirical scoring functions; the accuracy of the scoring function is strongly dependent on 
the similarity of the protein-ligand costructure to the training data set. 
As implied, shape-based scoring functions are based on a shape match between 
the ligand and the ligand binding site.157 These scoring functions are typically used as 
prefilters to eliminate compounds that are unable to fit into the ligand binding site.68,158 
Shape-based scoring functions are fast, but are limited relative to more accurate scoring 
functions that calculate binding affinities. Shape-based scoring functions typically 
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generate smooth energy surfaces using Gaussian functions,158 which are more tolerant to 
atomic variations and make protein clash interactions “softer.” This essentially helps 
minimize the effect of small structural variations that may occur during ligand binding. 
While the above scoring methods are generally useful in describing protein-ligand 
interactions, the simplifications used in each approach limits the overall accuracy in 
predicting the correct docked ligand pose.159,160 The major weakness of most docking 
programs has been shown to be the scoring function. One approach to compensate for 
this deficiency is to use a consensus score from a combination of scoring functions to 
rescore a docked pose. Consensus scoring107,161 has been shown in several examples to 
improve docking results compared to a single scoring function. However, like individual 
scoring functions, the improvement is not consistent and the proper choice of scoring 
functions to calculate a consensus score is typically based on trial and error. 
1.3.3 Virtual screening and assessment. Using molecular docking to identify 
lead candidates is an attractive approach for both functional genomics and the 
pharmaceutical industry; it allows for the rapid evaluation of millions of chemical 
compounds while using minimal resources. The process by which molecular docking is 
used to rank different compounds within a library based on a predicted binding affinity is 
known as virtual screening.162,163 A virtual screen requires a balance between optimizing 
speed and maximizing accuracy. Specifically, the goal of a virtual screen is the rapid and 
efficient separation of a small subset of active compounds from a relatively large random 
library of inactive compounds. Unfortunately, determining the effectiveness of a specific 
virtual screening process is challenging, where independent evaluators routinely generate 
inconsistent results.111,164-166 
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The ambiguous nature of the results from a virtual screen requires additional 
methods to evaluate its success. Typically, a virtual screening process is evaluated against 
a protein target with a set of known binders. Assessing the performance of a virtual 
screen is primarily based on the accuracy of the predicted ligand pose and binding 
affinity. The correct binding pose is often evaluated by calculating the RMSD between 
the docked and experimental ligand structures. The evaluation of binding affinity is 
typically based on the accurate ranking of known binders instead of the absolute scores 
because of the known limitations with calculating a binding energy. Other modes of 
performance assessment involve evaluating enrichment and generating diverse hit lists. 
162,166 
In a virtual screening protocol, every compound in a library (Ntot) is docked to the 
protein and a corresponding binding score is calculated. The binding score for the 
ligand’s best docked pose is used to rank the ligand relative to the entire library. A virtual 
screen never results in all the truly active compounds being top ranked.167 Instead, most 
virtual screening protocols set a binding score or ranking threshold to identify the 
predicted active compounds or “hits.” In general, top ranked compounds are expected to 
be enriched with active compounds compared to a random selection [Figure 1.6]  
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Figure 1.6 A theoretical distribution of compounds in a virtual screen based upon the 
docking score. The overlap between active and inactive compounds indicates that the 
scoring threshold used to identify a hit by virtual screening is critical. (Reprinted with 
permission, copyright 2008 by Springer)166 
 
A high enrichment factor (EF > 10) is considered the benchmark of success for a virtual 
screen.168 Enrichment is dependent on sensitivity (Se) and specificity (Sp). Sensitivity 
represents the true positive rate, which is the ratio of true positives (TP) found by the 
virtual screening vs. the total number of actives (A) in the library. The number of actives 
corresponds to both true positive (TP) and false negative (FN):166 
𝑆𝑒 = 𝑇𝑃𝑇𝑃 + 𝐹𝑁                                                                                                                     (1.5)  
Specificity is the measure of the true negative rate, which represents the ratio of 
true negatives (TN) to the total number of inactive compounds. The number of inactive 
compounds corresponds to both true negatives (TN) and false positives (FP):166 
𝑆𝑝 = 𝑇𝑁𝑇𝑁 + 𝐹𝑃                                                                                                                     (1.6) 
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The enrichment factor is a common method for evaluating the enrichment 
capabilities of a virtual screen:166 
𝐸𝐹 = 𝑇𝑃𝑇𝑃 + 𝐹𝑃𝑇𝑃 + 𝐹𝑁𝑁!"!                                                                                                               (1.7)  
The enrichment factor is dependent upon the ratio of active compounds to the 
total number of compounds in the library. As a result, enrichment scores are difficult to 
compare between virtual screens with different libraries. Also, the enrichment factor does 
not distinguish between high and low ranking compounds. 
Perhaps the more popular approach for evaluating enrichment is to generate a 
receiver operating characteristic (ROC) curve.169 The ROC curve is a plot of the true 
positive rate (Se) against the false positive rate (1-Sp) at varying thresholds for 
determining a hit. A ROC curve allows for the evaluation of a virtual screening method 
without using an arbitrary scoring threshold. Enrichment occurs when the resulting data 
point at a particular threshold resides above the diagonal (Se = 1-Sp), which corresponds 
to a random selection of compounds. In a perfect virtual screen where every active 
compound is identified as a hit and every inactive compound falls below the threshold, 
the ROC curve approaches the top left corner (Se = 1 and 1-Sp = 0) [Figure 1.7]. 
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Figure 1.7 A ROC curve is used to evaluate the enrichment of a virtual screen and select 
a scoring threshold. A ROC curve that approaches Se = 1 and 1-Sp = 0 represents perfect 
enrichment. The area under the ROC curve (AUC) represents the probability that a true 
active is identified. (Reprinted with permission, copyright 2008 by Springer)166 
 
Hit list diversity is also an important consideration for the success of a virtual 
screen because there is more value in identifying a few unique compounds instead of 
many compounds all based on the same chemical scaffold. One way that diversity can be 
determined is by comparing the structural similarities of hits from a virtual screen using a 
Tanimoto index170 and then clustering the results. Basically, a Tanimoto index is 
calculated based on the fraction of similar chemical sub-structures present in two 
structures. Generally, 1,365 chemical substructures are used to describe a structure. The 
substructures include individual elements, two-atom substructures, single rings, 
condensed rings, aromatic rings, other rings, chains, branches, and functional groups:170 
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where A represents the substructural features present in the first structure, B represents 
the substructural features present in the second structure, and C represents the 
substructural features common to both structures. Identical structures have a TI score of 
1, where completely dissimilar structures have a TI value of 0. 
 
1.4 SUMMARY OF WORK  
Combining ligand affinity screens by NMR with molecular docking/virtual 
screens provides an efficient approach to probing protein-ligand interactions. This 
dissertation focuses on the application of both NMR and molecular docking/virtual 
screening towards the structural determination and functional annotation of proteins, 
which may lead to novel therapeutic targets for disease treatment. 
Chapter 2 will illustrate the application of the Functional Annotation Screening 
Technology by NMR (FAST-NMR) towards the functional annotation of 21 hypothetical 
proteins from the Northeast Structural Genomics Consortium (NESG). FAST-NMR 
incorporates high-throughput NMR screens using both ligand-based and target-based 
approaches, which is followed by the use of molecular docking to generate protein-ligand 
costructures. These costructures, or more specifically the protein binding sites indicated 
by the location of the ligand relative to the protein, are then compared, by structure and 
sequence, to a database of binding sites using the Comparison of Active-site Similarity 
(CPASS) program. The function of the hypothetical protein is then inferred based upon 
the similarities of the binding site to those found in the database. In addition, the FAST-
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NMR procedure has been updated and streamlined to accommodate the high-throughput 
analysis of these proteins and will be described here. 
Chapter 3 and 4 will describe the development of the program, AutoDockFilter, 
that utilizes a post-filtering approach for rapidly (~35-45 min) identifying a protein-
ligand costructure generated by the molecular docking program AutoDock that best 
agrees with the experimentally determined chemical shift perturbations obtained from a 
simple 2D 1H-15N HSQC NMR screen. This tool is currently being used to generate the 
protein-ligand costructures used during the FAST-NMR process. Additionally, a 
companion program, CSP-Consensus, is described which attempts to remove some of the 
ambiguity in selecting a consensus binding site from the perturbed residues in a 2D 1H-
15N HSQC NMR experiment. 
The CPASS program has been updated to version 2, which includes surface 
accessibility, ligand root-mean square difference, Cβ distances, and implementation on 
the Open Science Grid (OSG; http://www.opensciencegrid.com). Chapter 5 will show the 
evaluation of the enrichment of functionally similar proteins in CPASS and the effect any 
structural differences in the binding site between apo- and holoproteins may have on the 
CPASS score. These investigations are then evaluated in the context of utility for the 
FAST-NMR project. 
Chapter 6 illustrates the application of virtual screening to replace the 
experimental high-throughput screening methodology of FAST-NMR. In this particular 
case, the protein YndB from Bacillus subtilis was determined to have a hydrophobic 
cavity which indicates a likelihood of binding lipid-like molecules. Unfortunately, lipids 
are not well-represented in the FAST-NMR compound library due to their hydrophobic 
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nature. A virtual screen of a lipid library was performed on YndB, which resulted in the 
identification of three subclasses of flavonoids as being highly enriched: 
chalcones/hydroxychalcones, flavanones, and flavones/flavonols. Experimental 2D 1H-
15N HSQC NMR titrations of chalcone, flavanone, flavone, and flavonol all showed 
binding to YndB that mimicked the virtual screening ranking. Interestingly, these 
molecules have not been identified among the natural products of Bacillus organisms but 
are important precursors to plant antibiotics, which hints at a stress response function for 
YndB that is important for the symbiotic relationship between B. subtilis and plants. 
Because virtual screening worked as a replacement for experimental high-
throughput NMR screens as seen in the YndB example, could it also be used to replace or 
supplement the high-throughput screens used in FAST-NMR? Chapter 7 will compare 
the results of virtual screening the function-based compound library to the results of the 
experimental high-throughput screens of the same compounds.  
Chapter 8 outlines the development of a pancreatic cancer ‘omics database and 
the process by which new therapeutic targets for pancreatic cancer might be discovered. 
From this database, an uncharacterized human protein DNAJA1 (DnaJ-like homolog 
family A member 1) was identified as being significantly down-regulated in the 
pancreatic cancer ‘omics studies. The solution structure of the J-domain of DNAJA1 was 
determined by NMR and then screened using the FAST-NMR process to identify a 
ligand-defined binding site. 
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CHAPTER 2 
THE FUNCTIONAL ANNOTATION OF HYPOTHETICAL PROTEINS FROM 
THE NORTHEAST STRUCTURAL GENOMICS CONSORTIUM‡ 
  
2.1 INTRODUCTION 
With over 27 million protein sequences known, determining the functional role of 
each protein represents an important opportunity to identify new therapeutic targets for 
drug discovery.1 The vast majority of these proteins are functionally annotated using 
sequence and/or structural homology to proteins of known function. However, the 
success of the various genome projects and structural genomics consortia is adding new 
protein sequences and structures, ~40% of which are often classified as "putative", 
"uncharacterized", or "unknown" proteins. Unfortunately, uncharacterized proteins are 
often "orphaned", because detailed and time intensive biochemical studies are required to 
functionally annotate a protein. These studies may include analyzing cell phenotypes 
through knockout libraries, monitoring gene expression levels, or utilizing pull-down 
assays.2-5 Nevertheless, "orphaned" proteins provide a unique opportunity to explore 
functional space and identify new biological targets for drug discovery. Therefore, 
developing methods to rapidly and accurately assign a function to uncharacterized 
proteins is of great importance. 
Because the interactions of proteins with other biomolecules or small molecules is 
the basis of a functional definition or classification, identifying the functional ligand, the 
functional epitope or ligand binding site, and the 3D structure of the protein-ligand 
costructure are invaluable for a functional annotation. A functional epitope or ligand 
                                                
‡ Jennifer Copeland contributed equally to all FAST-NMR work 
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binding site is evolutionarily conserved relative to the rest of the protein structure in order 
for the protein to maintain its biological function. Therefore, proteins that share similar 
binding site structures are expected to be functional homologs and bind a similar set of 
ligands.6,7 Correspondingly, numerous in silico approaches attempt to infer a function for 
an uncharacterized protein by predicting ligand binding sites using geometry-based, 
information-based, and energy-based algorithms.8-10 Unfortunately, unambiguously 
identifying the ligand binding site on a protein can be challenging without experimental 
evidence, especially for proteins with no known function. 
Functional Annotation Screening Technology using NMR (FAST-NMR)6,7 is an 
experimental approach that combines high throughput screening (HTS) by NMR with 
molecular docking and bioinformatics analysis in order to assign a function to a protein 
[Figure 2.1]. In this process, a compound library that contains approximately 460 
biologically relevant compounds11 is screened by NMR using a multistep approach.12 
First, a ligand-based screen using 1D 1H-NMR line-broadening experiments identifies 
potential binders. These hits are then verified in a target-based screen using a 2D 1H,15N-
HSQC experiment, where the occurrence of chemical shift perturbations (CSPs) allows 
for the identification of the ligand binding site. Molecular docking is then used to 
generate a rapid protein-ligand costructure13 that serves as input for the Comparison of 
Protein Active-Site Structures (CPASS) program.14,15 CPASS compares the sequence and 
structure of this NMR modeled ligand binding site to ~36,000 unique experimental ligand 
binding sites from the RCSB Protein Databank.1 Thus, the function of an uncharacterized 
protein can be inferred due to a similarity in binding sites to a protein with a known 
function that shares a similar ligand binding site.16 Additionally, information from the 
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identity of the ligands shown to bind in the 2D 1H,15N-HSQC screen, such as other 
proteins known to bind the ligand or metabolic pathways the ligand is involved with, can 
be used to help characterize the protein. Combining the experimental results of the 
FAST-NMR screen with available bioinformatics allows for a proposed function to be 
assigned to the protein. 
 
 
Figure 2.1 Flow chart for the application of FAST-NMR. 
 
 
The FAST-NMR and CPASS approach has been used previously for the 
successful annotation of two hypothetical proteins, SAV1430 from S. aureus7 and 
PA1324 from P. aeruginosa.17 It has also been used to identify a structural and functional 
similarity between the bacterial type III secretion system and eukaryotic apoptosis.18 In 
order to demonstrate the high-throughput nature of FAST-NMR, 20 functionally 
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uncharacterized proteins were screened using the FAST-NMR methodology and 
subsequently annotated. 
  
2.2 MATERIALS AND METHODS 
2.2.1 Hypothetical proteins from the NESG. A total of 32 different proteins 
were received from the Northeast Structure Genomics Consortium (NESG: 
http://www.nesg.org), with each protein consisting of an unlabeled and a labeled (15N or 
13C-15N) sample. These proteins were selected as representatives for both hypothetical 
and annotated proteins. Of these 32 proteins, 25 of them were successfully screened by 
FAST-NMR, where 20 of the proteins were hypothetical (Table 2.1). 
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Table 2.1 Uncharacterized proteins screened by FAST-NMR 
Organism Gene ID UniProt ID NESG ID PDB ID 
No. of 
Amino 
Acids 
Bacillus subtilis yjcQ O31639 SR346 2HGC 94 
Bacillus subtilis ykvR O31683 SR358 2JN9 96 
Bacillus subtilis ynzC O31818 SR384 3BHP 77 
Bacillus subtilis yozE O31864 SR391 2FJ6 74 
Bacteroides 
vulgatus 
BVU_390
8 A6L747 BvR153 2L01 69 
Bordetella 
bronchiseptica BB0938 Q7WNU7 BoR11 2EXN
19 128 
Caulobacter 
crescentus CC_0527 Q9AAR9 CcR55 2JQN 114 
Escherichia coli ytfP P0AE48 ER111 1XHS20 113 
Escherichia coli yrbA P0A9W6 ER115 1NY8 89 
Escherichia coli yggU Q8XCU6 ER14 1YH521 100 
Escherichia coli yjbR P0AF50 ER226 2FKI22 118 
Escherichia coli ydfO P76156 ER251 2HH8 150 
Escherichia coli ygdR P65294 ER382A 2JN0 53 
Escherichia coli ykfF P75677 ER397 2HJJ 79 
Escherichia coli yeiV P0AFV4 ER541 2K1G23 162 
Porphyromonas 
gingivalis PG_0361 Q7MX54 PgR37A 2KW7 124 
Rhodobacter 
sphaeroides 
RHOS4_1
2090 Q3J357 RhR5 2JRT 92 
Salmonella 
typhimurium STM0327 Q8ZRJ2 StR65 2JN8 107 
Silicibacter 
pomeroyl SPO1678 Q5LST8 SiR5 2OA4 93 
Staphylococcus 
saprophyticus SSP0609 Q49ZM2 SyR11 2K3A
24 155 
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2.2.2 Function-based compound library and mixtures. The compound library 
used for the FAST-NMR methodology consists of functional ligands such as metabolites, 
substrates, inhibitors, and cofactors that have been shown to bind proteins and influence 
activity.11 This focused library allows for functional information about the protein to be 
determined based upon the types of compounds that are shown to bind. The number of 
compounds in the library fluctuates as some compounds are removed due to cost and 
stability issues while other new compounds are added. Currently, the compound library 
contains 460 active compounds. The exact composition of the library can be found in the 
BioScreen database (http://bionmr.unl.edu/ligands). Stock solutions for each compound 
are stored at -80 °C in either dimethyl sulfoxide-d6 (DMSO-d6; Isotec) or D2O (Isotec) at 
a concentration of 20 mM. In order to minimize the number of NMR samples during the 
1D line-broadening screen, the compounds are combined into 117 mixtures that consist 
of 3-4 compounds each, which has been determined to be the optimal 1D NMR mixture 
size.25 The mixtures are created using equal volumes of individual compound stock 
solutions, leading to a final concentration of 4 mM per ligand in each mixture. 
2.2.3 Ligand-based screen. The NMR samples for the 1D line-broadening screen 
were prepared in 10 mM d19-bis-Tris (Isotec, St. Louis, MO) buffer at pH 6.5 in 99.99% 
D2O and 11.1 uM TMSP-d4 (Isotec, St. Louis, MO) to act as a chemical shift reference. 
Each sample had a 100 µM final concentration for each ligand in the mixture while the 
protein concentration varied from 10-25 µM. The 1D 1H NMR spectra were collected on 
a Bruker 500 MHz Avance spectrometer with a triple-resonance, Z-axis gradient 
cryoprobe and BACS-120 sample changer using 1D 1H excitation sculpting pulse 
sequence to improve water suppression and signal-to-noise. The data was processed using 
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ACD 1D NMR Processor. The spectra of the ligand mixtures with protein were visually 
compared to the spectra of the ligand mixtures without protein. A mixture was flagged as 
a potential binding event if the peak intensity of a protein-ligand sample decreased 
relative to the ligand-only sample. The potential binding ligand was identified by 
comparing the broadened peak to reference spectra of ligands known to be in the mixture. 
2.2.4 Target-based screen. For each compound that showed binding in the 1D 
line-broadening screen, an NMR sample of that compound in the presence of protein was 
prepared. The NMR sample consisted of the ligand at 400 µM concentration and the 
protein (15N-labeled or 5% 13C, 100% 15N-labeled) at 30 µM concentration in a 10 mM 
bis-Tris (Sigma-Aldrich) buffer at pH 6.5 and 10% D2O (Isotec). The 2D 1H-15N HSQC 
experiments were collected on the same 500 MHz spectrometer described above using 
the WATERGATE and water flip-back pulses for solvent suppression. The data was 
processed using NMRPipe26 and visualized in CCPNMR Analysis 
(http://www.ccpn.ac.uk).27 The resulting spectra were overlayed with the spectrum of the 
free protein, and protein-ligand spectra that showed significant perturbations of NMR 
peaks relative to the free protein spectra were designated as binders. 
2.2.5 Rapid generation of protein-ligand costructures. The ligand that caused 
the greatest magnitude chemical shift perturbations (CSPs) in the 2D 1H-15N HSQC 
screen was used to define the consensus binding site using CSP-Consensus (described in 
Chapter 4). The three dimensional structures of both the ligand and the protein were 
prepared for docking (correcting missing atoms) using UCSF Chimera.28 AutoDock 
4.2.329-31 with the AutoDockTools 1.5.4 31,32(http://mgltools.scripps.edu) graphical 
interface was used to calculate 120 protein-ligand costructures. The AutoDock grid was 
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set to encompass the consensus binding site identified from CSP-Consensus with a grid 
spacing of 0.375 Å. The docking was performed using the Lamarckian genetic algorithm 
with a population of 300 and 2,500,000 energy evaluations. The docked structure that 
best agreed with the experimental CSPs from the 2D 1H-15N HSQC experiment was 
identified using AutoDockFilter 2.0 (described in Chapter 3 and Chapter 4).13 
2.2.6 CPASS. The protein-ligand costructure generated from AutoDock and 
AutoDockFilter was submitted to the Comparison of Protein Active Site Similarity 
(CPASS) program and database (described in more detail in Chapter 5).14,15 CPASS takes 
the experimental binding site defined by the protein-ligand costructure and compares its 
structure and sequence to the active sites of ~36,000 proteins from the Protein Data Bank 
(PDB). Proteins that have very similar active sites would suggest a similarity in 
molecular function. 
2.2.7 Other bioinformatics tools. In addition to the results of CPASS, other 
bioinformatics approaches are used to provide additional context to the results of the 
FAST-NMR screen (Table 2.2). The identity of the compounds shown to bind in the 
target-based screen provides a significant amount of information as well. Knowledge of 
the type of proteins or metabolic pathways that incorporate the binding compound can 
allows for an addition line of evidence to evaluate possible functions. Overall, the 
agreement between multiple approaches toward determining the function of a protein 
provides greater confidence in the proposed annotation and could be used to guide further 
experiments.  
 
Table 2.2 Bioinformatics tools used for protein functional annotation 
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Bioinformatics 
Tool 
Use Web Address 
BioCyc33 Locating nearby genes/operons http://biocyc.org/ 
BLAST34,35 Identifying sequence homology http://blast.ncbi.nlm.nih.gov 
CASTp36 Comparison of experimental 
binding sites to binding pockets 
based on cavity size/shape 
http://sts-
fw.bioengr.uic.edu/castp 
CombFunc Gene ontology function prediction 
server which includes ConFunc,37 
BLAST,35 InterPro,38 Pfam2GO,39 
Phyre2,40 and 3DLigandSite41 
searches 
http://www.sbg.bio.ic.ac.uk/~m
wass/combfunc 
ConSurf42 Locating evolutionarily conserved 
residues to compare to 
experimental binding sites 
http://consurf.tau.ac.il/ 
CPASS14,15 Comparison of experimentally 
determined binding site to known 
protein binding sites 
http://cpass.unl.edu/ 
Delphi43 Predict electrostatic surface charge 
to compare to experimental binding 
sites 
http://wiki.c2b2.columbia.edu/
honiglab_public/index.php/Soft
ware:DelPhi 
ESG44 Sequence similarity-based GO 
annotation prediction 
http://kiharalab.org/web/esg.ph
p 
IntAct45 Database of experimental protein-
protein interactions 
http://www.ebi.ac.uk/intact/ 
InterPro38 Predict function based on protein 
family classification and domain 
identification 
http://www.ebi.ac.uk/interpro/ 
KEGG46 Database for identifying pathways 
which involve the protein or ligand 
http://www.genome.jp/kegg/ 
MarkUs47 Webtool to compare structure and 
sequence to any known functional 
annotations 
http://honiglab.c2b2.columbia.e
du/MarkUs/cgi-bin/submit.pl 
PDBeFold48 Global structure comparisons http://www.ebi.ac.uk/msd-
srv/ssm/ 
Pfam49 Protein family classification based 
on multiple sequence alignments 
and hidden Markov models 
http://pfam.sanger.ac.uk/ 
PROFESS50 Protein function and evolution 
analysis 
http://cse.unl.edu/~profess/ 
ProFunc51 Structure-based function prediction 
server that includes BLAST 
searches, structural similarity, 
structural template comparison, etc. 
http://www.ebi.ac.uk/thornton-
srv/databases/profunc/index.ht
ml 
RCSB PDB52,53 Protein structure database http://www.rcsb.org/ 
STRING54 Database of experimental and http://string-db.org/ 
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predicted protein interactions 
UniProtKB55 General reference for information 
on protein 
http://www.uniprot.org/ 
 
 
2.3 RESULTS AND DISCUSSION 
The 1D line-broadening screens for the 20 NESG proteins generated a total of 363 
total hits with an average 18 ± 7 hits per protein, which corresponds to a hit rate of 
approximately 4% for each protein [Figure 2.2]. Many of these 363 hits represent 
compounds that exhibited line-broadening for multiple proteins. When this duplication is 
accounted for, the 1D line-broadening screens of all 20 proteins sampled 32.4% of the 
functional compound library (149 unique hits). 
The majority of ligands identified during the 1D 1H NMR line-broadening screen 
were typically specific binders. Approximately 58.7% (213 total) of the binders from the 
1D 1H NMR line-broadening screen were shown to bind in the 2D 1H,15N-HSQC screens, 
which lowers the global hit rate to 10.7 ± 6.7 hits per protein (2.3%) [Figure 2.2], which 
was still significantly better than seen for traditional high-throughput assays in drug 
discovery (~0.5%). The 2D 1H,15N-HSQC screens identified a total of 114 unique 
binders, which represents 24.8% of the total functional compound library. Additionally, 
7.7% of the binders from the 1D 1H NMR line-broadening screen actually caused 
precipitation or aggregation of the protein as the 2D 1H,15N-HSQC spectra often exhibit 
unfolded characteristics or the disappearance of protein peaks. 
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Figure 2.2 A histogram demonstrating the number of compounds found to bind during 
the 1D 1H NMR line-broadening screen for each protein. Each bar is further divided 
based upon the results of the these binders during the 2D 1H,15N-HSQC screen: binder 
(blue); non-binder (red); and precipitation/aggregation (yellow). 
 
Compounds routinely identified during the 1D 1H NMR line-broadening screen may infer 
potentially promiscuous compounds (non-specific binders, protein aggregation, 
functional ambiguity, etc.). Compounds consistently found to show line-broadening in 
the 1D 1H NMR screen are listed in Figure 2.3. For example, suramin underwent line-
broadening in 10 different protein screens, which is the most of any compound. Suramin 
was confirmed as binder in the 2D 1H,15N-HSQC screen for four cases, but caused 
precipitation/aggregation for the remaining six proteins. Similarly, identifying 
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Figure 2.3 A histogram depicting how often a particular compound occurs as a 2D binder 
(blue), 2D non-binder (red), 2D precipitation/aggregation (yellow). 
 
 compounds that consistently yield positive results in the 2D 1H,15N-HSQC screen may 
indicate the compound is a promiscuous, non-specific binder. Ebselen may be an example 
of a non-specific binder, since it was identified in the 2D 1H,15N-HSQC screen for 6 
different proteins. Nevertheless, there is still value in investigating promiscuous binders, 
since a compound that binds to a large number of proteins may not represent a 
functionally relevant interaction. In the FAST-NMR screens of the NESG proteins, 6 
compounds (histamine, S-(-)-carbidopa, tyrphostin 25, (-)-riboflavin, nifedipine, Bay 11-
7082) appeared as specific binders in 5 different proteins. However, care should be taken 
before classifying such compounds as promiscuous binders. Some compounds, like 
histamine or riboflavin, are utilized in many biological pathways and, correspondingly, 
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are expected to have many binding interactions. So, the biological function(s) associated 
with the ligand also needs to be considered before classification as a promiscuous binder. 
As the number of FAST-NMR screens increases, the reliability of classifying particular 
compounds as promiscuous will improve. 
All 20 proteins obtained from NESG received a proposed functional annotation 
[Figure 2.3] based upon multiple factors: the identity of binders from the 2D 1H,15N-
HSQC screen, a similarity to a functionally characterized protein's active site using 
CPASS, and the results of common bioinformatics tools based on sequence and structure 
similarities. While all the data generated from the FAST-NMR screen does not guarantee 
finding a definitive and correct function for the protein, it did provide information to 
efficiently guide future experiments. FAST-NMR or similar approaches are, thus, 
necessary given the large number of functionally uncharacterized proteins that require 
some means of justifying initiating a detailed investigation. 
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Table 2.3 Proposed FAST-NMR functional annotations for the 20 NESG proteins. 
Gene ID NESG ID UniProt Annotation Proposed FAST-NMR Annotation 
yjcQ SR346 Uncharacterized protein yjcQ 
MarR-like transcriptional 
regulator involved in 
chemotaxis 
ykvR SR358 Uncharacterized protein ykvR 
Oxidoreductase involved in 
catechol response 
ynzC SR384 UPF0291 protein ynzC Activator of SOS-like response to pyrogallols 
yozE SR391 UPF0346 protein yozE 
DNA/RNA transferase 
related to sporulation and/or 
DNA packing  
BVU_3908 BvR153 Putative uncharacterized protein 
Z-DNA-binding 
protease/helicase 
BB0938 BoR11 Putative uncharacterized protein 
MOSC-like metal-sulfur 
cluster biosynthesis 
CC_0527 CcR55 Putative uncharacterized protein 
Dihydropyrimidase-like 
protein involved in 
pyrimidine metabolism 
ytfP ER111 
Gamma-
glutamylcyclotransferase 
family protein ytfP 
BtrG-like aminotransferase 
yrbA ER115 Uncharacterized protein yrbA 
BolA-like transcriptional 
regulator involved in cell 
wall formation/morphology 
during stress response  
yggU ER14 UPF0235 protein yggU 
Dehydrogenase related to 
amino acid biosynthesis 
under diverse environments 
yjbR ER226 Uncharacterized protein yjbR 
Transcriptional regulator 
involved in enterotoxin 
production 
ydfO ER251 Uncharacterized protein ydfO 
Qin prophage protein that 
responds to stress such as β-
lactam antibiotics 
ygdR ER382A Uncharacterized protein ygdR 
Membrane-associated 
oligopeptide transporter 
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2.3.1 Bacillus subtilis yjcQ (NESG ID: SR346). The 1D 1H NMR line-
broadening screen of SR346 identified a total of 19 compounds. Of these 19 compounds, 
13 (68.4%) were confirmed as binders in the 2D 1H,15N-HSQC screen, but only three 
compounds showed significant chemical shift perturbations (CSPs) [Figure 2.4A]. The 
tightest binder, tetracycline, produced 5 significant perturbations and several smaller 
perturbations [Figure 2.4B], which present a well-defined consensus binding site [Figure 
2.4C]. The binding site does have a few well-conserved residues but no significant 
hydrophobic or electrostatic characteristics [Figure 2.4D]. 
 
ykfF ER397 UPF0401 protein ykfF 
CP4-6 prophage protein 
involved in general stress 
response 
yeiV ER541 Probable endopeptidase Spr 
Endopeptidase acting on 
phenylalanine and/or 
tyrosine cleavage sites 
PG_0361 PgR37A Conserved domain protein Methanol dehydrogenase 
RHOS4_12090 RhR5 Putative uncharacterized protein 
DNA-binding transcriptional 
repressor involved in signal 
transduction 
STM0327 StR65 Putative cytoplasmic protein 
Permease transport and/or 
signaling 
SPO1678 SiR5 Putative uncharacterized protein 
DNA-binding transcriptional 
repressor involved in signal 
transduction 
SSP0609 SyR11 Putative secretory antigen 
N-acetylmuramoyl-L-alanine 
amidase-like protein 
involved in peptidoglycan 
hydrolysis/cell lysis 
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Figure 2.4 (A) Chemical structures of three compounds shown to bind SR346 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free SR346 (black) and SR346 bound 
with tetracycline (red). (C) The SR346-tetracycline costructure generated by AutoDock 
where residues with significant CSPs are colored red. (D) Surface representations of the 
SR346-tetracycline costructure: (left) ConSurf residue conservation where highly 
conserved residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes SR346 as an "uncharacterized protein yjcQ." Based on 
the results of the FAST-NMR approach, the function of SR346 appears to be similar to a 
MarR-like transcriptional regulator that is likely involved in chemotaxis. The yjcQ gene 
is regulated by SigD, which is important for the transcription of flagellin and motility 
genes as well as chemotaxis.56,57 Most sequence and structural analysis of SR346 
identifies it as a winged-helix DNA-binding protein with significant similarities to the 
MarR-like transcriptional regulators. MarR transcriptional regulators are important 
proteins for regulating multiple antibiotic resistance or organisms.58 This is intriguing as 
the two compounds that showed the greatest CSPs are both antibiotics. As a 
transcriptional regulator, the protein should bind DNA, yet the experimental ligand 
binding site does not occur in the predicted  DNA binding site (α3-helix).59 This may 
indicate ligand binding regulates (negatively or positively) DNA binding, and is a 
possible allosteric binding site.60 Unfortunately, CPASS was not able to identify many 
similar ligand binding sites. The highest similarity score was only 35.69%, which 
matched an immunoglobulin E protein.  This may represent a general similarity in 
chemotaxis and an immunological response, where both sense an external 
molecule/antigen and initiate a large scale response by the organism. 
2.3.2 Bacillus subtilis ykvR (NESG ID: SR358). The 1D 1H NMR line-
broadening screen of SR358 identified a total of 8 compounds. Seven (87.5%) of these 
compounds were confirmed as binders in the 2D 1H,15N-HSQC screen, while only three 
compounds showed significant CSPs [Figure 2.5A]. The tightest binder, histamine, 
showed 6 significant CSPs [Figure 2.5B], which formed a consensus binding site [Figure 
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2.5C]. This binding site is near highly conserved residues and has a slightly negative 
charge to complement the positively charged histamine [Figure 2.5D] 
 
 
Figure 2.5 (A) Chemical structures of three compounds shown to bind SR358 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free SR358 (black) and SR358 bound 
with histamine (red). (C) The SR358-histamine costructure generated by AutoDock 
where residues with significant CSPs are colored red. (D) Surface representations of the 
SR358-histamine costructure: (left) ConSurf residue conservation where highly 
conserved residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes SR358 as an "uncharacterized protein ykvR." Based on 
the results of the FAST-NMR approach, the function of SR358 may be an oxidoreductase 
related to the response of B. subtilis to catechols, which may include sporulation. The 
ykvR gene is located near a sporulation-related gene as well as a predicted AdoMet-
dependent methyltransferase. ESG strongly predicts an oxidoreductase function, such as 
dehydrogenases or oxidases, for this protein (100% probability). CPASS does identify a 
dihydrodiol dehydrogenase as a hit at 41.18%. Dihydrodiol dehydrogenases convert 
aromatic hydrocarbons into catechols,61 which is interesting since 3,5-dinitrocatechol was 
identified as a significant binder. Additionally, in B. subtilis, catechols are toxic and can 
induce a stress response, but it can be catabolized by a catechol-2,3-dioxygenase.62 
2.3.3 Bacillus subtilis ynzC (NESG ID: SR384). The 1D 1H NMR line-
broadening screen of SR384 identified a total of 16 compounds that showed line-
broadening. Nine (56.3%) of these compounds were confirmed as binders in the 2D 
1H,15N-HSQC screen while only two compounds showed significant perturbations 
[Figure 2.6A]. The tightest binder, 4,6-dinitropyrogallol, showed 9 significant 
perturbations [Figure 2.6B]. Unfortunately, only two of these perturbations could be 
reliably assigned. These two residues did not form a consensus binding site [Figure 
2.6C]. While both regions were investigated, one perturbed residues bordered upon a 
well-conserved region of the protein [Figure 2.6D]. 
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Figure 2.6 (A) Chemical structures of two compounds shown to bind SR384 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free SR384 (black) and SR384 bound 
with 4,6-dinitropyrogallol (red). (C) The SR384-4,6-dinitropyrogallol costructure 
generated by AutoDock where residues with significant CSPs are colored red. (D) 
Surface representations of the SR384-4,6-dinitropyrogallol costructure: (left) ConSurf 
residue conservation where highly conserved residues are magenta and poorly conserved 
residues are cyan; (center) Delphi electrostatics surface where the positively-charged 
surface is blue and negatively-charged surface is red; and (right) UCSF Chimera 
hydrophobicity surface where the hydrophilic surface is blue and the hydrophobic surface 
is orange. 
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UniProtKB characterizes SR384 as a "UPF0291 protein ynzC." Based on the 
results of the FAST-NMR approach, SR384 may be involved in detecting pyrogallol-like 
compounds, which inhibits quorum sensing, which activates an SOS-like response. The 
genes nearby ynzC are related to cell division and the SOS response, which is responsible 
for DNA repair.63,64 BLAST sequence similarity shows that the sequence is well 
conserved among Gram-positive organisms and the 2D binder 4,6-dinitropyrogallol and 
other pyrogallol compounds have been implicated in the inhibition of bacterial quorum 
sensing, which is involved in biofilm formation, bacterial virulence, and drug 
resistance.65 However, CPASS does not appear to identify any proteins directly related to 
cell division, SOS response, or bacterial pathogenicity. The top hit for CPASS (46.66%) 
is a protein related to fatty acid biosynthesis, which does not appear to be related to the 
proposed function. Since only 2 CSPs could be used to define the binding site, the 
proposed binding site may not be accurate, yet it does coincide with the highly conserved 
region of the protein. 
2.3.4 Bacillus subtilis yozE (NESG ID: SR391). The 1D 1H NMR line-
broadening screen of SR391 identified a total of 13 compounds that showed line-
broadening. Eight (61.5%) of these compounds were confirmed as binders in the 2D 
1H,15N-HSQC screen most of which showed significant perturbations [Figure 2.7A]. 
Histamine showed the most significant perturbations [Figure 2.7B], which generates a 
fairly consistent binding region [Figure 2.7C]. The experimental binding site does not 
appear to be well conserved, but does have a slightly negative electrostatic surface 
[Figure 2.7D]. 
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Figure 2.7 (A) Chemical structures of four compounds shown to bind SR391 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free SR391 (black) and SR391 bound 
with histamine (red). (C) The SR391-histamine costructure generated by AutoDock 
where residues with significant CSPs are colored red. (D) Surface representations of the 
SR391-histamine costructure: (left) ConSurf residue conservation where highly 
conserved residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes SR391 as a "UPF0346 protein yozE." Based on the 
results of the FAST-NMR approach, SR391 is likely a DNA/RNA transferase involved 
with bacterial communication regarding sporulation and/or DNA packing. The yozE gene 
has a similar phylogenetic profile to a sporulation regulatory gene involved in 
communication between bacteria66 and to a protein that promotes RNA polymerase 
assembly by catalyzing the reaction of a nucleoside triphosphate with RNA. Two of the 
weaker binders are nucleoside phosphates (UTP and AMP). A structural similarity search 
identifies the N-terminal fragment of Rad51 from humans, which is similar to the RecA 
protein from E. coli, but includes the additional N-terminal domain. There is some 
prediction of DNA binding activity for this N-terminal region in humans.67 The results of 
CPASS identify a type II DNA topoisomerase, which regulates super-twisting of DNA, 
with a very similar binding site (42.94%). Binding to DNA/RNA appears to be a common 
theme and appears to support the proposed FAST-NMR functional annotation. 
2.3.5 Bacteroides vulgatis BVU_3908 (NESG ID: BvR153). The 1D 1H NMR 
line-broadening screen of BvR153 identified a total of 17 compounds that showed line-
broadening. Only 3 (17.6%) of these compounds were confirmed as binders in the 2D 
1H,15N-HSQC screen, which only showed a small number of significant perturbations 
[Figure 2.8A]. Imidazole showed the most significant perturbations [Figure 2.8B]. While 
some of these CSPs do agree with imidazole binding in a small cavity on the protein 
surface, the small number of CSPs made it difficult to make a definitive assignment 
[Figure 2.8C]. Nevertheless, this pocket appears to be a likely ligand binding site, has a 
slight positive charge and is primarily hydrophobic, but is not well conserved [Figure 
2.8D]. 
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Figure 2.8 (A) Chemical structures of a compound shown to bind BvR153 in the 2D 1H, 
15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. (B) 
An overlay of 2D 1H, 15N-HSQC spectra of free BvR153 (black) and BvR153 bound with 
imidazole (red). (C) The BvR153-imidazole costructure generated by AutoDock where 
residues with significant CSPs are colored red. (D) Surface representations of the 
BvR153-imidazole costructure: (left) ConSurf residue conservation where highly 
conserved residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
 
UniProtKB characterizes BvR153 as a "putative uncharacterized protein." Based 
on the results of the FAST-NMR approach, BvR153 is a Z-alpha protease/helicase, which 
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is involved in the suppression of the mammalian interferon response pathway. The 
positive surface charge on this protein suggests DNA binding. BvR153 does appear to 
have significant structural similarity to several winged helix proteins that bind DNA 
according to PDBeFold. The best results all feature the Z-alpha domain of adenosine 
deaminases (1.95 Å RMSD), which bind Z-DNA and convert adenosine to inosine.68 The 
binding compound imidazole represents a substructure of both adenosine and inosine. 
Viruses often utilize the Z-alpha domains to regulate interferon response pathway of their 
host.69 CPASS identifies a NS3 protease/helicase bound to an indoline-based inhibitor at 
46.02% similarity. NS3 protease/helicase is an essential protein in the life cycle of the 
hepatitis C virus, and is often the target of drug discovery efforts.70 The Bacteriodes 
vulgatis organism, from which BvR153 originates, is a gut microbe but is also 
responsible for infections, and may utilize BvR153 to suppress the interferon response 
pathway in a similar manner to hepatitis C NS3 protease/helicase. 
2.3.6 Bordetella bronchiseptica BB0938 (NESG ID: BoR11). The 1D 1H NMR 
line-broadening screen of BoR11 identified a total of 19 compounds that showed line-
broadening. Twelve (63.2%) of these compounds were confirmed as binders in the 2D 
1H,15N-HSQC screen, which had many significant perturbations [Figure 2.9A]. The most 
significant perturbations occurred upon binding with methiothepin [Figure 2.9B], and the 
perturbations form a well-defined consensus binding site [Figure 2.9C]. This region is 
very well conserved and exhibits a negatively charged surface [Figure 2.9D]. 
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Figure 2.9 (A) Chemical structures of four compounds shown to bind BoR11 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free BoR11 (black) and BoR11 bound 
with methiothepin (red). (C) The BoR11-methiothepin costructure generated by 
AutoDock where residues with significant CSPs are colored red. (D) Surface 
representations of the BoR11-methiothepin costructure: (left) ConSurf residue 
conservation where highly conserved residues are magenta and poorly conserved residues 
are cyan; (center) Delphi electrostatics surface where the positively-charged surface is 
blue and negatively-charged surface is red; and (right) UCSF Chimera hydrophobicity 
surface where the hydrophilic surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes BoR11 as a "putative uncharacterized protein." Based 
on the results of the FAST-NMR approach, the function of BoR11 is likely involved in 
metal-sulfur cluster biosynthesis similar to MOSC. InterPro and Pfam suggests that 
BoR11 has a MOSC-like domain, which is important for metal-sulfur cluster 
biosynthesis.71 There does not appear to be any structures in the PDB similar to BoR11, 
but it does adopt a β-barrel type fold, which is commonly found in membrane proteins, 
transport proteins, as well as MOSC proteins. The tightest binder, methiothepin, contains 
a couple of sulfur groups while the binder ethacridine bears structural similarity to the 
molybdenum cofactor present in MOSC proteins. The results of CPASS indicate a strong 
preference for sulfur-based chemistry with nitrite reductase (34.68%), arylsulfatase 
(33.08%), and methyltransferases (32.63%) as some of the top hits. 
2.3.7 Caulobacter crescentus CC_0527 (NESG ID: CcR55). The 1D 1H NMR 
line-broadening screen of CcR55 identified a total of 22 compounds that showed line-
broadening. Nearly all of the compounds, 21 (95.5%), were confirmed as binders in the 
2D 1H,15N-HSQC screen [Figure 2.10A]. Fifteen of these compounds produce significant 
CSPs, but ciprofloxacin was selected to generate a costructure [Figure 2.10B]. The CSPs 
create a well-defined consensus binding site [Figure 2.10C], which is well conserved 
[Figure 2.10D]. 
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Figure 2.10 (A) Chemical structures of six compounds shown to bind CcR55 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free CcR55 (black) and CcR55 bound 
with ciprofloxacin (red). (C) The CcR55-ciprofloxacin costructure generated by 
AutoDock where residues with significant CSPs are colored red. (D) Surface 
representations of the CcR55-ciprofloxacin costructure: (left) ConSurf residue 
conservation where highly conserved residues are magenta and poorly conserved residues 
are cyan; (center) Delphi electrostatics surface where the positively-charged surface is 
blue and negatively-charged surface is red; and (right) UCSF Chimera hydrophobicity 
surface where the hydrophilic surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes CcR55 as a "putative uncharacterized protein." Based on 
the results of the FAST-NMR approach, CcR55 is likely involved in pyrimidine 
metabolism and acts similarly to dihydropyrimidase. The CC_0527 gene is found near a 
dihydroorotate dehydrogenase, which is involved in pyrimidine metabolism. Sequence 
similarity searches identify only uncharacterized proteins. A PDBeFold structural 
similarity search identified a modest similarity (2.9 Å RMSD) to cholera enterotoxin, 
where both proteins exhibit the ADP-ribosylation fold. While ADP is not found in the 
compound library, ATP and cyclic AMP were both found as binders in the 2D 1H,15N-
HSQC screen. The top CPASS hit is dihydropyrimidase bound to lysine Nz-carboxylic 
acid (27.79%), which is involved in pyrimidine metabolism and is similar to the 
dihydroorotate dehydrogenase. 
2.3.8 Escherichia coli ytfP (NESG ID: ER111). The 1D 1H NMR line-
broadening screen of ER111 identified a total of 18 compounds that showed line-
broadening. Of these compounds, 15 (83.3%) were confirmed as binders in the 2D 
1H,15N-HSQC screen, which had many significant perturbations [Figure 2.11A]. The 
most significant perturbations occurred upon binding with glutamate, however phenol red 
was used for costructure generation since the residues with significant CSPs could be 
more reliably assigned [Figure 2.11B]. The perturbed residues identify a pocket for 
binding [Figure 2.11C], which is highly conserved, positively charged, and fairly 
hydrophobic [Figure 2.11D]. 
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Figure 2.11 (A) Chemical structures of four compounds shown to bind ER111 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free ER111 (black) and ER111 bound 
with phenol red (red). (C) The ER111-phenol red costructure generated by AutoDock 
where residues with significant CSPs are colored red. (D) Surface representations of the 
ER111-phenol red costructure: (left) ConSurf residue conservation where highly 
conserved residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
 
UniProtKB characterizes ER111 as a "gamma-glutamylcyclotransferase family 
protein ytfP." Based on the results of the FAST-NMR approach, ER111 is likely a BtrG-
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like aminotransferase. The ytfP gene is located near several potentially related genes: 
predicted outer membrane protein and surface antigen; glycogen synthase; methionine 
sulfoxide reductase A; quinolinate synthase; tRNA sulfurtransferase; glucose-1-
phosphate adenyltransferase; and ChpB-ChpS toxin-antitoxin system. However, most 
sequence and structure similarity searches However, InterPro identifies ER111 as having 
a AIG2-like domain which includes BtrG, a protein used during butirosin antibiotic 
production,72 and gamma-glutamyl cyclotransferases, proteins involved in glutathione 
production. BLAST sequence similarity and PDBeFold structural similarity also 
identifies high similarity to AIG2-like proteins. Both of these proteins function by 
cleaving a protecting glutamate, consistent with our observation that ER111 binds 
glutamate.  BtrG cleaves off a protecting glutamyl group from an antibiotic, such as an 
aminocoumarin like novobiocin, which was also identified as a strong binder in the 
FAST-NMR screen. ER111 does not have the conserved Glu residue that serves as a 
proton acceptor in enzymes with gamma-glutamyl cyclotransferase activity,73 which 
indicates that ER111 is likely not a gamma-glutamyl cyclotransferase. The binding site 
generated from the costructure is large (26 amino acids), which causes most CPASS 
results to fall under a 30% similarity. Nevertheless, a human gamma-glutamyl 
cyclotransferase bound to pyroglutamic acid was identified by CPASS, but with a very 
low 20.57% similarity.  
2.3.9 Escherichia coli yrbA (NESG ID: ER115). The 1D 1H NMR line-
broadening screen of ER115 identified a total of 10 compounds that showed line-
broadening. Only one compound (10%) was confirmed as a binder in the 2D 1H,15N-
HSQC screen [Figure 2.12A]. The only binding compound, ATP, only exhibit a few 
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significant CSPs [Figure 2.12B]. These CSPs form a consensus binding site [Figure 
2.12C], which is not well conserved but is positively charged [Figure 2.12D]. 
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Figure 2.12 (A) Chemical structures of a compound shown to bind ER115 in the 2D 1H, 
15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. (B) 
An overlay of 2D 1H, 15N-HSQC spectra of free ER115 (black) and ER115 bound with 
ATP (red). (C) The ER115-ATP costructure generated by AutoDock where residues with 
significant CSPs are colored red. (D) Surface representations of the ER115-ATP 
costructure: (left) ConSurf residue conservation where highly conserved residues are 
magenta and poorly conserved residues are cyan; (center) Delphi electrostatics surface 
where the positively-charged surface is blue and negatively-charged surface is red; and 
(right) UCSF Chimera hydrophobicity surface where the hydrophilic surface is blue and 
the hydrophobic surface is orange. 
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UniProtKB characterizes ER115 as an "uncharacterized protein." Based on the 
results of the FAST-NMR approach, ER115 is likely a BolA-like transcriptional regulator 
involved in cell wall formation/morphology during stress response. A BLAST sequence 
similarity search identifies numerous proteins that are considered DNA-binding 
transcriptional regulators or members of the BolA family. InterPro and Pfam also 
identifies ER115 as a BolA domain. PDBeFold suggests that ER115 is also structurally 
similar to the BolA proteins (2.76 Å RMSD). BolA proteins has distinct effects on the 
morphology of the peptidoglycan cell wall, are involved in stress response, and induces 
the transcription of penicillin binding proteins and β-lactamases. 74,75 This is consistent 
with the observed binding to ATP in a positively charged surface. STRING has also 
identified the BolA protein and signal peptidase I to have similar phylogenetic profiles, 
while UDP-N-acetylglucosamine 1-carboxyvinyltransferase76 and a predicted ABC-type 
organic solvent transporter77 are found to coexpress with ER115. All of these proteins are 
related to the cell wall. Additionally, the binding site has a positive region that may 
indicate DNA-binding as a transcriptional regulator. All of this supports the role that 
ER115 likely plays in cell well formation/morphology during stress response. CPASS 
was unable to find any related binding sites in the database. 
2.3.10 Escherichia coli yggU (NESG ID: ER14). The 1D 1H NMR line-
broadening screen of ER14 identified a total of 14 compounds that showed line-
broadening. Of these compounds, 11 (78.6%) were confirmed as binders in the 2D 
1H,15N-HSQC screen [Figure 2.13A]. Bromocresol green produced the greatest number 
of perturbations [Figure 2.13B]. The consensus binding site identified from the 
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significant perturbations forms around a small pocket [Figure 2.13C], which is highly 
conserved [Figure 2.13D]. 
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Figure 2.13 (A) Chemical structures of three compounds shown to bind ER14 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free ER14 (black) and ER14 bound with 
bromocresol green (red). (C) The ER14-bromocresol green costructure generated by 
AutoDock where residues with significant CSPs are colored red. (D) Surface 
representations of the ER14-bromocresol green costructure: (left) ConSurf residue 
conservation where highly conserved residues are magenta and poorly conserved residues 
are cyan; (center) Delphi electrostatics surface where the positively-charged surface is 
blue and negatively-charged surface is red; and (right) UCSF Chimera hydrophobicity 
surface where the hydrophilic surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes ER14 as a "UPF0235 protein yggU." Based on the 
results of the FAST-NMR approach, ER14 may be a dehydrogenase probably related to 
amino acid biosynthesis under diverse environments. A BLAST sequence similarity 
search primarily finds uncharacterized proteins, except there is 69% sequence identity to 
an osmotic shock response integral membrane protein. The ER14 protein is structurally 
similar to some ribosomal proteins (2.47 Å RMSD) according to PDBeFold. CPASS 
identifies a formaldehyde dehydrogenase (methane metabolism/microbial metabolism in 
diverse environments) bound to NAD at 38.55% similarity, and quinate/shikimate 
hydrogenase (phenylalanine, tryptophan, and tyrosine biosynthesis) bound to NAD at 
37.10% similarity. Additionally, of the several genes near yggU, one is pyrroline-5-
carboxylate reductase, an NAD-dependent enzyme involved in proline biosynthesis. 
2.3.11 Escherichia coli yjbR (NESG ID: ER226). The 1D 1H NMR line-
broadening screen of ER226 identified a total of 26 compounds that showed line-
broadening. Of these compounds, 17 (65.4%) were confirmed as binders in the 2D 
1H,15N-HSQC screen [Figure 2.14A]. Both bromophenol blue and bithionol produced 
many significant perturbations, but bromophenol blue was used for further analysis 
[Figure 2.14B]. Only some of the perturbed residues could be assigned, leaving a small 
binding pocket with perturbed residues on the edge  [Figure 2.14C]. The binding site is 
not particularly well conserved and is only slightly positively charged [Figure 2.14D].  
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Figure 2.14 (A) Chemical structures of four compounds shown to bind ER226 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free ER226 (black) and ER226 bound 
with bromophenol blue (red). (C) The ER226-bromophenol blue costructure generated by 
AutoDock where residues with significant CSPs are colored red. (D) Surface 
representations of the ER226-bromophenol blue costructure: (left) ConSurf residue 
conservation where highly conserved residues are magenta and poorly conserved residues 
are cyan; (center) Delphi electrostatics surface where the positively-charged surface is 
blue and negatively-charged surface is red; and (right) UCSF Chimera hydrophobicity 
surface where the hydrophilic surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes ER226 as an "uncharacterized protein yjbR." Based on 
the results of the FAST-NMR approach, ER226 is likely a transcriptional regulator 
possibly related to the production of enterotoxin synthesis. STRING identifies some 
genes with similar phylogenetic profiles to yjbR, which include a bifunctional DNA-
binding transcriptional repressor/NMN adenylyltransferase (NAD biosythesis) and an 
acetolactate synthase II (branched chain amino acid synthesis). The structure of ER22622 
indicates “double wing” DNA-binding motif with structural similarity to MotCF and 
TATA-binding proteins.78,79  Unfortunately, while the DNA-binding capability is clear, 
the role of the DNA-binding is less clear. BLAST identifies some sequence similarity to 
methylated-DNA-(protein)-cysteine S-methyltransferases (34%), which is involved in 
alkylated DNA repair. PDBeFold indicates that ER226 has some structural similarity a 
type III secretion chaperones (3.48 Å RMSD), which are often used to inject virulence 
proteins into the cells of their host.80 CPASS identifies cholera toxin B bound to 
galactoside-based inhibitors as the top hits (45.78%). Cholera toxin is related to the heat-
labile enterotoxin found in Escherichia coli, and a galactose-based compound, X-GAL, 
was identified as a binder. This hints at a possible virulence role for ER226. 
2.3.12 Escherichia coli ydfO (NESG ID: ER251). The 1D 1H NMR line-
broadening screen of ER251 identified a total of 36 compounds that showed line-
broadening. Of these compounds, 24 (66.7%) were confirmed as binders in the 2D 
1H,15N-HSQC screen [Figure 2.15A]. Fifteen of these compounds showed a significant 
number of perturbations that made selecting the tightest binder difficult. Ultimately, 
methyl-6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate (DMCM) was chosen to 
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represent the tightest binder [Figure 2.15B]. Despite the many perturbations, the 
perturbed residues were very difficult to assign reliably. The most significant 
perturbations that could be assigned appear near a potential binding pocket [Figure 
2.15C]. This binding pocket has some nearby highly conserved residues and is also 
positively charged [Figure 2.15D]. 
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Figure 2.15 (A) Chemical structures of seven compounds shown to bind ER251 in the 
2D 1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 
2A. (B) An overlay of 2D 1H, 15N-HSQC spectra of free ER251 (black) and ER251 
bound with DMCM (red). (C) The ER251-DMCM costructure generated by AutoDock 
where residues with significant CSPs are colored red. (D) Surface representations of the 
ER251-DMCM costructure: (left) ConSurf residue conservation where highly conserved 
residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes ER251 as an "uncharacterized protein ydfO." Based on 
the results of the FAST-NMR approach, ER251 is related to a Qin prophage protein that 
promotes a bacterial response to environmental stress such as β-lactam antibiotics. 
STRING indicates that the ydfO gene has a similar phylogenetic profile as the Qin 
prophage and DLP12 prophage. Pfam predicts that ydfO belongs to a bacteriophage DE3 
family that only occurs in E. coli and Salmonella. The gene ydfO has also been 
experimentally-determined to be related to the Qin prophage.81 It has also been 
experimentally shown to be related to improving survivability of E. coli while under 
peroxide stress.81 Additionally, deletion of the entire Qin prophage gene, which includes 
ydfO, significantly lowers survivability in the presence of ampicillin,81 which is a 
significant binder to ER251. CPASS was unable to produce any significant results to 
support or refute the proposed annotation. 
2.3.13 Escherichia coli ygdR (NESG ID: ER382A). The 1D 1H NMR line-
broadening screen of ER251 identified a total of 17 compounds that showed line-
broadening. Only one of these compounds (5.9%) could be confirmed as a binder in the 
2D 1H,15N-HSQC screen [Figure 2.16A]. Suramin was the only binder but it did produce 
numerous perturbations [Figure 2.16B]. The location of the CSPs on the protein surface 
forms a groove, where suramin appears to readily bind [Figure 2.16C]. This binding 
groove has some nearby conserved residues, a slight negative charge, and hydrophobic 
characteristics [Figure 2.16D]. 
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Figure 2.16 (A) Chemical structures of a compound shown to bind ER382A in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free ER382A (black) and ER382A bound 
with suramin (red). (C) The ER382A-suramin costructure generated by AutoDock where 
residues with significant CSPs are colored red. (D) Surface representations of the 
ER382A-suramin costructure: (left) ConSurf residue conservation where highly 
conserved residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes ER382A as an "uncharacterized lipoprotein." Based on 
the results of the FAST-NMR approach, ER382A is likely membrane-associated 
oligopeptide transporter. The only genes near ygdR are a predicted NADP-dependent 
aldo-keto reductase and a predicted inner membrane protein.  However, PDBeFold 
indicates that ER382A is structurally similar (1.95 Å RMSD) to the C-terminal domain of 
the biotin holoenzyme synthetase, which has been shown to biotinylate a 23-residue 
peptide.82 While the best binder suramin is a heparin mimic and not a peptide, it does 
have some characteristics similar to a peptide, such as the larger size and amide groups. 
Additionally, experimental evidence shows that the entire ER382 protein transports di- 
and tripeptides, and likely belongs to the proton-dependent oligopeptide transporter 
(POT) family.83 The electrostatics and hydrophobicity of the ER382A binding site likely 
provides the specificity for the types of peptides that are transported. CPASS did not find 
any similar binding sites to the experimental binding site, likely due to the very large size 
of the binding site. 
2.3.14 Escherichia coli ykfF (NESG ID: ER397). The 1D 1H NMR line-
broadening screen of ER397 identified a total of 14 compounds that showed line-
broadening. Nine of these compounds (64.3%) were confirmed as binders in the 2D 
1H,15N-HSQC screen [Figure 2.17A]. The perturbations were small in magnitude, where 
novobiocin represented the tightest binder [Figure 2.17B]. The majority of CSPs formed 
a consensus binding site on the protein surface [Figure 2.17C], where some residues 
within this binding site were identified as being highly conserved by ConSurf. [Figure 
2.17D]. 
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Figure 2.17 (A) Chemical structures of two compounds shown to bind ER397 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free ER397 (black) and ER397 bound 
with novobiocin (red). (C) The ER397-novobiocin costructure generated by AutoDock 
where residues with significant CSPs are colored red. (D) Surface representations of the 
ER397-novobiocin costructure: (left) ConSurf residue conservation where highly 
conserved residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes ER397 as a "UPF0401 protein ykfF." Based on the 
results of the FAST-NMR approach, ER397 is likely a CP4-6 prophage involved in 
survivability of the cell and antibiotic resistance. The gene for ykfF is found in between 
CP4-6 prophage genes indicating that ykfF is likely a CP4-6 prophage protein, but the 
function is unknown. The entire CP4-6 prophage has been shown to increase 
survivability of the cell in the presence of quinolone and β-lactam antibiotics.81 
Novobiocin (aminocoumarin) and amoxicillin (β-lactam) were both shown to be binders, 
which supports the relationship to antibiotics. From PDBeFold, ER397 is structurally 
similar to an integrin cassette protein  (1.82 Å RMSD) and a glyoxalase/bleomycin 
resistance protein (2.33 Å RMSD), but BLAST sequence similarity did not identify any 
similarity between ER397 and functionally characterized proteins. CPASS was unable to 
identify any similar binding sites. 
2.3.15 Escherichia coli yeiV (NESG ID: ER541). The 1D 1H NMR line-
broadening screen of ER541 identified a total of 23 compounds that showed line-
broadening. Of these compounds, 13 (56.5%) were confirmed as binders in the 2D 
1H,15N-HSQC screen [Figure 2.18A]. The compound (±)-6-methyl-5,6,7,8-
tetrahydropterine (6-MPH4) represents the best binder with several significant 
perturbations [Figure 2.18B]. The majority of the perturbations were not able to be 
assigned, however the perturbations occur near a binding pocket that can fit the 6-MPH4 
molecule [Figure 2.18C]. This binding pocket is highly conserved and positively charged 
[Figure 2.18D]. 
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Figure 2.18 (A) Chemical structures of three compounds shown to bind ER541 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free ER541 (black) and ER541 bound 
with 6-MPH4 (red). (C) The ER541-6-MPH4 costructure generated by AutoDock where 
residues with significant CSPs are colored red. (D) Surface representations of the ER541-
6-MPH4 costructure: (left) ConSurf residue conservation where highly conserved 
residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
 
UniProtKB characterizes ER541 as a "probable endopeptidase Spr." Based on the 
results of the FAST-NMR approach, ER541 is most likely an endopeptidase involved in 
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cell wall hydrolysis. The yeiV gene is located near a putative lipoprotein and is found to 
coexpress with the same lipoprotein and a DNA-binding transcriptional dual regulator. 
According to PDBeFold, there is a high structural similarity (1.87 Å RMSD) between 
ER541 and the NlpC/P60 protein domain families, which belong to the C40 peptidases. 
These peptidases typically hydrolyze specific peptide linkages in bacterial cell walls, and 
are likely involved in cell wall hydrolysis during cell growth, division, and lysis.84 The 
active site is predicted to include a Cys-His-His catalytic triad, which is present in the 
experimental binding site for FAST-NMR.23 CPASS also finds a NLP/P60 family protein 
bound to cysteinesulfonic acid (34.80%). Given this information, ER541 is likely an 
endopeptidase. However, the specific peptide linkage that is cleaved is unknown. Among 
the binders, 6-MPH4 is a cofactor of phenylalanine and tyrosine hydroxylase while 
tyrphostin 25 is a tyrosine kinase inhibitor. Additionally, there are other amino-acid based 
binders such as cyclo(His-Pro) and N-p-tosyl-L-phenylalanine chloromethyl ketone. This 
may suggest that the cleavage site might involve a phenylalanine or tyrosine. 
2.3.16 Porphyromonas gingivalis PG_0361 (NESG ID: PgR37A). The 1D 1H 
NMR line-broadening screen of PgR37A identified a total of 27 compounds that showed 
line-broadening. Of these compounds, 16 (59.3%) were confirmed as binders in the 2D 
2D 1H,15N-HSQC screen [Figure 2.19A]. Seven of these compounds produce significant 
perturbations with acecainide being selected to generate a costructure [Figure 2.19B]. 
The perturbations map to a groove on the protein in which acecainide fits [Figure 2.19C]. 
This is highly conserved and slightly hydrophobic [Figure 2.19D]. 
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Figure 2.19 (A) Chemical structures of six compounds shown to bind PgR37A in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free PgR37A (black) and PgR37A bound 
with acecainide (red). (C) The PgR37A-acecainide costructure generated by AutoDock 
where residues with significant CSPs are colored red. (D) Surface representations of the 
PgR37A-acecainide costructure: (left) ConSurf residue conservation where highly 
conserved residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes PgR37A as a "conserved domain protein." Based on the 
results of the FAST-NMR approach, PgR37A may be an alcohol dehydrogenase, possibly 
a methanol dehydrogenase. A BLAST sequence similarity search identified mostly 
uncharacterized proteins, except for the beta-propeller domain from methanol 
dehydrogenase,85 which has a similar domain structure as PgR37A. A 44.1% sequence 
identity was observed between PgR37A and the beta-propeller domain. The Pfam and 
InterPro also suggests PgR37A has a TPM domain, which is predicted to be involved in 
the photosystem II (PSII) repair cycle. PDBeFold indicates some structural similarity to 
alanyl-tRNA synthetases (3.14 Å RMSD) and glycerol dehydratase (4.16 Å RMSD).  The 
CPASS similarity search found a formate dehydrogenase bound to NADPH as a 
promising match (27.24%) to the PgR37A-acecainide complex. Despite the low CPASS 
similarity, the binding site share very similar residues. One of the binders identified from 
the FAST-NMR screen is the strongly oxidizing riboflavin 5'-phosphate, which is capable 
of catalyzing a dehydrogenase reaction. The above evidence appears to support a 
dehydrogenase activity. 
2.3.17 Rhodobacter sphaeroides RHOS4_12090 (NESG ID: RhR5). The 1D 1H 
NMR line-broadening screen of RhR5 identified a total of 12 compounds that showed 
line-broadening. However, only one of these compounds (8.3%) was confirmed as a 
binder in the 2D 1H,15N-HSQC screen [Figure 2.20A]. This compound, 3,5-
dinitrocatechol, did exhibit 7 significant perturbations [Figure 2.20B]. The majority of the 
perturbations form a consensus binding site [Figure 2.20C], which has a few conserved 
residues, a positive charge, and is hydrophobic [Figure 2.20D]. 
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Figure 2.20 (A) Chemical structures of one compound shown to bind RhR5 in the 2D 1H, 
15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. (B) 
An overlay of 2D 1H, 15N-HSQC spectra of free RhR5 (black) and RhR5 bound with 3,5-
dinitrocatechol (red). (C) The RhR5-3,5-dinitrocatechol costructure generated by 
AutoDock where residues with significant CSPs are colored red. (D) Surface 
representations of the RhR5-3,5-dinitrocatechol costructure: (left) ConSurf residue 
conservation where highly conserved residues are magenta and poorly conserved residues 
are cyan; (center) Delphi electrostatics surface where the positively-charged surface is 
blue and negatively-charged surface is red; and (right) UCSF Chimera hydrophobicity 
surface where the hydrophilic surface is blue and the hydrophobic surface is orange. 
 
UniProtKB characterizes RhR5 as a "putative uncharacterized protein." Based on 
the results of the FAST-NMR approach, RhR5 is likely a DNA-binding transcriptional 
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repressor involved in signal transduction. STRING identifies three proteins that have 
similar phylogenetic profiles: ctrA two component transcriptional regulator (signal 
transduction during cell cycle regulation); 2'-deoxycytidine 5'-triphosphate deaminase 
(deoxypyrimidine metabolism); and histidyl-tRNA synthetase (histidine transfer RNA 
biosynthesis). A BLAST sequence similarity search only identified uncharacterized 
proteins, but both Pfam and InterPro predict RhR5 to have a winged-helix-turn-helix 
transcription repressor DNA-binding domain, which is also supported by the presence of 
a positively charged surface. RhR5 also has significant structural similarity (1.5 Å - 2.5 Å 
RMSD) to several helix-turn-helix DNA-binding proteins. CPASS finds several high 
scoring hits (48%), where the top 5 hits all bind to a sugar phosphate, thus hinting at the 
DNA-binding properties. 
2.3.18 Salmonella typhimurium STM0327 (NESG ID: StR65). The 1D 1H 
NMR line-broadening screen of StR65 identified a total of 13 compounds that showed 
line-broadening. Four of these compounds (30.8%) were confirmed as binders in the 2D 
1H,15N-HSQC screen [Figure 2.21A]. However, the perturbations for all of these 
compounds are very small [Figure 2.21B]. One of the two perturbations borders a cavity 
on the protein  [Figure 2.21C], which is well conserved [Figure 2.21D]. 
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Figure 2.21 (A) Chemical structures of four compounds shown to bind StR65 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free StR65 (black) and StR65 bound with 
nifedipine (red). (C) The StR65-nifedipine costructure generated by AutoDock where 
residues with significant CSPs are colored red. (D) Surface representations of the StR65-
nifedipine costructure: (left) ConSurf residue conservation where highly conserved 
residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes StR65 as a "putative cytoplasmic protein." Based on the 
results of the FAST-NMR approach, StR65 is probably related to permease transport or 
signaling. The only nearby gene to STM0327 is a putative permease. A BLAST sequence 
similarity search found only uncharacterized proteins, while a PDBeFold structure 
similarity search identified an oxygen detoxification protein (2.23 Å RMSD), a circadian 
clock protein (3.00 Å RMSD), and a regulatory protein involved in recombination (3.77 
Å RMSD). CPASS identifies numerous proteins with the top hit being DNA repair and 
telomere maintenance protein bound to N-dimethyl-lysine (37.96%). However, the 
annotation of StR65 is very difficult due to the lack of supporting information and the 
weak binding of the compounds. 
2.3.19 Silicibacter pomeroyl SPO1678 (NESG ID: SiR5). The 1D 1H NMR line-
broadening screen of SiR5 identified a total of 22 compounds that showed line-
broadening. Of these compounds, 13 (59.1%) were confirmed as binders in the 2D 
1H,15N-HSQC screen [Figure 2.22A]. β-NADPH produces the greatest number of 
perturbations [Figure 2.22B], which when mapped to the protein surface highlight a 
binding groove [Figure 2.22C]. This groove is well conserved and has a slight positive 
charge [Figure 2.22D]. 
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Figure 2.22 (A) Chemical structures of three compounds shown to bind SiR5 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free SiR5 (black) and SiR5 bound with β-
NADPH (red). (C) The SiR5-β-NADPH costructure generated by AutoDock where 
residues with significant CSPs are colored red. (D) Surface representations of the SiR5-β-
NADPH costructure: (left) ConSurf residue conservation where highly conserved 
residues are magenta and poorly conserved residues are cyan; (center) Delphi 
electrostatics surface where the positively-charged surface is blue and negatively-charged 
surface is red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic 
surface is blue and the hydrophobic surface is orange. 
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UniProtKB characterizes SiR5 as a "putative uncharacterized protein." Based on 
the results of the FAST-NMR approach, SiR5 is probably a DNA-binding transcriptional 
regulator involved in signal transducation. The only nearby gene to SPO1678 is a two 
component transcriptional regulator, which is involved in signal transduction during . 
Three additional proteins have similar phylogenetic profiles: ctrA two component 
transcriptional regulator (signal transduction during cell cycle regulation); 2'-
deoxycytidine 5'-triphosphate deaminase (deoxypyrimidine metabolism); histidyl-tRNA 
synthetase (histidine transfer RNA biosynthesis); and a flagellar protein. Interestingly, 
with the exception of the flagellar protein, the phylogenetic profiles for SiR5 are very 
similar to the results previously observed for the Rhodobacter sphaeroides RhR5 protein 
(section 2.3.17). A BLAST search demonstrated that SiR5 has 52% identity to RhR5 and 
40% identity to transposases. InterPro and Pfam predict that SiR5 has a winged-helix-
turn-helix transcription repressor DNA-binding domain, which is supported by the 
presence of the slightly positive charged surface. PDBeFold indicates that SiR5 also has 
significant structural similarity to the helix-turn-helix proteins, including RhR5 (2.29 Å 
RMSD). The CPASS similarity search does not find many high scoring hits. Like RhR5, 
SiR5 is likely a DNA-binding transcriptional repressor. However, the FAST-NMR 
screening results for SiR5 and RhR5 are significantly different in the types of ligands 
bound and the location of the binding site on the protein, despite the many similarities in 
the proteins. The binding sites of both proteins are both along the edge of a highly 
conserved region of the protein where the DNA would likely bind. Despite the 
differences, both RhR5 and SiR5 have enough similarities to suggest a similar function. 
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2.3.20 Staphylococcus saprophyticus SSP0609 (NESG ID: SyR11). The 1D 1H 
NMR line-broadening screen of SyR11 identified a total of 19 compounds that showed 
line-broadening. Of these compounds, 17 (89.5%) were confirmed as binders in the 2D 
1H,15N-HSQC screen [Figure 2.23A]. Suramin produced the greatest perturbations 
[Figure 2.23B]. The perturbed residues extend across the surface of the protein [Figure 
2.23C], and represents residues that are well conserved [Figure 2.23D]. 
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Figure 2.23 (A) Chemical structures of six compounds shown to bind SyR11 in the 2D 
1H, 15N-HSQC screen. The entire list of binding ligands can be found in Appendix 2A. 
(B) An overlay of 2D 1H, 15N-HSQC spectra of free SyR11 (black) and SyR11 bound 
with suramin (red). (C) The SyR11-suramin costructure generated by AutoDock where 
residues with significant CSPs are colored red. (D) Surface representations of the SyR11-
suramin costructure: (left) ConSurf residue conservation where highly conserved residues 
are magenta and poorly conserved residues are cyan; (center) Delphi electrostatics 
surface where the positively-charged surface is blue and negatively-charged surface is 
red; and (right) UCSF Chimera hydrophobicity surface where the hydrophilic surface is 
blue and the hydrophobic surface is orange. 
 
UniProtKB characterizes SyR11 as a "putative secretory antigen." Based on the 
results of the FAST-NMR approach, SyR11 is likely involved in cell lysis by 
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metabolizing peptidoglycan linkages in the cell wall. STRING identifies a methicillin 
resistance protein as having a similar phylogenetic profile, which is also a protein 
involved in the formation of the peptidoglycan cell wall.86 A BLAST search only finds a 
sequence similarity (70% identity) between SyR11 and secretory antigen SsaA in other 
Staphylococcus organisms. SsaA belong to the CHAP domain family, which are N-
acetylmuramoyl-L-alanine amidases that function mainly in cell wall metabolism by 
hydrolyzing the link between amino acids and N-acetylmuramoyl (sugar group).87 
PDBeFold identifies a couple of structures that are similar to SyR11: a putative 
staphyloxanthin biosynthesis protein (2.79 Å RMSD) and a bifunctional 
glutathionylspermidine sythetase/amidase (3.13 Å RMSD). Both of these protein matches 
exhibit the CHAP domain. Additionally, the structure of N-acetylmuramoyl-L-alanine 
compound is very similar to N-acetyl-D-mannosamine, which was shown to bind in the 
FAST-NMR screen. CPASS does not find any similar binding sites above 30% due to the 
large size of the binding site, but there is a 1,4-β-N-acetylmuramidase lysozyme bound 
with sucrose found as the second best hit (22.98%). This is interesting as 1,4-β-N-
acetylmuramidase lysozyme catalyzes the hydrolysis of N-acetylmuramic acid and N-
acetyl-D-glucosamine residues in the peptidoglycan cell wall. 
 
2.4 CONCLUSIONS 
Determining the function of proteins for which sequence and structural homology 
have failed is a daunting task that normally would require a significant amount of time 
and resources to solve using standard approaches like gene knockouts, pull-down assays, 
or monitoring of expression levels. The FAST-NMR methodology provides a high-
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throughput, tiered approach that can potentially annotate a protein over the span of a few 
days. The speed of this approach is of particular interest given the large number of 
"orphaned" proteins for which little is known. Even though the FAST-NMR approach 
does not necessarily provide definitive proof of a protein's function, it can provide a 
logical initial assumption that can be used to intelligently guide future studies by 
identifying the protein's binding site and the types of compounds that bind the protein. 
The 20 NESG proteins screened in this study required the preparation of 
approximately 3,000 NMR samples and nearly a month of cumulative NMR experiment 
time. Each protein, by itself, could realistically go from receipt of a protein sample to a 
proposed function in approximately a week. However, much of that time can be reduced 
by automating the sample preparation and NMR data analysis. This truly makes FAST-
NMR rapid enough to address the ever-growing number of "orphan" proteins. 
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APPENDIX 2A A list of the results of the 2D 1H,15N-HSQC screen for each protein of 
the compound hits found during the 1D line-broadening screen. The compounds are 
categorized as 2D binders if any peaks were perturbed in the 2D 1H,15N-HSQC. The 
compounds are categorized as 2D non-binders if no peaks are perturbed. If the 2D 
1H,15N-HSQC spectra do not represent a well-folded protein, the compound is classified 
as 2D precipitation/aggregation. 
 
Gene ID 
(NESG ID) 2D Binders 2D Non-Binders 
2D Precipitation /  
Aggregation 
yjcQ (SR346) tetracycline pyridoxin (vitamin B6)  
 kanamycin pepstatin A  
 lorglumide L-histadine  
 (±)-epinephrine aquacobalamin  
 penicillin G citrate  
 allopurinol hydralazine  
 L-2-aminoadipic 
acid 
  
 berenil   
 lidocaine   
 Bay 11-7085   
 bepridil   
 histamine   
 adenine (vitamin 
B4) 
  
    
ykvR (SR358) histamine citrate  
 haloperidol 
metabolite I 
  
 
3,5-
dinitrocatechol 
  
 L-2-aminoadipic 
acid 
  
 allopurinol   
 adenine (vitamin 
B4) 
  
 dansylglycin   
    
ynzC (SR384) 4,6-
dinitropyrogallol 
penicillin G suramin 
 orange II adrenochrome bromocresol green 
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 triethylenetetrami
ne trientine 
tyrphostin 1  
 (-)-riboflavin idazoxan  
 4-amino-2-
nitrophenol 
acetoacetate  
 tyrphostin 25   
 4-methylpyrazole   
 2-amino-phenol   
 imidazole   
    
yozE (SR391) histamine citrate bromophenol blue 
 4-methylpyrazole 2-amino-4-methylphenol  
 chlorotetracycline berenil  
 3,5-
dinitrocatechol 
clofibrate  
 UTP   
 
N-succinyl-Ala-
Ala-Pro-Phe p-
nitroanilide 
  
 AMP   
    
BVU_3908 
(BvR153) imidazole 
6,7-dimethyl-5,6,7,8-
tetrahydropterine 
 
 S-(-)carbidopa (±)-epinephrine  
 (-)-riboflavin 
(2S,3S)-trans-3-phenyl-2-
oxiranylmethyl-4-
nitrophenyl carbonate 
 
  dimethyl-2-oxoglutarate  
  2-aminofluorene  
  nalidixic acid  
  Mordant orange I  
  lumicolchicine  
  PTH-tryptophan  
  flavanone  
  tyrphostin 1  
  2-deoxyguanosine-5-
monophosphate 
 
  nitrendipine  
  Bay 11-7082  
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BB0938 
(BoR11) methiothepin β-NADPH suramin 
 3,5-
dinitrocatechol 
6-amino-3-methylpurine 
bisbenzimide H 
33258 
 ethacridine 
N-tert-butyldimethylsilyl-
N-
methyltrifluoroacetamide 
 
 
4-
chloromercuriben
zoic acid 
adrenochrome  
 (-)-riboflavin ebselen  
 acecainide   
 idazoxan   
 S-(-)carbidopa   
 L-valine   
 2-pyridineacetic 
acid 
  
 tyrphostin 1   
 nifedipine   
    
CC_0527 
(CcR55) ciprofloxacin trans-chalcone  
 
N-p-tosyl-L-
phenylalanine 
chloromethyl 
ketone 
  
 nalidixic acid   
 bromocresol green   
 ATP   
 
(±)-6-methyl-
5,6,7,8-
tetrahydropterine 
  
 Mordant orange I   
 suramin   
 duroquinone   
 naproxen   
 phenylbutazone   
 N-   
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phenylanthranilic 
acid 
 8-
methoxypsoralen 
  
 cAMP   
 chelerythrine   
 6-amino-3-
methylpurine 
  
 picotamide   
 captopril   
 penicillin G   
 idazoxan   
 ebselen   
    
ytfP (ER111) phenol red aminophylline  
 orange II berenil  
 L-glutamate ciprofloxacin  
 novobiocin   
 lidocaine   
 rifampicin   
 progesterone   
 buspirone   
 kaempferol   
 
L-2-aminoadipic 
acid 
  
 eserine 
(physostigmine) 
  
 
N-acetyl-L-
tryptophan 3,5-
bis(trifluoromethy
l) benzyl ester 
  
 tetracycline   
 amoxicillin   
 adenine (vitamin 
B4) 
  
 ethacridine   
    
yrbA (ER115) ATP apigenin Bay 11-7085 
  lumicolchicine  
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  clofibrate  
  adenine (vitamin B4)  
  mycophenolic acid  
  ebselen  
  nifedipine  
  2-cyclohexen-1-one  
    
yggU (ER14) bromocresol green chelerythrine suramin 
 Mordant orange I ciprofloxacin  
 β-NADPH   
 ATP   
 colchicine   
 8-
methoxypsoralen 
  
 imidazole   
 penicillin G   
 
(±)-6-methyl-
5,6,7,8-
tetrahydropterine 
  
 safrole   
 bisbenzimide H 
33258 
  
    
yjbR (ER226) bromophenol blue 2,6-diisopropylphenol doxycycline 
 bithionol nalidixic acid suramin 
 tetracycline adenine (vitamin B4)  
 X-GAL 1-octanol  
 CTP (±)-camphor  
 bepridil 1-methylhistamine  
 thiamine 
pyrophosphate 
cAMP  
 histamine   
 flutamide   
 lumicolchicine   
 chlorotetracycline   
 cephalexin   
 (±)-verapamil   
 3-(1-naphthyl)-D-
alanine 
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 homovanillic acid   
 PTH-tryptophan   
 
menadione 
(vitamin K3) 
  
    
ydfO (ER251) DMCM β-NADPH indomethacin 
 
N-
phenylanthranilic 
acid 
cyclo(His-Pro) sulindac sulfide 
 phenylpyruvic 
acid 
L-tyrosine meclofenamic acid 
 kynurenic acid 6,7-dimethyl-5,6,7,8-
tetrahydropterine 
bromocresol green 
 ampicillin acetoacetate diclofenac 
 nifedipine  adrenochrome 
 acecainide  orange II 
 daidzen   
 progesterone   
 Mordant orange I   
 Bay 11-7082   
 S-(4-nitrobenzyl)-
6-thioinosine 
  
 4,6-
dinitropyrogallol 
  
 resveratrol   
 genistein   
 doxycycline   
 (±)-camphor   
 trans-chalcone   
 menadione 
(vitamin K3) 
  
 S-(-)-carbidopa   
 cromolyn   
 tyrphostin 25   
 
(±)-6-methyl-
5,6,7,8-
tetrahydropterine 
  
 (-)-riboflavin   
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ygdR 
(ER382A) suramin daphnetin L-histadine 
  CTP tyrphostin 25 
  
1-phenyl-1-
cyclopropanecarboxylic 
acid 
 
  histamine  
  (-)-cotinine  
  
2-deoxyguanosine-5-
monophosphate 
 
  1-methylimidazole  
  timolol  
  mecamylamine  
  AMP  
  Bay 11-7085  
  nifedipine  
  bepridil  
  aquacobalamin  
    
ykfF (ER397) novobiocin nalidixic acid  
 ethacridine L-histadine  
 allopurinol L-2-aminoadipic acid  
 lidocaine tyrphostin 1  
 3-indoleacetic 
acid 
cyclo(His-Pro)  
 clindamycin   
 amoxicillin   
 lorglumide   
 bepridil   
    
yeiV (ER541) 
(±)-6-methyl-
5,6,7,8-
tetrahydropterine 
acetoacetate coenzyme A 
 duroquinone imidazole β-NADPH 
 tyrphostin 25 
(2S,3S)-trans-3-phenyl-2-
oxiranylmethyl-4-
nitrophenyl carbonate 
Mordant orange I 
 hydralazine ebselen orange II 
 menadione 6-amino-3-methylpurine sulindac sulfide 
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(vitamin K3) 
 ampicillin   
 S-(-)-carbidopa   
 adrenochrome   
 safrole   
 cyclo(His-Pro)   
 
N-p-tosyl-L-
phenylalanine 
chloromethyl 
ketone 
  
 Bay 11-7082   
 dimethyl 2-
oxoglutarate 
  
    
PG_0361 
(PgR37A) acecainide 4-methylpyrazole  
 bromocresol green Bay 11-7085  
 riboflavin 5'-
phosphate 
serotonin  
 ethacridine adenine (vitamin B4)  
 tyrphostin 25 (±)-6-methyl-5,6,7,8-
tetrahydropterine 
 
 
N-succinyl-Ala-
Ala-Pro-Phe p-
nitroanilide 
(±)-epinephrine  
 ATP nalidixic acid  
 histamine S-(-)-carbidopa  
 methiothepin ebselen  
 1-
methylimidazole 
nifedipine  
 AMP flavanone  
 2'-deoxyadenosine 
5'-monophosphate 
  
 phenylpyruvic 
acid 
  
 (-)-riboflavin   
 Bay 11-7082   
    
RHOS4_1209 3,5- penicillin G  
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0 
(RhR5) 
dinitrocatechol 
  1-methylhistamine  
  berenil  
  bepridil  
  adenine (vitamin B4)  
  6-amino-3-methylpurine  
  hydralazine  
  lorglumide  
  allopurinol  
  lidocaine  
  cyclo(His-Pro)  
    
STM0327 
(StR65) nifedipine pepstatin A suramin 
 1-octanol L-glutamate ebselen 
 tyrphostin 25 2,6-diisopropylphenol  
 bromophenol blue aquacobalamin  
  clofibrate  
  acridine  
  duroquinone  
    
SPO1678 
(SiR5) β-NADPH riboflavin-5’-phosphate sulindac sulfide 
 acecainide ebselen suramin 
 orange II 6,7-dimethyl-5,6,7,8- 
tetrahydropterine 
 
 nifedipine 
N-p-tosyl-L-
phenylalanine  
chloromethyl ketone 
 
 Bay 11-7082 PTH-tryptophan  
 2-aminophenol adrenochrome  
 hydralazine penicillin G  
 menadione 
(vitamin K3) 
  
 duroquinone   
 4-amino-2-
nitrophenol 
  
 S-(-)-carbidopa   
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 cyclo(His-Pro)   
    
SSP0609 
(SyR11) suramin ebselen 
didecyldimethyl- 
ammonium bromide 
 Bay 11-7082   
 nifedipine   
 rutin   
 N-acetyl-D-
mannosamine 
  
 
N-succinyl-Ala-
Ala-Pro-Phe p-
nitroanilide 
  
 imidazole   
 chelerythrine   
 penicillin G   
 sepiapterin   
 6-amino-3-
methylpurine 
  
 2-aminofluorene   
 daunorubicin   
 4-
hydroxytamoxifen 
  
 safrole   
 trans-chalcone   
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CHAPTER 3 
RAPID PROTEIN-LIGAND COSTRUCTURES USING CHEMICAL SHIFT 
PERTURBATIONS AND AUTODOCK§ 
 
3.1 INTRODUCTION 
Structure-based drug design utilizes the known three-dimensional structures of 
biologically relevant proteins to develop drug candidates in a rational yet relatively rapid 
manner.1,2 However, this process requires an in-depth understanding of the molecular 
processes that govern the interaction between a target protein and a potential drug. 
Knowledge of the precise location and orientation, or pose, of the drug molecule when 
bound to the protein-ligand complex can be experimentally determined using X-ray 
crystallography or NMR, but these techniques require a significant amount of time, 
usually on the order of weeks to months.3,4 A number of NMR approaches have been 
described to shorten this time frame that includes NOE based protein-ligand models,5,6 
differential chemical shift perturbations between two or more bound ligands,7 SOS-
NMR,8 and NMR-DOC.9 These approaches still suffer from significant experimental 
drawbacks that limit their practical use to routine determination of a large number of 
protein-ligand costructures. In order to facilitate the high-throughput screening of 
thousands of compounds, the application of molecular docking simulations for filtering 
and evaluating drug candidates is a common alternative.10 
Molecular docking is the process of predicting the structure of a protein-ligand 
complex using only the structures of the individual components. Most molecular docking 
                                                
§ Chapter was adapted from Stark, J. and Powers, R. Rapid protein-ligand costructures using chemical shift 
perturbations. J Am Chem Soc 130, 535-545 (2008). Reprinted with permission, copyright 2012 by the 
American Chemical Society. 
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software applications have two key parts: (1) a search algorithm that samples different 
locations and conformations of the ligand with respect to the protein and (2) a scoring 
method to evaluate the results of the search algorithm.11 For molecular docking to be 
useful in drug discovery, these key parts should be both fast and accurate. These two 
requirements are often in opposition to each other, requiring necessary compromises that 
commonly end in ambiguous results or failure.12-16 There are numerous molecular 
docking software applications that utilize different search and scoring algorithms, where 
AutoDock is currently the most cited of these applications17 and has been demonstrated 
to outperform other docking tools in a virtual screen of a compound library.15 
In AutoDock 4,18,19 the protein is represented as a three-dimensional grid which is 
searched with a Lamarckian genetic algorithm that explores the different translational, 
rotational, and torsional degrees of freedom of the ligand relative to the grid. An 
estimated free energy of binding is used to evaluate the docked ligand conformations and 
comprises several terms that include dispersion/repulsion, directional hydrogen bonding, 
electrostatics, desolvation, and conformational energy. As a result of the searching 
algorithm, the accuracy of an AutoDock calculation is often dependent on the number of 
torsional degrees of freedom in the ligand and the size of the grid that represents the 
protein or the binding site.16,20 The accuracy can be improved by increasing both the 
population size and the number of energy evaluations for the Lamarckian genetic 
algorithm.16,21 Unfortunately, these modifications often lead to a drastic increase in 
computational time (tens of hours) that significantly reduces the throughput required for 
iterative structure-based drug design. Furthermore, increasing these parameters does not 
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guarantee that the lowest-energy conformer predicted by AutoDock will result in a 
correct protein-ligand model. 
Prior knowledge of the ligand binding site would potentially improve the 
accuracy of the docking calculations by minimizing the grid volume that must be 
searched as well as limiting the possible conformations of the ligand that have 
energetically favorable interactions with the protein.16 One rapid method of locating the 
binding site is by identifying the amino acid residues that experience chemical shift 
perturbations (CSPs) in a 2D 1H-15N HSQC NMR titration experiment due to their 
proximity to the bound ligand.7,22,23 
Chemical shift perturbations (CSPs) can also be used to filter the docking results 
by selecting a pose consistent with the observed chemical shift changes.24 The protein-
protein docking program HADDOCK25 uses CSPs and mutagenesis to create ambiguous 
interaction restraints, which define an upper boundary for the distance one residue can be 
from any atom of the bound molecule. These restraints are combined with a complete set 
of structural restraints that define the protein-free conformation in a simulated annealing 
protocol using CNS26 to calculate a costructure. A similar approach can be used to 
provide criteria to select the best ligand conformation(s) generated from an AutoDock 
calculation. 
Our approach for rapidly determining an accurate ligand binding orientation 
utilizes CSPs from a 2D 1H-15N HSQC NMR experiment to both guide and filter an 
AutoDock costructure calculation. By using CSPs to define the likely ligand binding site, 
the AutoDock 3D grid is reduced to a volume encompassing only the binding site, thus 
decreasing the search space sampled by the ligand. Furthermore, an NMR energy 
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function based on the magnitude of CSPs is shown to be an effective filtering tool to 
select the best ligand conformation. 
 
3.2 MATERIALS AND METHODS 
 3.2.1 Preparation of the ligand and target protein. The analysis of the 
reliability of using CSPs to guide and filter molecular docking was demonstrated with the 
X-ray structures for 19 distinct protein-ligand complexes (Table 3.1) present in the 
Protein Data Bank (http://www.pdb.org).27,28 The ligands were removed from the protein-
ligand complex and saved as a separate coordinate file. All solvent molecules and ions 
were also removed with the exception of ions deemed to be biologically relevant to 
ligand binding. Any missing heavy atoms for the amino acid residues were added using 
Swiss-PDBView (http://www.expasy.org/spdbv).29 All hydrogens were added to the 
protein and ligand using standard protonation states at a neutral pH. 
Docking was also performed using the corresponding unbound structures for each 
of the 19 protein-ligand complexes. This permitted a comparison of the docking 
performance using both bound and unbound protein structures. Protein files were 
prepared in the same manner as above. In addition, the backbone coordinates of the 
apoprotein were aligned with the bound protein structure prior to the AutoDock 
calculation (Table 3.1). The ligand conformation in the original X-ray structure of the 
complex was then used to measure a root mean square deviation (RMSD) between the 
docked ligand conformers calculated using the bound and apoprotein structures. 
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Table 3.1 RMSD comparison between the ligand-bound and unbound proteins. 
 RMSD(Å)  
PDB ID full protein binding site binding site  
bound/unbound backbone backbone all atom resolution 
1A6W/1A6U 0.33 0.29 0.77 2.00/2.10 
1ACJ/1QIF30,31 0.38 0.30 0.63 2.80/2.10 
1BLH/1DJB32,33 0.25 0.20 1.39 2.30/2.10 
1BYB/1BYA34 0.29 2.48 2.36 1.90/2.20 
1C83/1SUG35,36 0.23 0.19 0.77 1.83/1.95 
1IVD/1NNA37,38 1.04 0.54 0.82 1.90/2.50 
1LPC/1LP839 0.14 0.27 0.58 1.70/1.65 
1MRG/1AHC40,41 0.27 0.17 1.15 1.80/2.00 
1MTW/2TGA42,43 0.34 0.93 1.10 1.90/1.80 
1QPE/3LCK44,45 0.25 0.31 0.40 2.00/1.70 
1RBP/1BRQ46,47 0.59 0.73 1.55 2.00/2.50 
1SNC/1STN48,49 0.67 0.85 2.09 1.65/1.70 
1STP/2RTA50,51 0.77 0.40 1.11 2.60/1.39 
2CTC/2CTB52 0.17 0.38 1.72 1.40/1.50 
2H4N/2CBA53,54 0.21 0.17 0.26 1.90/1.54 
2PK4/1KRN55,56 0.50 0.25 1.10 2.25/1.67 
2SIM/2SIL57 0.14 0.16 0.23 1.60/1.60 
3PTB/2PTN43,58 0.11 0.16 0.31 1.70/1.55 
6CPA/5CPA59,60 0.36 0.52 1.68 2.00/1.54 
 
 
3.2.2 Prediction of ligand binding sites and chemical shift perturbations. The 
NMR-predicted binding site for each protein complex was determined by identifying all 
of the amino acid residues within 6.0 Å of any atom in the ligand using RasMol 2.7.3.1.61 
These residues were anticipated to incur a chemical shift perturbation when the protein is 
titrated with the ligand. The coordinates of the residues that composed this binding site 
were then saved as a separate structure file that was used to define the grid size for the 
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guided docking. Chemical shift perturbations were then estimated using a simple linear 
relationship based on the distance between the amide nitrogen for each residue in the 
binding site to the nearest ligand atom. 
3.2.3 Molecular docking. AutoDock 4.0118,19 with the AutoDockTools 1.4.5 
(http://mgltools.scripps.edu) graphical interface was used to simulate 120 different 
binding conformations for each protein-ligand pair. In the analysis where the docking 
was not guided by the NMR-predicted binding site (blind-docking), grid maps were 
generated with 0.547 spacing and set to an appropriate size that encompasses the entire 
protein. The CSP-guided docking analysis also used the 0.547 Å spacing, but the grid 
map size was set to encompass those amino acid residues that were determined to be 
within 6.0 Å of the ligand. The docking calculations were performed using the 
Lamarckian genetic algorithm default settings with a population size of 300 and 500,000 
energy evaluations. The AutoDock calculations took, on average, 37 ± 32 min per 
protein-ligand pair to complete on an Intel Xeon 3.06 GHz dual processor Linux 
workstation. The calculation time increased proportionally with the number of rotatable 
bonds in the ligand. 
3.2.4 Filtering of docked ligand conformations. The resulting 120 docked 
ligand conformations were filtered using our AutoDockFilter (ADF) program, which 
utilized the magnitude of the chemical shift perturbations to select the best conformers 
instead of relying on the ambiguity inherent in choosing the best cluster based solely on 
the AutoDock empirical binding energy. 
ADF calculates a pseudodistance (dCSP) based on the magnitude of the NH 
chemical shift perturbations for each residue in a 1H-15N HSQC NMR experiment. We 
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assumed linear relationships are present between the magnitudes of the CSPs and the 
distances to the nearest ligand atom. Also, the shortest possible CSP pseudodistance 
allowed is 3 Å. This minimizes any bias to large chemical shift changes that may result 
from multiple factors in addition to proximity of the ligand. This pseudodistance is then 
compared to the shortest distance (ds) between any atom in the residue that incurred an 
NH CSP and any atom in each docked ligand conformer. A violation energy is attributed 
to the conformer only when the shortest distance in the docked protein-ligand costructure 
is larger than the pseudodistance predicted from CSPs. Thus, the pseudodistance based on 
CSP only represents an upper distance boundary. The violation energy is summed for 
each separate CSP to generate an overall NMR energy (ENMR): 
𝐸!"# = 𝑘 (∆!"#$)!!!!!                                                                                                             (3.1) 
where 
∆!"#$=< 𝑑!"# − 𝑑!    𝑑!"# < 𝑑!0                                    𝑑! ≤ 𝑑!"#                                                                                           (3.2) 
An RMSD is then calculated by ADF between each docked ligand conformation 
relative to the ligand with the lowest NMR energy. The structures are then clustered 
based on this RMSD value using the k-means method.62 If a particular docked 
conformation has an NMR energy that is beyond two standard deviations from the 
average, it is excluded from the cluster. Only the best cluster from ADF was used for 
further analysis. The graphical representations of the proteins and ligands in this paper 
were prepared using VMD Molecular Graphics Viewer.63 
3.2.5 Molecular docking using a flexible binding site. A new feature in 
AutoDock 4.01 allows for rotatable bonds in the side chain of any selected residue in the 
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receptor protein. A flexible binding site was used in the docking of tacrine to the free 
acetylcholinesterase structure (PDB-ID: 1QIF). This was done to account for the 
observation that Phe330 had flipped into the active site of acetylcholinesterase, partially 
blocking access to tacrine. Seven residues within the previously defined binding site were 
allowed to have flexible sidechains: Trp84, Tyr121, Phe330, Tyr334, Trp432, His440, 
and Tyr442. The amino acids were chosen based on their proximity to Phe330 and tacrine 
in the X-ray crystal structure of the complex (PDB-ID: 1ACJ). Not all of the residues in 
the binding site were defined as flexible due to a limitation in the number of allowable 
rotatable bonds. The AutoDock calculation with flexible side chains took approximately 
4.5 h to complete using the identical docking parameters and computer hardware as the 
previous calculations. 
A further analysis of CSPs to guide and filter an AutoDock molecular docking 
calculation was performed using published 1H and 15N chemical shift data obtained from 
the solution structure of staphylococcal nuclease in both the unbound64 and thymidine 
3’,5’-bisphosphate complexed forms.65,66 The magnitude of the CSPs were calculated 
using a common weighting approach: 
𝐶𝑆𝑃 = !!! !!!!!!                                                                                                                         (3.3)            
where δN and δH represent respectively the changes in 15N and 1H chemical shifts upon 
ligand binding.67 
The binding site was determined by first selecting residues with CSPs greater than 
one standard deviation from the mean and mapping these residues onto the 
Staphylococcus aureus molecular surface. These residues corresponded to Ile18, Asp19, 
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Phe34, Leu37, Leu38, Val39, Lys84, Ala60, Lys110, Tyr113, Val114, and Tyr115. This 
was further filtered by visually selecting only those residues that clustered together on the 
protein’s molecular surface, consistent with a consensus binding site. It was important to 
select the residues predicted to interact with the ligand in the consensus binding site. 
Some general factors that were considered include the presence of a contiguous surface 
of residues with CSPs (residues separated by <5 Å from nearest neighbors), residues 
clustered about a central point (encircling a binding pocket), surface accessibility, 
proximity to a surface feature (presence of intervening residues), relative distance to the 
main cluster of residues, and the relative magnitude of the observed CSPs. Another 
consideration was the number of residues that form a cluster, where a larger cluster size 
(≥4) increases the likelihood that a ligand binding site has been correctly identified. 
Residues Leu37, Leu38, Val39, Tyr113, Val114, and Tyr115 form the main 
contiguous CSP surface along one edge of a pocket on the S. aureus molecular surface. 
Residues Ile18, Asp19, and Lys84 exhibit some of the largest CSPs and were proximal to 
the same pocket as the main CSP cluster of six residues. In effect, residues Ile18, Asp19, 
Leu37, Leu38, Val39, Lys84, Tyr113, Val114, and Tyr115 encircle this binding pocket. 
Residue Ala60 was excluded because it is > 10 Å from this main cluster of residues and 
is on the opposite face of the protein. Residue Phe34 was excluded because it is not 
surface exposed and is part of the hydrophobic core of the protein. Residue Lys110 was 
excluded because it is outside the ring of residues encircling the binding pocket (i.e., 
residues Val39 and Tyr113 separate Lys110 from the binding pocket). Lys110 would not 
be expected to interact directly with thymidine 3’,5’-bisphosphate. It also had the second-
lowest CSP among the 12 residues initially selected. 
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Docking calculations were performed using the X-ray structures of the unbound 
(PDB-ID: 1EY0) and the thymidine 3’,5’-bisphosphate complexed (PDB-ID: 1SNC) 
staphylococcal nuclease protein structure. The ligand coordinates were removed from the 
protein-ligand complex and stored as a separate file for docking. The AutoDock grid was 
positioned and sized to cover the residues with experimental CSPs. The grid was also 
large enough to include the entire thymidine 3’,5’-bisphosphate molecule. Docking 
calculations were performed using the same parameters as before. Filtering of results 
using ADF was performed using the experimental CSPs. 
 
 
Figure 3.1 Flow diagram illustrating the overall process of generating a rapid protein-
ligand costructure using CSP data to guide and filter the molecular docking results from 
AutoDock. 
 
 
3.3 RESULTS AND DISCUSSION 
The overall methodology for the rapid determination of a protein-ligand 
costructure has three steps [Figure 3.1]: (i) identification of the binding site by mapping 
CSPs from a 1H-15N HSQC NMR experiment, (ii) guiding the AutoDock calculations 
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using the identified binding site, and (iii) using the relative magnitude of the CSPs to 
filter the resulting ligand conformers from AutoDock. The ability of the protocol to 
accurately predict a protein-ligand costructure based on CSPs was demonstrated using 
multiple model systems and an experimental data set for S. aureus nuclease complexed to 
thymidine 3’,5’-bisphosphate. 
3.3.1 Protein-ligand model systems. Due to the scarcity of available chemical 
shift and structural data for complexed and unbound forms of multiple protein-ligand 
systems, the methodology was primary demonstrated using empirically predicted 
chemical shift perturbations based on existing X-ray structures in the PDB. A total of 19 
distinct pairs of protein structures with a variety of biological activity were identified and 
used for the docking simulation (Table 3.1). 
NMR chemical shift changes were routinely and widely used to map protein-
ligand interactions based on the generally accepted protocol that residues proximal to the 
bound ligand will experience higher CSPs compared to residues distal to the ligand 
binding site.68,69 Thus, CSPs were estimated by assuming a simple linear relationship 
between the magnitude of the CSPs and the distance from the amino acids’ NH atoms 
and the nearest ligand atom. This was clearly a simple approximation since other factors 
besides proximity to the bound ligand contribute to CSPs. These factors include hydrogen 
bonding, electrostatics and ring current effects.70 Unfortunately, a robust approach to 
predict ligand-induced chemical shift changes in a protein-ligand system using ab initio 
methods is not available because of the complexity of the system (e.g., number of atoms). 
The absolute magnitude of the predicted CSPs is not critical since the CSPs are 
only used as an upper bound constraint to filter the poses predicted by AutoDock. 
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Additionally, a 3 Å distance cutoff is used to avoid any bias or distortion from unusually 
large CSPs. Effectively, the relative magnitude of the CSPs determines the conformer(s) 
selected by the AutoDockFilter (ADF) program. Again, this is based on the generally 
accepted premise that residues that incur the largest relative CSPs are predicted to be 
closer to the docked ligand. ADF simply identifies the conformer that maximizes an 
interaction with residues with the largest CSPs. This is also similar to the protocol 
implemented by HADDOCK25 where CSPs and mutagenesis are used to create 
ambiguous interaction restraints, which define upper boundaries for the distances 
residues may be from any atom of the bound molecules in a protein-protein docking 
calculation. 
3.3.2 Comparison of blind docking and CSP-guided docking. Blind docking is 
commonly used to generate protein-ligand complexes when a binding site is 
undetermined.16,21 The approach requires scanning the entire protein surface, where the 
scoring function is used to both identify the binding site and select the best conformer. It 
may be extremely challenging to identify the correct ligand binding site when the binding 
energies between multiple distinct binding sites are within the error of the calculations. 
The AutoDock binding energies are estimated to have an error of 2.2 kcal/mol.71 A 
comparison of results obtained between CSP-guided docking and blind docking 
demonstrated the expected advantages of guided docking to a known ligand binding site. 
On average, blind docking generated 63 ± 37 distinct clusters in AutoDock using a 2.0 Å 
RMSD tolerance for each cluster. This large number of clusters generated a 
corresponding large average RMSD of 15.40 ± 6.40 Å relative to the original X-ray 
structure. 
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The CSP-guided docking calculations yielded a relatively tight clustering of 
conformers (16 ± 23 distinct clusters) where the average RMSD was 2.31 ± 1.15 Å. This 
was a dramatic and expected improvement relative to blind docking. A comparison using 
all the conformers within 2.2 kcal/mol of the lowest-energy conformer was made 
between the CSP-guided and blind dockings. This comparison demonstrates that the 
average RMSD of the CSP-guided conformers was significantly better relative to the 
blind docking conformers [Figure 3.2]. In addition, molecular dockings for ligands with 
greater than five rotatable bonds typically showed better results with the CSP-guided 
docking. Flexible ligands added a significant amount of complexity to the AutoDock 
calculation that was simplified by applying a smaller search space. 
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Figure 3.2 Comparison of RMSD values of the docked ligand conformers relative to the 
original ligand conformation in the protein-ligand X-ray structure. AutoDock calculations 
used either CSP-guided docking without ADF filtering (green) or blind docking (red). 
Conformers within 2.2 kcal/mol of the lowest energy conformer were selected. 
 
Focusing a docking calculation into a smaller volume of the protein minimizes the 
search space for the ligand and allows the docking resources to be spent orienting the 
ligand into an energetically favorable position and conformation instead of finding the 
binding site. Using the binding site determined by CSPs to focus an AutoDock grid is 
expected to eliminate some of the inherent ambiguity in identifying the correct ligand 
pose since the uncertainty regarding the correct ligand binding site has been removed. 
3.3.3 Lowest-energy cluster is not necessarily the best conformer. Using a 
blind approach, AutoDock calculated a large number of clusters that are clearly outside of 
the know ligand binding site observed in the original X-ray crystal structure [Figure 3.3]. 
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For AutoDock, selecting the lowest-energy cluster and the most populated cluster were 
the two most common methods for identifying the most accurate conformers. In our 
analysis, the lowest-energy cluster represented the best docked conformers in 10 out of 
the 19 docking calculations performed (53% accuracy). The best docked cluster of 
conformers was only selected in 6 instances (32% accuracy) when the most populated 
cluster was used, and 5 of those were also the lowest-energy cluster. This caused a 
significant ambiguity in evaluating the accuracy of any particular protein-ligand 
costructure based solely on the AutoDock binding energy. However, it should be noted 
that AutoDock does generate at least one conformer out of the 120 conformers that is 
within 2.0 Å of the actual binding pose in 14 out of the 19  protein-ligand blind docking 
calculations. Thus, an accurate conformer is often generated by an AutoDock calculation, 
but the binding energy is not a reliable mechanism to identify the best conformer. 
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Figure 3.3 Surface representation of the ribosome-inactivating protein (PDB ID: 1MRG) 
with the lowest-energy adenosine conformer for each cluster calculated by AutoDock 
superimposed on the protein structure. The conformer with the lowest RMSD relative to 
the X-ray structure is colored yellow. Each cluster is labeled with the cluster ranking, the 
average binding energies, and standard deviation of the binding energies. 
 
One of the main reasons the lowest-energy cluster may not contain the most 
accurately docked conformer appears to arise from the low sensitivity of the AutoDock 
binding energy to identify distinct binding sites and ligand conformations. This is 
especially true when the relative differences in the binding energies between the clusters 
calculated by AutoDock are taken into consideration. A representative conformer for 
each cluster calculated by AutoDock for adenosine docked to the ribosome-inactivating 
protein (RIP, PDB-ID: 1MRG) is illustrated in [Figure 3.3]. A difference of only 0.83 
kcal/mol is observed between the lowest- and highest-energy clusters. This energy 
difference is significantly smaller than the 2.2 kcal/mol estimate for the error in the 
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AutoDock binding energy. Thus, the lowest-energy cluster is not appreciably different 
from the remaining clusters in the docking of adenosine to RIP. Specifically, an energy 
difference of only 0.43 kcal/mol is observed between the cluster with the lowest RMSD 
relative to those of the X-ray structure and the lowest-energy cluster. If the error in the 
AutoDock binding energy follows a normal distribution, this would partially explain why 
the correct conformer is not always present in the lowest-energy cluster. 
An additional reason the best conformer is not present in the lowest-energy cluster 
may be attributed to the protocol AutoDock uses to define members of a cluster. 
AutoDock selects the conformer with the lowest binding energy to represent the first 
conformer of the first cluster. Conformers that are within the RMSD tolerance of the 
lowest-energy conformer (2.00 Å for this study) are place in the first cluster regardless of 
binding energy. The remaining conformer with the lowest binding energy starts the next 
cluster that will include all of the remaining conformers within the RMSD tolerance. This 
continues until all of the conformers are placed in a cluster. Thus, the best conformer can 
easily be excluded from the first cluster, despite similar binding energies. 
Even though the conformers in any particular cluster are within 2.0 Å of each 
other, the binding energies can vary enough that some conformers in the lowest-energy 
cluster actually have a higher binding energy than conformers in other clusters. This 
again suggests that simply using the binding energy to select for the best pose is 
ambiguous and unreliable for any specific protein-ligand costructure. 
On the basis of our results, choosing the lowest-energy clusters in a blind docking 
will result in identifying an incorrect binding site and a wrong conformer 47% of the 
time. Interestingly, the lowest-energy cluster represents the best docked pose in 14 of the 
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19 docking calculations with CSP-guided docking. Again, this is a significant 
improvement relative to blind docking; however, an ambiguity in identifying the correct 
conformer still remains. A wrong conformer is still identified 26% of the time. This 
ambiguity can be remedied by also using the CSPs to further filter the docking results to 
select conformers that agree with the NMR experimental data. 
3.3.4 CSP-guided docking with ADF filtering. Our AutoDockFilter (ADF) 
program identifies the “best” conformer from an AutoDock calculation based on a 
consistency with the experimental CSPs. ADF replaces the ambiguous AutoDock binding 
energy with an NMR violation energy [Equations 3.1 and 3.2]. The ADF-selected 
conformer has a minimal distance between each protein residue with a CSP and the 
docked ligand. Filtering the CSP-guided docking with ADF consistently resulted in the 
identification of a cluster of conformers with a high similarity to the original X-ray 
costructure [Figure 3.4A]. This is a significant improvement in accuracy relative to the 
blind docking and the CSP-guided docking with ADF. It completely eliminates the 
ambiguity encountered by relying on the AutoDock binding energy. 
Obtaining an RMSD < 3 Å from an experimental protein-ligand structure was 
generally considered a good result in a docking calculation.72 The conformers selected 
from the CSP-guided docking with ADF filtering had RMSD averages of 1.17 ± 0.74 Å. 
These results are also significantly better than the conformers selected by CSP-guided 
docking without ADF filtering (2.02 ± 1.05 Å). The improvement is even more 
pronounced when compared to blind docking (12.91 ± 7.81 Å). [Figure 3.5] illustrates the 
improvement obtained using the CSP-guided docking with ADF filtering for each of the 
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19 protein-ligand structures. Thus, the CSP-guided docking with ADF filtering represents 
a significant improvement in rapidly obtaining accurate protein-ligand structures. 
Only one ligand docking exhibited an average RMSD of over 2.00 Å when guided 
and filtered using CSPs. The relatively large RMSD average and deviation for 
phosphonate docked to carboxypeptidase A (PDB-ID: 6CPA) occurs because the ligand 
is partially solvent exposed [Figure 3.4B]. In solution, this solvent exposed region of the 
phosphonate is probably ill-defined and adopts multiple conformations similar to the 
results seen with AutoDock. Therefore, the higher RMSD difference observed between 
the X-ray structure and the docked conformer is irrelevant because the X-ray structure 
simply represents one of many equivalent conformations. 
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Figure 3.4 Superposition of the CSP-guided docking with ADF filtering conformers 
(blue) with the original X-ray structures (yellow) for (A) benzamidine complexed with 
trypsin (PDB-ID: 3PTB), (B) a phosphonate complexed with carboxypeptidase (PDB-ID: 
6CPA), and (C) S. aureus nuclease complexed to thymidine 3’,5’-bisphosphate (PDB-ID: 
1SNC). The nuclease-thymidine 3’,5’-bisphosphate docked model is based on 
experimental NMR chemical shift data. 
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Figure 3.5 Comparison of RMSD values of the docked ligand conformers relative to the 
original ligand conformation in the protein-ligand X-ray structure. AutoDock calculations 
used the CSP-guided docking with ADF filtering (green) and (A) the CSP-guided 
docking without ADF filtering (red) or (B) blind docking (red). Conformers within 2.2 
kcal/mol of the lowest-energy conformer were selected for the CSP-guided docking 
without ADF filtering and blind docking. 
 
 137 
3.3.5 CSP-guided docking with ADF filtering using apoproteins. A ligand 
binding to a protein structure may result in significant changes in the protein structure. 
This is illustrated by the backbone or active-site RMSD differences observed between the 
19 apoprotein structures and the corresponding protein-ligand complexes (Table 3.1). A 
deviation as large as 2.48 Å was observed for the ligand binding site of β-amylase (PDB-
ID: 1BYB, 1BYA) when it binds glucose. Therefore, the accuracy of the conformers 
obtained using the CSP-guided docking with ADF filtering protocol was further 
evaluated using unbound structures. 
The AutoDock calculation and analysis was repeated using the 19 apoprotein 
structures following the identical procedure applied to the bound protein structures. The 
CSP-guided docking and ADF filtering with the apoproteins yielded results similar to 
those from the docking with the bound protein structures [Figure 3.6]. However, there 
were four examples where docking of the ligand to the unbound protein structure resulted 
in a ≥ 2.00 Å increase in the RMSD relative to the corresponding protein-ligand X-ray 
structure. The observed RMSD binding site differences between the bound and free 
protein structures did not solely explain these docking results (Table 3.1). In fact, the 
protein X-ray structures with the largest binding site changes upon ligand-binding did not 
necessarily yield significantly different docking results. 
 138 
 
Figure 3.6 Comparison of RMSD values of the best docked ligand conformers relative to 
the original ligand conformation in the protein-ligand X-ray structure. The AutoDock 
calculation was performed by docking the ligand to either the bound protein structure 
(green) or the free protein structure (blue). The calculations used CSP-guided docking 
followed by ADF filtering to select the best conformers. 
 
The worst docking results were seen with the free acetylcholinesterase structure 
(PDB-ID: 1QIF) that incurred a modest all atom deviation of 0.63 Å in the tacrine 
binding site between the bound and free X-ray structures. The best AutoDock-calculated 
tacrine conformer using the free acetylcholinesterase structure had a 3.91 Å RMSD from 
the original acetylcholinesterase-tacrine X-ray structure (PDB-ID: 1ACJ). This compared 
poorly to an average RMSD of 0.51 Å obtained for the tacrine conformers docked to the 
bound form of acetylcholinesterase. This large deviation in the docked tacrine conformers 
was due to the side chain of Phe330 flipping into the free acetylcholinesterase binding 
site and essentially blocking tacrine from binding deep into the ligand pocket [Figure 
3.7A]. The side-chain flipping of Phe330 is a known “gatekeeper” mechanism of ligand 
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binding to acetylcholinesterase.73 This steric hindrance due to side-chain dynamics 
appears to be a common source of docking error that was encountered using apoproteins. 
 
Figure 3.7 Comparison of tacrine docking to the free acetylcholinesterase structure 
(PDB-ID: 1QIF) using (A) static and (B) flexible acetylcholinesterase binding site 
residues. An overlay of the binding site residues (green) and tacrine (yellow) from the X-
ray acetylcholinesterase-tacrine structure (PDB-ID: 1ACJ) with the binding site residues 
(red) for the free acetylcholinesterase structure used for the AutoDock calculation with 
the resulting best docked tacrine conformation (blue). The RMSD’s between the docked 
and X-ray structure of tacrine using the static and flexible binding sites are 3.91 and 1.78 
Å, respectively. 
 
Importantly, the magnitude of the NMR violation energy provides a valuable 
measure of the inherent accuracy of the AutoDock results and an efficient means to 
identify these incorrectly docked structures due to protein mobility. A comparison of the 
NMR violation energy with the RMSD between the docked and X-ray ligand structures is 
shown in [Figure 3.8]. An NMR violation energy > 1500 is correlated with the poorly 
docked ligand conformers obtained with the apostructures. Therefore, obtaining a large 
NMR violation energy would call into question the reliability of the docked structure. 
This would imply that further analysis or a detailed dynamic simulation would be 
required in order to obtain an accurate docked protein-ligand costructure. Of course, the 
NMR violation threshold of 1500 is based on our simulated docking using empirically 
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determined CSPs. This threshold may change for protein-ligand costructures that are 
calculated using experimentally determined CSPs. 
Docking a ligand into a static protein structure is a common simplification to 
improve performance, but it is an assumption that can cause inaccuracies as observed 
above. AutoDock 4 attempts to alleviate the static receptor problem by incorporating 
side-chain flexibility in addition to the existing ligand flexibility. However, adding this 
additional flexibility significantly increased the AutoDock calculation time. Different 
ligand conformers needed to be evaluated against the various amino acid side-chain 
orientations in the binding site. AutoDock calculations using a static receptor required, on 
average, 37 ± 32 min. Conversely, an AutoDock calculation that docked tacrine into the 
free acetylcholinesterase structure allowing 7 amino acid side chains within the binding 
site to be flexible required 4.5 hours to complete. Despite the dramatic increase in 
calculation time, there was a significant improvement in the accuracy of the docked 
tacrine structure Figure 3.7B]. The RMSD of the docked tacrine structure relative to the 
original X-ray structure dropped from 3.91 to 1.78 Å [Figure 3.8]. 
3.3.6 Docking with experimental NMR data. While the analysis using 
empirically predicted chemical shift perturbations appeared to support the reliability of 
using CSP-guided docking and ADF filtering to rapidly obtain accurate protein-ligand 
costructures, a full evaluation of the methodology required an analysis with experimental 
chemical shift perturbation data. 1H and 15N chemical shift data for the free solution 
structure of staphylococcal nuclease64 and the complex with thymidine 3’,5’-
bisphosphate were readily available.65,66 Similarly, the X-ray structures of the unbound 
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(PDB-ID: 1EY0) and the complexed (PDB-ID: 1SNC) forms of staphylococcal nuclease 
were accessible through the PDB. 
Experimental CSPs may arrive from either a direct interaction with the bound 
ligand or indirectly through a protein conformational change that may occur distal from 
the ligand binding site. Thus, correct utilization of the CSPs to guide and filter an 
AutoDock calculation requires removing CSPs not resulting from a direct ligand 
interaction. In practice, CSPs greater than one standard deviation from the average CSP 
are mapped onto the protein surface to visually identify a consensus ligand binding site. 
This subset of CSPs is then used to guide the AutoDock grid for the docking calculation 
which is followed by ADF to select the best conformers based on consistency with these 
CSPs. 
The experimental staphylococcal nuclease CSPs were used to guide and filter the 
docking of thymidine 3’,5’-bisphosphate to the bound conformation of the protein 
[Figure 3.4C]. The best conformers using experimental CSPs had an average RMSD of 
1.63 ± 0.35 Å relative to the original nuclease-thymidine 3’,5’-bisphosphate X-ray 
structure with a corresponding average NMR violation energy of 681 ± 333. These results 
compared well to the thymidine 3’,5’-bisphosphate conformers obtained with the 
empirical CSPs, where an average RMSD of 1.58 ± 0.27 Å and an average NMR 
violation energy of 788 ± 409 were obtained. 
A similar comparison was observed for the docking of thymidine 3’,5’-
bisphosphate to the unbound nuclease structure (PDB-ID: 1EY0). The experimental CSPs 
generated conformers with an average RMSD of 1.96 ± 0.32 Å and an average NMR 
violation energy of 667 ± 449 where the empirically predicted CSPs resulted in 
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conformers with an average RMSD of 1.96 ± 0.31 Å and an average NMR violation 
energy of 914 ± 327. In effect, the experimental and empirical CSPs yielded essentially 
identical models of a nuclease-thymidine 3’,5’-bisphosphate costructure [Figure 3.8]. 
This suggested that the use of empirically predicted CSPs to evaluate the reliability of 
CSP-guided docking and ADF filtering method is a reasonable approach. Also, the results 
with the experimental staphylococcal nuclease data clearly indicated that the CSP-guided 
docking and ADF filtering method works equally well with experimental CSPs. It also 
suggests that an NMR violation threshold of 1500 may be applicable to identifying 
poorly docked structures using experimental CSPs since the NMR violation energies 
calculated for the nuclease-thymidine 3’,5’-bisphosphate costructure using experimental 
and empirical CSPs were similar. These results also demonstrate that the high accuracy 
obtained with the method is not simply an artifact of the empirical CSPs. 
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Figure 3.8 Comparison of the empirical NMR violation energy (logarithmic scale) 
against the corresponding RMSD for the best docked conformers using the bound form 
(circles) and the free form (squares) of the protein structure. The RMSD is relative to the 
ligand’s conformation in the original X-ray structure. The circled data points correspond 
to the docking results using the experimental CSPs for staphylococcal nuclease. The 
docking results for acetylcholinesterase (PDB-ID: 1ACJ, 1QIF) are highlighted yellow 
and are indicated with an arrow. The acetylcholinesterase results also include the flexible 
protein docking results (seven residues) using the free protein structure (triangle). 
 
  
3.4 CONCLUSIONS 
Combining experimental NMR chemical shift perturbations (CSPs) with 
AutoDock ligand docking calculations provides an efficient approach to rapidly obtain 
accurate (1.17 ± 0.74 Å) protein-ligand models. The CSPs are first used to guide an 
AutoDock calculation by defining the size and position of the AutoDock grid. The CSPs 
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are then used in combination with our AutoDockFilter (ADF) program to select the best 
conformer cluster consistent with the CSPs using an empirical NMR violation energy. 
ADF assumes a linear relationship between the magnitude of CSPs and the distance 
between the ligand and the protein residues that incurred the CSP. The NMR violation 
energy correlates with the accuracy of the docked structures obtained using the empirical 
CSPs and the S. aureus nuclease experimental CSPs, where an observed energy > 1500 
implies an unreliably docked structure. The poor docking generally occurred within 
apoprotein structures that required a conformational change to accommodate the bound 
ligand. Additional protein dynamics such as side-chain flexibility are required to improve 
the accuracy of these docked ligands. 
The docking method described typically requires 37 ± 32 min per protein-ligand 
complex. Since a 2D 1H-15N HSQC NMR experiment can be collected in ≤ 15 min, 
reliable and accurate protein-ligand costructures can by rapidly obtained in less than an 
hour. Thus, an efficient initial approach to structure-based drug discovery can be 
achieved by combining high-throughput NMR screening with CSP-guided and ADF-
filtered AutoDock calculations. Of course, X-ray or NMR structures will still be required 
as the project matures since further refinement of the chemical leads mandates a higher-
quality costructure than the 1-2 Å accuracy obtained by molecular docking. 
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CHAPTER 4 
AUTODOCKFILTER 2.0 AND CSP-CONSENSUS 
  
4.1 INTRODUCTION 
In Chapter 3, the theoretical principles behind the AutoDockFilter (ADF) program 
were described. This program was shown to be feasible as a technique to rapidly generate 
protein-ligand costructures using chemical shift perturbations (CSPs) from a 2D 1H-15N 
HSQC experiment to guide the docking process and then filter the resulting docked poses 
that best agree with those same CSPs.1 The ADF program proved to be effective in 
removing the ambiguity that results from the 2.2 kcal/mol estimate for the error in the 
AutoDock binding energy.1,2  
Unfortunately, the original ADF program was tested under ideal conditions on 
protein-ligand systems where the CSPs were calculated, with only one example, being 
tested on experimental CSPs. As is often the case when developing software, the 
application of the original ADF program during the FAST-NMR screens reported in 
Chapter 2 revealed some flaws that required addressing: (i) the use of absolute CSP 
magnitudes to calculate the pseudodistance, (ii) the difficulty of defining the consensus 
binding site, and (iii) the uneven number of CSPs within a proposed binding site.  
In order to address these problems, the ADF program was updated and underwent 
significant modifications. The new version of the program, AutoDockFilter 2.0 (ADF 
2.0), was written in Python (http://www.python.org). ADF 2.0 was designed to increase 
the usability and flexibility of the program. This included the incorporation of modifiable 
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parameters, the automatic output of the protein-ligand co-structure coordinate files, and 
easy implementation as a web-based program. 
As a companion to the ADF 2.0 program, another program, CSP-Consensus 
(CSPC), was developed to minimize the guesswork involved with defining a consensus 
binding site from CSPs. This program uses hierarchical clustering of the distances 
between perturbed residues in order to generate a dendrogram. The program can then use 
a distance cutoff based on the size of the ligand to define the consensus binding site. 
Importantly, the program generates a grid map file that encompasses the size and position 
of the consensus binding site for easy use in AutoDock. 
 
4.2 MATERIAL AND METHODS 
4.2.1 Modifications to AutoDockFilter 2.0. The primary modification to the 
AutoDockFilter program involved how the pseudodistances are calculated. The original 
ADF program generated specific pseudodistances based on the absolute magnitude of the 
CSPs. Unfortunately, this caused problems when dealing with ligand binding events that 
had smaller CSPs than average because of weak binding interactions. The presence of 
small CSPs would result in long pseudodistances when absolute magnitude of the CSPs 
was employed. These long pseudodistances were unlikely to be violated resulting in 
NMR violation energies equal to zero for all of the docked poses. This effectively 
rendered the filtering of the AutoDock poses useless. As discussed in Chapter 1 
[Equation 1.1], the magnitude of a chemical shift perturbation is related to the 
dissociation constant (KD) of the ligand and the concentration of the ligand.3 If a 2D 1H-
15N HSQC titration of protein-ligand pair that exhibited large CSPs were repeated with a 
 152 
smaller concentration of ligand, the absolute magnitude of the CSPs would decrease 
despite the fact that the ligand would be located in the same binding site with identical 
intermolecular distances. Therefore, using the absolute magnitude to determine the 
pseudodistance would only be useful under very specific and defined circumstances. 
Instead, a relative CSP was used to calculate a pseudodistance by comparing the CSP for 
each amino acid relative to each other CSP in the dataset. 
In ADF 2.0, the CSP magnitudes are converted to a pseudodistance (dCSP) as 
defined by a linear relationship between an upper and lower boundary (see eqn. 4.1). By 
default, ADF 2.0 uses 1.5 standard deviations from the median CSP magnitude to define 
the upper boundary (CSPU), while the median CSP magnitude is used to define the lower 
boundary (CSPL). The median is used instead of the mean to minimize the effect of 
extreme CSPs on defining the lower boundary. These boundaries are then converted to 
pseudodistances where the upper CSP boundary (CSPU) is set at a minimum 
pseudodistance of 3 Å (dmin) and the lower CSP boundary (CSPL) is set at a longer 
pseudodistance of 6.5 Å (dlong). These boundaries are used to calculate the 
pseudodistance (dCSP) for a specific CSP [Equation 4.1]: 
𝑑!"# = (CSP− 2CSP! − CSP!)CSP! − CSP!) (𝑑!"#$ − 𝑑!"#                                                                     (4.1) 
 As in the original ADF, 3 Å is the default minimum pseudodistance that is 
assigned, while there is no limit to the maximum pseudodistance. ADF 2.0 has built in 
scalable settings so that these boundaries and distances can be set to different values 
during execution. CSPs that exceed upper CSP boundary are considered extreme 
perturbations and are treated differently than in the original ADF program.  
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The original ADF program set these extreme CSPs to the minimum 
pseudodistance of 3 Å. An evaluation of the amino acid residues with extreme CSPs 
showed that the majority of these residues were not significantly closer to the ligand than 
the other residues with relatively normal CSPs. This was not too surprising as extreme 
CSPs were likely the result of the residue experiencing other significant factors that 
influence the magnitude of the CSP, such as electrostatics, and ring current effects.4 
Therefore, the filtering process should not bias the results towards these residues with a 
small pseudodistance. In order to address this issue in ADF 2.0, extreme CSPs can now 
be set to a specific distance value (the default is 5 Å).  
The new ADF 2.0 program also modifies the way the results are clustered by 
using a rank and file method similar to the clustering system used in the AutoDock 
program. The ligand poses are sorted from the lowest NMR violation energy to the 
highest. The first ligand pose is automatically assigned to the first cluster. The next pose 
is also assigned to the first cluster if its structural root mean squared deviation (RMSD) is 
less than a defined RMSD tolerance (default is 2 Å); otherwise, the pose becomes the 
first member of a second cluster. The process is continued for all remaining docked poses 
by comparing its structural RMSD to each cluster, and then either assigning the pose to 
the cluster with the lowest RMSD or forming a new cluster if the RMSD is not lower 
than the RMSD tolerance. 
In order to evaluate the beneficial impact of the new pseudodistance calculation 
and clustering process, the AutoDock results and calculated CSPs for the protein-ligand 
systems described in Chapter 3 were repeated using the new ADF 2.0 program. The 
results obtained from ADF 1.0 and ADF 2.0 were then compared. 
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In addition to the fundamental changes to the ADF program, several beneficial 
tools were added. ADF 2.0 now has the option to modify most of the parameters used in 
the filtering calculation. Additionally, ADF 2.0 automatically outputs the protein-ligand 
costructure of the lowest energy cluster. Additional options include outputting the 
structures of other clusters as well as the costructure with the lowest AutoDock binding 
energy. ADF 2.0 has also been made available as a web-based client (courtesy of Brad 
Worley). Both the source code and web-based client can be found at 
http://bionmr.unl.edu. 
4.2.2 Defining the binding site with CSP-Consensus. CSPs are commonly used 
as markers for identifying residues near to the bound ligand.5,6 Ideally, every residue 
within 6 Å of that ligand would exhibit significant chemical shift changes, and the 
binding site would be clearly identified. In practice, this is rarely observed. Chemical 
shift changes occur due to a change in the chemical environment of the residue. These 
changes may result from the proximity of a bound ligand, the formation or breaking of 
hydrogen bonds, perturbations in electrostatics, presence or absence of ring current 
effects, or an overall changes in the protein structure resulting from a binding event.4 
Therefore, not all significant CSPs observed are the result of proximity to the ligand nor 
do all residues near a bound ligand exhibit significant CSPs. This ultimately makes 
defining the binding site more difficult than just selecting the most perturbed residues. 
The program CSP-Consensus (CSPC) was developed in order to address this 
difficulty by selecting the residues with significant CSPs and identifying the residues that 
form a consensus binding site using the size of the ligand and hierarchical clustering 
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analysis. CSPC attempts to minimize the subjective nature of visually defining a binding 
site by mapping the perturbed residues to the surface of a protein. 
CSPC requires the input of the residues with significant CSPs as well as the 
protein and ligand structures. From the list of significantly perturbed residues, a distance 
matrix is created from the amide-to-amide distance between each residue. This distance 
matrix is then subjected to a centroid/UPGMC hierarchical clustering algorithm7, which 
starts by grouping the two residues with the smallest pairwise amide-amide distance. A 
node is placed at the centroid distance between these two points. This new node is then 
treated as a single cluster for the next comparison, which looks for the shortest distance 
from another residue or cluster to this centroid distance. This process continues until all 
the residues have been clustered. The final clusters are defined by setting a maximum 
cluster distance threshold, which is based on the size of the ligand. By default, this 
threshold is set to one-half of the longest distance between any atom in the ligand plus 6 
Å. This distance represents the possibility of clustering two perturbed residues that occur 
on opposite sides of the ligand. If no ligand file is input, the distance threshold is set to a 
default of 15 Å. The CSPC program outputs several files that include: (i) a results table, 
(ii) a dendrogram of the pairwise clustering, (iii) a CSP file to be used in ADF 2.0, and 
(iv) an AutoDock grid file with the size and location of the grid set around the clustered 
residues. 
4.2.3 Evaluation on protein-ligand systems with experimental CSPs. The 
evaluation of the ability of ADF 2.0 to guide and filter AutoDock results was performed 
using 8 protein-ligand complexes (Table 4.1) in the RCSB Protein Data Bank8,9 (PDB; 
http://www.rcsb.org) for which the chemical shifts of both the apo- and holo- forms of 
 156 
the protein were available in the Biological Magnetic Resonance Data Bank (BMRB; 
http://www.bmrb.wisc.edu). The ligands were removed from the protein-ligand complex 
and saved as a separate coordinate file. Any missing heavy atoms for the amino acid 
residues were added using UCSF Chimera10 (http://www.cgl.ucsf.edu/chimera). All 
hydrogen atoms were added to the protein and ligand using standard protonation states at 
pH 7.0. 
 
Table 4.1 RMSD comparison between the ligand-bound and unbound proteins 
 RMSD (Å)  
PDB ID full protein binding site binding site BMRB Entry 
bound/unbound backbone backbone all atom bound/unbound 
1AKE/4AKE11,12 8.257 3.063 3.541 5746/5720 
1EII/1B4M13,14 3.158 2.723 3.342 4682/4681 
1JKN/1F3Y15,16 4.163 1.883 2.676 5054/4448 
1JOK/1JOO17 5.092 0.902 2.725 494/495 
1JW5/1JW418 0.296 0.259 1.112 4987/4986 
1X6K/1SVJ19,20 1.755 0.661 1.724 6030/6029 
2B8G/2B8F 0.870 1.526 3.278 6599/6600 
2H3I/2H3F21 6.507 1.823 2.286 5960/7250 
 
Ligands were also docked into the apo-structures for each of the 8 protein-ligand 
complexes in order to evaluate the utility of this approach in the likely scenario that a 
holoprotein structure is unavailable. The backbone coordinates of the apoprotein were 
aligned with the holoprotein structure prior to the AutoDock calculation. The ligand 
conformation in the original holoprotein structure was then used to measure an RMSD 
between the docked ligand conformers calculated using both the apo- and holoprotein 
structures. 
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The NMR-predicted binding site for each protein complex was determined using 
the published 1H and 15N chemical shift data obtained from the solution structure of each 
protein in both the unbound and bound forms. The magnitude of the CSPs were 
calculated using a common weighting approach: 
 
𝐶𝑆𝑃 = 𝛿!5 ! + 𝛿!!2                                                                                                           (4.2) 
where δN and δH represent the changes in 15N and 1H chemical shifts, respectively, upon 
ligand binding.22 
 In order to evaluate the capabilities of ADF 2.0 to identify the docking 
conformers that most agree with the experimental CSPs, the binding sites of the proteins 
were first defined by determining all residues with an amide group within 6 Å of the 
ligand in the holoprotein structure. The CSPs for each of these residues is then used by 
ADF 2.0 to filter the molecular docking results. 
Unfortunately, identifying the binding site without prior knowledge would 
represent the most likely case for programs like AutoDock and ADF 2.0. Therefore, an 
evaluation of the ADF guiding and filtering process was performed using only knowledge 
of the chemical shifts for both the apo- and holoproteins. A preliminary binding site is 
determined by selecting residues with CSPs greater than one standard deviation from the 
mean. The residues that compose this preliminary binding site are then input into the new 
companion program, CSP-Consensus (described in section 4.2.2), to select a consensus 
binding site. The consensus binding site and the associated CSPs are then used to guide 
and filter the docking process. 
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AutoDock 4.2.323-25 with AutoDockTools 1.5.425,26 (http://mgltools.scripps.edu) 
graphical interface was used to simulate 120 different binding conformations for each 
protein-ligand pair. The grid maps were generated using 0.375 Å spacing and set to an 
appropriate size that encompasses all of the perturbed residues as well the size of the 
ligand. The docking calculations were performed using the Lamarckian genetic algorithm 
default settings with a population size of 300 and 2,500,000 energy evaluations. The 
results of each docked calculation were then input into the ADF 2.0 program using the 
default parameters. 
 
4.3 RESULTS AND DISCUSSION 
4.3.1 Modifications to AutoDockFilter 2.0. The new ADF 2.0 software 
incorporates a significant modification to the calculation of the pseudodistances from 
CSP magnitudes. Instead of using absolute CSP magnitudes, relative CSP magnitudes are 
used to account for the effects of weaker binders. A comparison between the results 
obtained with ADF 1.0 and ADF 2.0 using the original 19 protein-ligand systems 
described in Chapter 3 is shown in Figure 4.1. As expected, ADF 2.0 performs essentially 
equivalent to the original ADF program since the original dataset did not have an inherent 
scaling problem. The absolute CSP magnitudes from the original 19 protein-ligand 
dataset were equivalent in magnitude to the CSPs used to define the linear relationship 
between CSPs and intermolecular distances. This illustrates that the new pseudodistance 
calculations used in ADF 2.0 results in the same relative NMR violation energy for a 
given protein-ligand system. 
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Figure 4.1 Comparison of the RMSD values of the docked ligand conformers relative to 
the original ligand conformation in the protein-ligand X-ray structure. AutoDock 
calculations used the CSP-guided docking with filtering using the original ADF program 
(green) and the updated ADF 2.0 (red). ADF 2.0 does appear to mimic the success of the 
original program when dealing with calculated CSPs. 
 
However, the biggest effect of changing to a relative CSP magnitude in ADF 2.0 
is the comparison of NMR energies between protein-ligand systems. In Chapter 3, an 
obvious correlation existed between the NMR violation energy and the RMSD of the 
ADF-selected docked poses from the actual ligand pose found in the holoprotein 
structure. An NMR violation energy above 1,500 indicated an inaccurate result due to 
either poor docking results or structural changes between the free and bound versions of 
the protein. The use of relative CSP magnitudes in ADF 2.0 does appear to follow this 
same general correlation with regards to the calculated data [Figure 4.2]. But a clear 
distinction between a correct and incorrect model is not as clearly apparent.  
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Figure 4.2 Comparison of the NMR violation energy (logarithmic scale) against the 
corresponding RMSD for the best-docked conformers using calculated CSPs and the 
bound/free (circle/square) forms of the protein structure. The RMSD is relative to the 
ligand's conformation in the original X-ray structure. The red data points correspond to 
the docking results using the experimental CSPs for staphylococcal nuclease. Error bars 
represent variability within the best cluster selected by ADF 2.0. 
 
 
4.3.2 Defining the binding site with CSP-Consensus. The CSPC program 
attempts to objectively evaluate whether residues exhibiting significant CSPs should be 
clustered together to define a consensus binding site using the size of the ligand and 
distance between each perturbed residue. The CSPC program outputs a dendrogram 
where the distance between each cluster represents the pairwise distance between the 
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centroids. A threshold distance that is based on the size of the ligand is then used to set 
the cutoff for the final cluster size. 
The clustering technique used by CSPC is effective at clustering together 
perturbed residues that would visually appear to define a consensus binding site [Figure 
4.3A,B]. In the case of thymidine-3’,5’-bisphosphate (THP) binding with staphylococcal 
nuclease, 14 of the 15 residues that exhibited significant CSPs would be clustered 
together based on amide-amide distances. The excluded residue (Tyr 54) is 18.63 Å from 
the centroid of the other 14 residues. This would suggest that THP, with a length of 10.6 
Å, is unlikely to cause a perturbation in Tyr54 due to proximity while also causing a 
similar perturbation to the 14 other residues. 
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Figure 4.3 (A) A dendrogram of amino acid residues in staphylococcal nuclease (SNase) 
that show a significant chemical shift perturbation upon binding of thymidine-3’,5’-
bisphosphate (THP). The residues are clustered using the centroid/UPGMC hierarchical 
clustering algorithm. Amino acids are placed in the same cluster if the node connecting 
two or more residues/clusters falls under a specified distance threshold that is defined by 
the size of the ligand causing the perturbation (green). In this case, Tyr54 (blue) is above 
the distance 11 Å distance threshold and is placed in its own cluster. (B) A representation 
of THP bound to SNase with the residues identified in the CSP-Consensus dendrogram 
are mapped onto the surface of the protein. Tyr54 (blue) is clearly separated from the 
consensus of perturbed residues and is excluded. 
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While these 14 residues are clustered together to form a consensus binding site to 
be used for guiding and filtering AutoDock, only 8 of these residues are within 6 Å of the 
correct ligand pose. While those 6 “extra” residues would make the AutoDock grid size 
bigger, the real concern involves the bias these “distant” residues may have on the 
filtering process. However, when dealing with protein-ligand systems where the 
holoprotein structure is not known, there is no foolproof way to exclude these 6 residues. 
It would be possible to combine information of predicted consensus binding site residues 
from CSPC and residues in predicted binding cavities from programs like CASTp27 or 
ConSurf28 to eliminate these residues. 
4.3.3 Evaluation on protein-ligand systems with experimental CSPs. Because 
the development of the original ADF program, the availability of both apo- and 
holoprotein solution structures has allowed for the further evaluation of ADF using 
experimentally determined CSPs. The results of ADF 2.0 filtering on 8 distinct protein-
ligand systems with experimental data were evaluated using two approaches. In the first 
approach, the CSPs used to define the binding site were selected based on which residues 
are known to be within 6 Å of the correct pose. This approach includes residues that 
would not be considered to have significant CSPs, and is intended to illustrate the 
capabilities of ADF 2.0 to filter the AutoDock results with the ideal binding site. The 
second evaluation explored the capabilities of ADF 2.0 filtering under experimental 
conditions where the binding site is determined based on only those residues that exhibit 
significant perturbations and form a consensus cluster in CSPC. Both of these approaches 
were then compared to the ligand pose AutoDock suggests is best based on binding 
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energy (first AutoDock cluster) as well as the best pose generated by AutoDock that 
agrees most with the correct ligand pose [Figure 4.4]. 
 
 
Figure 4.4 Comparison of the RMSD values of the docked ligand conformers on the 
bound protein relative to the original ligand conformation in the protein-ligand NMR 
structure. The best possible docked pose calculated by AutoDock (blue) is compared to 
the docked poses with the best AutoDock binding energy (red), the best-docked poses 
selected by ADF 2.0 using the CSPs of the known binding site (purple), and the best-
docked poses selected by ADF 2.0 using experimentally determined binding sites (green). 
Error bars represent variability within the best cluster selected by either AutoDock or 
ADF 2.0. 
 
As indicated in Chapter 3, AutoDock is pretty effective at generating a docked 
pose that is close to the correct ligand pose (1.52 ± 0.61 Å RMSD). This is especially 
remarkable because only three of the protein-ligand systems (1eii, 1jok, 2b8g) have 
ligands with less than 10 torsional degrees of freedom, and one system (1ake) has a 
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ligand with 22 torsional degrees of freedom. However, when AutoDock ranks these 
docked poses by binding energy, the best-docked pose (first AutoDock cluster) is often 
not selected (4.40 ± 2.42 Å RMSD). This is likely due to the inherent error of 
approximately 2.2 kcal/mol when AutoDock calculates a binding energy.2  
ADF 2.0 improves upon the results of AutoDock in almost every case when the 
best ADF 2.0 pose (first ADF 2.0 cluster) using the ideal binding site is selected (3.53 ± 
1.71 Å RMSD). However, the best ADF-predicted costructures for 1eii and 1jkn still had 
poor RMSD values. A visual inspection of these costructures show that the poor RMSD 
values are the result of a flipped ligand pose being selected. This is not unexpected as 
ADF only evaluates the minimum distance from any atom in the ligand to the amide of 
the residues; it does not specify that a particular ligand atom must be near the residue. 
This leads to flipped ligands that have small NMR violation energies. While this is not 
ideal for predicting ligand poses for a drug discovery effort, it does not hinder the ability 
of ADF 2.0 to predict the binding site that could then be compared to other binding sites 
for functional annotation using FAST-NMR and CPASS as described in Chapter 2. If 
these ligand poses were flipped back, the average RMSD would significantly improve to 
an RMSD of 2.25 ± 0.60 Å. 
ADF 2.0 still improves upon the results of AutoDock when using ligand-defined 
binding sites from experimental CSPs (2.92 ± 1.02 Å RMSD). As previously described, 
experimentally-defined binding sites may include residues that are not within 6 Å of the 
correct ligand pose. These residues at the edge of the predicted ligand binding site may 
bias the filtering of the AutoDock poses. This is exactly the case with the best ADF pose 
for 1jw5, where the extra residues from the experimentally-defined binding site had 
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greater perturbations compared to the residues of the ideal binding site. This effectively 
shifts the selection of the best ADF pose closer to the extra residues with greater CSPs. 
Despite this observation, the filtering results for ADF 2.0 still significantly improved 
upon the best-docked structures predicted by AutoDock without ADF. 
The new ADF 2.0 has also been show to improve upon the AutoDock results 
when using CSPs to dock a ligand into an apoprotein structure. [Figure 4.5]. The best-
docked pose generated by AutoDock using an apoprotein structure has a higher RMSD 
relative to the correct docked pose from the holoprotein structure (3.33 ± 0.93 Å RMSD). 
This difference is likely a result of errors associated from aligning the bound and 
unbound forms of the structure as well as any structural differences in the binding site. 
Again, the best-docked poses predicted by AutoDock using only binding energies fails to 
correlate with the correct ligand pose in the holoprotein structure (8.92 ± 4.84 Å RMSD). 
While some of this failure is due to structural differences between the bound and 
unbound forms, four of the predicted poses have an RMSD of upwards of 16 Å. The ADF 
2.0 predicted poses are essentially equivalent to or significantly better than the AutoDock 
predicted poses (5.68 ± 1.94 Å RMSD), yet these results are consistently worse than the 
results seen using the bound form of the protein. The structural differences between the 
apo- and holo- structures can affect several factors such as: (i) correctly defining the 
consensus binding site, (ii) side chain residues sterically hindering access into the binding 
site, (iii) distances between perturbed residues may be further apart in the apostructure, 
increasing the NMR violation energy for the correct pose. These factors appear to have a 
significant effect on the results of the docking and filtering. Thus, using an apostructure is 
more likely to lead to a lower accuracy costructure due to the rigid nature of the protein 
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during docking. Unfortunately, this issue can only really be addressed by implementing 
fully flexible proteins into the docking process or utilizing protein structure ensembles, 
which comes with its own share of difficulties.1,29-32 
 
 
Figure 4.5 Comparison of the RMSD values of the docked ligand conformers on the 
unbound protein relative to the original ligand conformation in the protein-ligand NMR 
structure. The best possible docked pose calculated by AutoDock (blue) is compared to 
the docked poses with the best AutoDock binding energy (red), and the best-docked 
poses selected by ADF 2.0 using experimentally determined binding sites (green). Error 
bars represent variability within the best cluster selected by either AutoDock or ADF 2.0. 
 
 The NMR violation energies when evaluated with the experimental data indicate 
that there is no real trend between an absolute NMR violation energy and RMSD from 
correct pose when comparing different protein-ligand systems [Figure 4.6]. Essentially, 
the NMR violation energy has little value outside the particular protein-ligand system 
being investigated. This is not too surprising since experimental binding sites will include 
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some extraneous residues and may be missing other relevant residues. Additionally, CSPs 
are not solely affected by proximity, so the relative perturbation of a residue in one 
protein-ligand system does not necessarily have the same pseudodistance in another 
protein-ligand system despite a similar relative perturbation. This effectively eliminates 
the utility of using the NMR violation energy as a direct evaluation of the accuracy of the 
predicted costructure. However, there may still be value in the NMR violation energy 
with respect to the identity of residues with significantly violated pseudodistances. The 
per residue violation energy may indicate residues that should be excluded from the 
binding site definition or residues that should be defined as conformationally flexible in 
the AutoDock simulation.  
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Figure 4.6 Comparison of the NMR violation energy (logarithmic scale) against the 
corresponding RMSD for the best-docked conformers using the experimental CSPs of the 
known binding site (blue circle) and the experimentally predicted binding site using the 
holoprotein structure (red square) and apoprotein structure (yellow triangle). The RMSD 
is relative to the ligand's conformation in the original NMR structure. The yellow points 
and arrows represent the corrected RMSD and NMR violation energy for the docked 
poses that are flipped. Error bars represent variability within the best cluster selected by 
ADF 2.0. 
 
 
4.4 CONCLUSIONS 
AutoDockFilter has previously demonstrated the benefits of using chemical shift 
perturbations from a 2D 1H-15N HSQC NMR experiment to guide and filter the results of 
docking calculations from AutoDock. AutoDockFilter 2.0 builds upon the success of the 
original program by implementing the use of relative CSP magnitudes to calculate the 
pseudodistance while adding features to expand the usability and flexibility of the 
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program. AutoDockFilter 2.0 was able to identify accurate protein-ligand costructures 
using CSPs from the ideal binding site (2.25 ± 0.60 Å RMSD) and the experimentally 
determined binding site (2.92 ± 1.02 Å RMSD). This is a definite improvement over the 
best protein-ligand costructures predicted by AutoDock alone (4.40 ± 2.42 Å RMSD). 
Additionally, a companion program, CSP-Consensus, was developed in order to address 
the difficulties of determining a consensus binding site. CSP-Consensus calculates 
amide-amide distances between perturbed residues and uses hierarchical clustering and 
the size of the ligand to identify the residues that best represent a consensus binding site. 
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CHAPTER 5 
EVALUATION OF FUNCTIONAL SIMILARITY WITH CPASS 2.0 
  
5.1 INTRODUCTION 
 Determining the structural and biochemical functions of proteins is essential to 
our understanding of biology and the potential application for medical advances. The 
success of the various genome projects1,2 is rapidly increasing the number of known 
protein sequences (~27,000,000) in the UniProtKB database.3,4 Obviously, an 
experimental determination of a function for each of these proteins is not feasible, thus, 
computational approaches are often used to annotate the function based on global 
sequence or structural homology to proteins with an experimentally determined function.5 
Despite this approach, nearly 40% of these proteins are still functionally unannotated. 
The molecular function of a protein is often defined by the structural arrangement 
and chemical properties of the amino acids that interact with a functionally relevant 
molecule. This binding site, or active site, tends to be more evolutionarily stable than the 
rest of the protein. Correspondingly, proteins with a similar function would likely also 
have similar active sites.6 There are several computational tools that attempt to predict the 
location of a protein active site by finding common sequence motifs,7,8 ligand 
“hotspots”,9 structural cavities/clefts,10-12 evolutionarily conserved residues,13-16 similar 
molecular surfaces, 17 or structural motifs.18-20 However, the predictive nature of these 
approaches often leads to the identification of ambiguous binding sites, which makes 
functional characterization difficult. 
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 The Comparison of Protein Active Site Structures (CPASS; 
http://cpass.unl.edu)21,22 program is used in conjunction with the FAST-NMR23,24 
methodology (described in Chapter 2) to compare the sequence and structure of an 
experimentally-determined binding site to a database of binding sites in order to elucidate 
a functional relationship. Because CPASS defines a binding site as every amino acid 
residue within 6 Å of a bound ligand, a comprehensive database of binding-sites can be 
created from the protein-ligand costructures found in the RCSB Protein Data Bank25,26 
(PDB; http://www.rcsb.org). Therefore, a CPASS calculation performs an exhaustive 
search, where a comparison occurs between the query binding site and every unique 
binding site from the PDB. 
 The CPASS program and database has been recently updated to version 2, which 
adds significant enhancements that reduce the time to run a calculation to ~1 hour, 
improves the user interface, and increases the size of the CPASS database to ~36,000 
distinct binding sites.22 Additionally, the CPASS v2.0 similarity function has been 
modified to included three new features that enriches the selection of similar active sites: 
(1) a comparison of the solvent accessible surface area (SASA) of the aligned residues; 
(2) the root mean square different (RMSD) between the two bound ligands in the active 
site; and (3) the addition of the Cβ position to the distance calculation between aligned 
residues.22  This chapter focuses on the enhanced capabilities of CPASS v2.0 to identify 
similar protein active sites; and the potential effect of experimental variability on the 
reliability of the CPASS similarity score. Additionally, CPASS v2.0 was used during the 
functional annotation of 21 proteins of unknown function (described in Chapter 2), and 
the overall trends are reported here. 
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5.2 MATERIAL AND METHODS 
5.2.1 Evaluation of CPASS functional similarity. Evaluating the reliability of 
CPASS to identify a functional homolog requires a quantitative approach to define 
functional similarity, which is difficult to determine.27  Gene Ontology (GO) terms28 are 
currently the most common approach to functional annotation, but they are often 
incomplete, generic, and often dependent on global sequence homology. Conversely, the 
Enzyme Commission (E.C.) classification,29 provides a well-defined, hierarchical 
approach to define functional similarity between enzymes due to its focus on enzyme 
activity. Thus, E.C. was chosen to evaluate the ability of CPASS to identify functional 
homologs. 
The capabilities of CPASS v2.0 were evaluated using two different proteins with 
enzymatic activity: aspartate transaminase (PDB: 1yaa; E.C. 2.6.1.1);30 and glutamine-
tRNA ligase (PDB: 1gtr; E.C. 6.1.1.18).31 The ligand binding site from each protein 
structure was compared against the entire CPASS database of ~36,000 ligand-defined 
binding sites using the default CPASS v2.0 parameters, which includes the new additions 
to the similarity function of ligand RMSD, solvent accessible surface area, and the Cβ 
position within the distance calculation. 
Three different methods were used to define what constitutes as a functionally 
similar active site (true positive). The first method only considered proteins with the same 
E.C. classification (i.e., all four E.C. numbers are identical) as true positives. The second 
method used a broader definition of E.C. classification (i.e., only the first three E.C. 
numbers are identical). The third method used a very broad definition of functional 
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homology by defining all active sites that bind the same ligand as the query protein as 
being functionally similar. Receiver operating characteristics (ROC) curves (described in 
Chapter 1) were generated using the three different definitions of a true positive. The true 
positive rates were plotted against false positive rates over the full range of CPASS 
similarity scores. In addition, distribution curves were used to plot the fraction of 
negatives and positives at each CPASS similarity score using a bin size of 10. The 
fraction simply corresponds to the number of positives or negatives per bin relative to the 
total number of positives or negatives.  
5.2.2 Tolerance of active-site variations. CPASS was designed to compare 
ligand binding sites. Ideally, most ligand binding sites would be identified from an 
experimentally determined protein-ligand costructure, but that approach is not always 
available. In some cases, the location of the ligand binding site may be inferred from 
other sources, such as site-directed mutagenesis, NMR chemical shift perturbations, 
bioinformatics, or computer modeling. However, these approaches may introduce 
variations in the location of the binding site that would negatively affect the CPASS 
comparison. 
In many cases, models of protein-ligand costructures are generated from NMR or 
X-ray structures of the unbound form of the protein. However, many proteins undergo 
significant structural changes upon the binding of a ligand, which may lead to significant 
changes in the binding site of the protein. Since the CPASS database is generated from 
experimentally determined protein-ligand costructures from the PDB, CPASS 
comparisons to ligand-defined binding sites using the unbound protein structure could 
hinder the ability of CPASS to identify a similar binding site. Therefore, comparing a 
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ligand-defined binding site using the unbound protein structure may hinder the ability of 
CPASS to identify a similar binding site. 
To evaluate the effect that structural changes in the bound and unbound forms of 
the protein may have on the CPASS comparison, 10 proteins with known bound and 
unbound structures (Table 5.1) were selected from the PDB for comparison in CPASS. 
The bound and unbound forms of the protein were structurally aligned in UCSF 
Chimera32 (http://www.cgl.ucsf.edu/chimera). After the alignment, the coordinates of the 
ligand in the bound protein structure were added to the unbound protein structure. 
CPASS calculations with default parameters were performed on both the bound structure 
and unbound structure with the added ligand coordinates. 
 
 
Table 5.1 RMSD and residue comparison between the ligand-bound and unbound 
proteins 
 RMSD(Å) number of 
PDB ID binding site binding site binding site residues 
bound/unbound backbone all atom bound/unbound (matched) 
1AKE/4AKE33,34 3.063 3.541 67/42 (27) 
1EII/1B4M35,36 2.723 3.342 45/42 (33) 
1JKN/1F3Y37,38 1.883 2.676 31/19 (18) 
1JOK/1JOO39 0.902 2.725 19/20 (19) 
1JW5/1JW440 0.259 1.112 21/21 (21) 
1MX8/1MX7 1.565 2.323 39/37 (35) 
1X6K/1SVJ41,42 0.661 1.724 35/32 (30) 
2B8G/2B8F 1.526 3.278 10/10 (10) 
2H3I/2H3F43 1.823 2.286 31/33 (30) 
2K0X/2K0Y 0.920 2.362 11/13 (11) 
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In addition to the structural differences between the bound and unbound forms of 
the protein, determining the exact location, or pose, of the ligand with respect to the 
protein can introduce additional variability when compared to an experimentally 
determined protein-ligand costructure. Because CPASS defines the ligand binding site for 
a protein as any residue within 6 Å of the ligand, the location of the ligand is important. 
Tools like NMR chemical shift perturbations and molecular docking can be combined to 
improve the accuracy of the ligand pose (as seen in Chapter 3 and Chapter 4); however, 
trying to predict the exact ligand pose is still very challenging.  
The effect of the variability of a ligand’s pose was evaluated by redocking 
maltose into the bound form of maltodextrin-binding protein (PDB ID: 1ANF).40 
AutoDock 4.2.344-46 with the AutoDockTools 1.5.446,47 (http://mgltools.scripps.edu) 
graphical interface was used to simulate 100 different ligand poses for maltose docked 
with the maltodextrin-binding protein. The docking calculation was done using the 
Lamarckian genetic algorithm with default parameters. From the results of this 
calculation, 5 poses were selected to represent increasing variation from the correct pose 
found in the bound protein structure [Figure 5.1]. The coordinates of these 5 poses were 
then added to the bound structure file. The maltose-maltodextrin-binding protein docked 
model was then submitted to CPASS using default parameters. 
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Figure 5.1 An illustration of docked maltose in the binding pocket of maltodextrin-
binding protein (PDB: 1JW5). The experimental ligand conformation (yellow) is 
compared to 5 docked ligand poses of decreasing accuracy to the correct structure: 1.50 
Å RMSD (blue); 2.02 Å RMSD (red); 3.27 Å RMSD (green); 4.81 Å RMSD (purple); 
and 6.77 Å RMSD (orange). 
 
In many cases where the protein has an unknown function, the identity of the 
molecule(s) that interact with that protein is also unknown. High-throughput screens of a 
compound library are often used to help identify molecules that show specific binding to 
the protein in question. Depending upon the composition of the compound library, 
compounds that are shown to be binders are probably not the natural ligand for the 
protein in vivo. However, these compounds often have similar physicochemical features 
to the natural ligand, but some differences in the binding pose of the ligand would be 
expected. CPASS does not directly use the ligand in the database search, but it does 
define the size of the ligand binding site.  Thus, the identity of the ligand may affect the 
CPASS outcome.  
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In order to test the effect of ligand size on CPASS performance, two larger 
saccharides similar to maltose, 3-glucose amylose and 4-glucose amylose, were also used 
to define the ligand binding site for a CPASS search. 3-glucose amylose and 4-glucose 
amylose were docked to the bound form of maltodextrin-binding protein40 using 
AutoDock and the same docking parameters described above. From each of the docking 
calculations, 5 unique poses were selected that show significant overlap with the true 
binding pose of maltose, but also exhibited an extension in the size of the ligand binding 
site [Figure 5.2A,B]. These unique poses were then submitted to CPASS for evaluation. 
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Figure 5.2 An illustration of the experimental pose of maltose (yellow) and 5 docked 
poses of (A) 3-glucose amylose and (B) 4-glucose amylose in the binding pocket of 
maltodextrin-binding protein (PDB: 1JW5). The docked poses of each sugar were 
selected based on a similarity to the original maltose pose and sampling of unique space 
around the maltose binding site. 
 
5.2.3 CPASS comparisons of proteins of unknown function. To date, most of 
the evaluations of CPASS used well-characterized proteins of known function, where a 
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correct result was known and could be found by CPASS. Additionally, CPASS has 
previously contributed towards the functional annotation of a few other proteins with 
unknown functions: Staphylococcus aureus protein SAV1430,23 Pseudomonas 
aeruginosa protein PA1324,48 Pyrococcus horikoshii protein PH1320,24 Homo sapiens 
protein Q13206,24 and Salmonella typhimurium protein PrgI.49 However, evaluating the 
performance of CPASS under experimental conditions similar to FAST-NMR is 
necessary for the continued improvement of the program. 
Twenty-one proteins of unknown function from the Northeast Structural 
Genomics Consortium (NESG; http://www.nesg.org) were screened using the FAST-
NMR approach (see Chapter 2), which resulted in the identification of compounds shown 
to bind to each protein and the generation of protein-ligand costructures using a guided 
and filtered molecular docking approach (see Chapter 3 and Chapter 4). The 
experimentally determined, ligand-defined binding sites from these costructures were 
then compared to other ligand-defined binding sites from the PDB using CPASS v2.0. 
  
5.3 RESULTS AND DISCUSSION 
5.3.1 Evaluation of CPASS functional similarity. Receiver operating 
characteristics (ROC) curves for the CPASS calculations of aspartate transaminase 
[Figure 5.3A] and glutamine-tRNA ligase [Figure 5.3B] illustrate the overall ability of 
CPASS to identify true positives relative to false positives. The straight-line in the graph 
indicates the expected results if the CPASS predictions were completely random. Curves 
that approach the upper-left of the graph indicate better performance of the method to 
select true positives from the database based on CPASS similarity scores. As apparent in 
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[Figure 5.3A,B], the enrichment in the ROC curves and the corresponding improvement 
in CPASS performance follow the increasing strictness in the functional classification of 
true positives. The ROC curves, where true positives are based on identical E.C. 
numbers, is essentially ideal. The ROC curve based on a broader E.C. similarity (only the 
first three numbers are identical) performs worse than the ROC curves of the stricter E.C. 
classification. However, this is still an improvement over the ROC curves that are 
generated when true positives are based only on proteins binding the same ligand. These 
results are not surprising since a stricter classification of function minimizes the number 
of proteins that are incorrectly characterized as true positives. It is important to note that 
in all cases the number of true positives based on identical E.C. numbers for both proteins 
is extremely small (2 – 28) relative to the size of the CPASS database (~36,000), even for 
proteins that are well represented in the PDB. This occurs because the CPASS database 
has been deliberately filtered to remove identical or highly similar ligand-binding sites.  
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Figure 5.3 ROC curves showing the true positive rate relative the false positive rate of 
CPASS calculations for (A) aspartate transaminase (E.C. 2.6.1.1) and (B) glutamine-
tRNA ligases (E.C. 6.1.1.18). True positives are defined based on three levels of 
functional homology between the query protein and the CPASS database: true positives 
have exact same E.C. classification (blue); true positives have first three E.C. numbers 
being identical (red); and true positives have same binding ligand (green).  
 
The high CPASS performance is also illustrated by the distribution of the true 
positives and true negatives as a function of CPASS scores for both aspartate 
transaminase [Figure 5.4A] and glutamine-tRNA ligase [Figure 5.4B], which indicate 
that true negatives peak at a CPASS score of ~10%. True positives have a range of 
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CPASS scores, but a threshold of ~20 – 30% is expected to identify the majority of 
functionally homologous proteins, while excluding essentially all of the true negatives. 
 
 
Figure 5.4 Distribution curves showing the fraction of negatives (red) and positives 
(blue) as a function of CPASS similarity scores (bin size of 10%) for (A) aspartate 
transaminase (E.C. 2.6.1.1) and (B) glutamine-tRNA ligases (E.C. 6.1.1.18). 
 
5.3.2 Tolerance of active-site variations. Ten proteins with known bound and 
unbound structures were evaluated with CPASS. The RMSD between the bound and 
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unbound backbone amino acid residues ranged from a small difference (0.259 Å) up to 
significant difference (3.063 Å). Superimposing the ligand coordinates of the bound 
protein structure into the unbound protein structure allowed for a comparison of ligand-
defined binding sites using CPASS. The CPASS similarity scores for the first functional 
match (true positive) and the first functional non-match (false positive) were compared 
between the bound and unbound binding sites. The difference in CPASS similarity score 
for both was plotted against the active site backbone RMSD [Figure 5.5]. It is not 
surprising to see that as the structural differences between the binding sites of the bound 
and unbound proteins grows, the CPASS similarity score for the first functional match 
decreases. As the RMSD between the binding sites reaches ~2.0 Å, the CPASS similarity 
score typically drops by at least 10%. For an RMSD greater than 2.0 Å, the CPASS score 
can change even more drastically, where a decrease in the CPASS similarity score of 
almost 60% occurred for an RMSD of ~3.0 Å. While the first functional non-match 
typically had improved CPASS similarity scores for the unbound binding site, the 
CPASS scores did not increase with increasing RMSDs. In other words, functional non-
matches (false positives) are unlikely to have a significantly high CPASS similarity score 
when using the unbound form of the protein. Instead, the CPASS similarity scores for the 
true positives decrease. Thus, the gap between the similarity scores of a true positive and 
a false positive will diminish with an increase in the structural difference between the 
bound and unbound forms. It is actually possible for the true positive to score much lower 
than the false positive. 
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Figure 5.5 Comparison of the difference in CPASS similarity scores for the first 
functionally similar result (blue square) and the first functionally dissimilar result (red 
circle) using the original protein-ligand costructure and the unbound costructure with the 
ligand superimposed. 
 
The location of the bound ligand can also have an effect on the CPASS similarity score. 
In the case of maltodextrin-binding protein, the maltose ligand was redocked into the 
bound protein structure. The comparison between the RMSDs of the correct ligand pose 
and 5 docked ligand poses to the CPASS similarity scores of the first functional match 
(true positive) and first functional non-match (false positive) illustrates the importance of 
the ligand conformation [Figure 5.6]. Identifying a correct functional match declines as 
the ligand conformation gets further from the correct ligand pose. Once again, the effect 
on the CPASS scores for functional non-matches is not significantly influenced.   
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Figure 5.6 Comparison of CPASS similarity scores for the first functionally similar 
result (blue square) and the first functionally dissimilar result (red circle) against the 
RMSD of the docked maltose from the correct maltose pose in maltodextrin-binding 
protein (PDB: 1JW5). 
 
Similar to ligand location, ligand size also influences the ligand-defined binding 
site, and, correspondingly, the CPASS similarity score. Docking a 3-sugar and 4-sugar 
amylose into the binding site of the maltodextrin-binding protein, allows for the 
evaluation of using larger ligands in a CPASS search. The ligand-defined binding site 
will likely include additional residues, which increases the number of residues to match. 
If these additional residues are not functionally relevant and are unmatched in a 
functional homolog, it will decrease the CPASS similarity score.  The CPASS similarity 
scores for the first functional match (true positive) and functional non-match (false 
positive) was compared to the percentage of residues in the larger binding sites that 
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match the original protein-ligand costructure binding site [Figure 5.7]. As expected, the 
CPASS similarity score decreased with the increasing, irrelevant size of the ligand 
binding site. It should be noted that the CPASS similarity scores for the functional non-
matches is also reduced. Unfortunately, the decrease in the CPASS similarity score for 
functional matches is more pronounced and leads to a smaller gap in the similarity scores 
between true positives and false positives. 
 
 
Figure 5.7 CPASS similarity scores for the first functionally similar result (blue) and the 
first functionally dissimilar result (red) as a function of the percent similarity in the 
ligand-binding site query. The active site residue match corresponds to the percentage of 
the residues in the 3-glucose amylose (square) and 4-glucose amylose (circle) defined 
ligand-binding site that are the same as the ligand-defined binding site from the original 
maltose-bound protein (PDB: 1JW5). Five unique poses of the docked 3-glucose amylose 
and 4-glucose amylose are shown. 
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All three evaluations illustrate that any change to the ligand-defined binding site 
has an effect on the CPASS similarity score. The degree of the effect is primarily 
dependent upon the size of the query’s binding site. An increase in the number of 
residues in the binding site leads to a higher CPASS reference score, the sum of the 
CPASS similarity function scores for each residue in the query's binding site when 
compared to itself. Comparing the CPASS reference score for the binding sites of the 10 
bound and unbound proteins with the resulting CPASS similarity score shows that 
smaller binding sites have a smaller separation between true positives and false positives 
[Figure 5.8]. The CPASS similarity score for functionally similar binding sites is not 
dependent on the size of the ligand binding site, as long as the ligand-binding site is 
accurately defined. Interestingly, the size of the binding site does exhibit a trend in 
CPASS similarity scores when evaluating functionally dissimilar binding sites. Smaller 
binding sites tend to have higher CPASS similarity scores for functionally dissimilar 
proteins. Simply, the smaller number of residues in the query binding site have a higher 
probability of finding a match to a functionally unrelated protein with a large binding 
site. A few residues may serendipitously share a similar spatial arrangement. 
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Figure 5.8 Comparison between the ligand-binding site size dependent CPASS reference 
score and the CPASS similarity score. The first functionally similar (blue square) and 
first functionally dissimilar (red circle) results are shown. 
 
5.3.3 CPASS comparisons of proteins of unknown function. The true 
biological function of the proteins investigated with FAST-NMR in Chapter 2 is 
unknown. Thus, a direct evaluation of the CPASS performance is not possible. However, 
an exploration of the general trends seen in the CPASS results for proteins of unknown 
function screened by FAST-NMR does provide valuable insights to further improve 
CPASS. 
For the 21 proteins of unknown function successfully screened by FAST-NMR, 
the CPASS similarity score averaged 41.0% ± 11.4%. The highest score was 69.54% and 
the lowest score was 21.71%. A low CPASS score is probably indicative of a lack of a 
functional homolog in the CPASS database. The CPASS similarity scores follow the 
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previously described size dependent trend [Figure 5.9]. The highest similarity score has 
the smallest binding site (7 residues), while the lowest similarity score has the largest 
binding site (35 residues). This trend does not directly indicate that the top hit in a 
CPASS search is not a functional homolog; however, none of the proposed functions for 
the proteins described in chapter 2 matched the top CPASS hit. 
 
 
Figure 5.9 Comparison between the CPASS reference score and the highest CPASS 
similarity score for the 21 functionally unannotated proteins screened by FAST-NMR. 
 
As mentioned previously, there are several factors from the FAST-NMR 
screening result that may affect the CPASS similarity score. There may be significant 
structural differences between the bound and unbound forms of the protein. The FAST-
NMR methodology uses the protein’s unbound structure in combination with molecular 
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docking to generate a protein-ligand costructure.  There is no reliable method to correct 
for structural variations due to ligand binding except by experimentally determining the 
protein-ligand costructure using X-ray crystallography or NMR. Additionally, the 
location of the ligand is determined using a combination chemical shift perturbations and 
molecular docking. While this approach is certainly more accurate in determining the 
ligand pose than either method alone, the average RMSD from the correct ligand pose is 
still approximately 3.5 Å (see Chapter 4). As previously demonstrated, this 
conformational error may significantly lower the CPASS similarity score for a functional 
match [Figure 5.6]. Finally, the size of ligands shown to bind in a FAST-NMR screen 
often varies significantly, and are likely different from the natural ligand. Again, this has 
been shown to negatively impact the CPASS similarity score [Figure 5.7]. This last issue 
might be addressed in FAST-NMR by performing a detailed CPASS analysis using 
known binders of varying sizes. 
 
5.4 CONCLUSIONS 
CPASS 2.0 has been shown to be very effective in selecting for proteins with high 
functional similarity. In general, a CPASS similarity score of 30% or greater indicates a 
greater likelihood of functional homology. However, the variability in defining a binding 
site using predictive or screening approaches can significantly influence CPASS 
similarity calculations, where differences in bound and unbound structures, errors in 
docking a ligand to the structure, and variations in ligand size all appear to decrease the 
CPASS similarity score for a well-characterized protein. Additionally, an evaluation of 
the CPASS results from a FAST-NMR screen of 21 proteins of unknown function 
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highlights the impact of these issues. Specifically, these experimental problems hinder 
the ability of CPASS to reliably rank functional homologs as the top hit.. 
While experimental and computational variability will always be an issue, one 
approach to minimize their effect would be to prioritize the matching process. As 
mentioned previously, the reason protein structural differences and ligand size/location 
affect the CPASS similarity score is due to the way CPASS defines the ligand binding 
site. Every residue within 6 Å of the ligand is defined by CPASS as the binding site. 
While residues at the edge of the 6 Å cutoff are scaled to minimize the impact of small 
structural variations, the majority of the residues in the binding site are essentially 
equivalent in terms of importance to the CPASS scoring function. Unfortunately, not 
every residue located within this binding site is necessary for the molecular function of 
the protein, and thus would not necessarily be conserved. Implementing a weighting 
function for each residue in the query based on predicted or known importance may help 
prioritize binding sites in the database that have similar sequence and structure between 
these important residues.  
Unfortunately, the greatest problem facing the functional annotation of unknown 
proteins with CPASS is the size of functional space represented by the database. The 
number of protein structures represented in the PDB is still significantly smaller than the 
number of known protein sequences. Therefore, the query protein may represent the first 
member of a functional class of proteins present in the PDB. Structural genomics is 
attempting to address this problem by prioritizing experimental structure determination 
efforts. This is leading to significant increase in the number of unique protein structures. 
But, unfortunately, the majority of structures deposited in the PDB lack a biologically 
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relevant ligand. Since the CPASS database is generated from proteins with bound ligands 
in the PDB, a functional class that does not have a representative structure with a bound 
ligand would not appear in the results from a CPASS query. This is especially a concern 
for proteins that binds another biomolecule (protein, DNA, RNA) instead of a small 
molecular weight compound.. These problems may be addressed by expanding the size of 
the CPASS database to potentially include predicted binding sites for unique proteins 
with no bound ligands. The inclusion of protein-protein or protein-DNA binding sites 
would also expand the searchable functional space. However, introducing either of these 
approaches to expand the database does introduce its own challenges. 
 Despite these issues, CPASS still provides valuable information based on the 
partial similarities that do exist, especially when combined with other bioinformatics 
approaches and experimental data. Additionally, CPASS can also be used to help 
understand the evolutionary relationships between proteins based on the changes that 
occur in the binding site. 
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CHAPTER 6 
THE SOLUTION STRUCTURE AND FUNCTION OF YNDB, AN AHSA1 
PROTEIN FROM B. SUBTILIS ** 
  
6.1 INTRODUCTION 
The Bet v 1 protein from birch is a major allergen with high sequence similarity 
to the plant PR-10 pathogenesis-related proteins, which are involved in the response of 
plants toward microbial infection.1 As the Bet v 1 proteins structure was solved,2 
numerous other proteins from among eukaryotes, archaea, and bacteria have been 
identified as having the same characteristic fold.3 The Bet v 1-like superfamily of 
proteins now contains ~10,135 sequences and consists of 13 unique families. The four 
largest families in the Bet v 1-like superfamily are the polyketide cyclases (3,475 
sequences), the ring hydroxylase α-chain (2,022 sequences), the activator of Hsp90 
ATPase homolog 1-like protein (AHSA1) family (1,762 sequences), and the StAR-
related lipid transfer (START) family (1,026 sequences). The sequence similarity among 
the different Bet v 1-like families tends to be relatively low (0-38%), but all contain the 
same helix-grip fold that forms a hydrophobic cavity in between the long C-terminal α-
helix and the antiparallel β-sheet.3 This hydrophobic cavity has been shown to 
preferentially bind to lipids, sterols, polyketide antibiotics, and other hydrophobic 
molecules.3 
Although the Bet v 1-like superfamily members share a similar fold, the 
biological functions vary across the different families. The ring hydroxylases degrade 
                                                
** Chapter 5 was adapted from Stark, J. L., et al. Solution structure and function of YndB, an AHSA1 
protein from Bacillus subtilis. Proteins 78(16), 3328-3340 (2010). Reprinted with permission, copyright 
2010 by John Wiley and Sons. 
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polycyclic aromatic hydrocarbons into non-aromatic cis-diols,4 the START family 
appears to be involved in steroidogenesis,5,6 whereas the polyketide cyclase family is 
involved with the biosynthesis of polyketide-based antibiotics and pigments.7 Members 
of the AHSA1 family are named after the human activator of Hsp90 ATPase protein 
(Aha1). Although the proteins of this family have similar structures, the functions for 
most of the AHSA1 family members, except for its namesake, are ambiguous and are 
currently classified by UniProtKB8 as either a general stress protein or a conserved 
putative protein of unknown function. The eukaryotic protein Aha1 is proposed to 
interact with the middle domain of heat shock protein 90, which stimulates its ATPase 
activity.9,10 The domain organization of many homologous eukaryotic proteins in the 
AHSA1 family also suggests a function that is similar to Aha1. Conversely, homologous 
prokaryotic proteins have a much more diverse domain organization suggesting a wide 
range of possible functions.3 
Of the 80 total structures solved for 59 members of the Bet v 1-like superfamily, 
32 have ligands bound. The types of ligands that have been experimentally determined to 
bind Bet v 1-like proteins include membrane lipids, plant hormones, secondary 
metabolites, polycyclic aromatic hydrocarbons, and DNA/RNA.3 There are 12 total 
proteins in the AHSA1 family with known structures. The only protein in the AHSA1 
family with a solved structure of its protein-ligand complex is the self-sacrificing 
resistance protein CalC from Micromonospora echinosporato,11 where CalC is shown 
bound to calicheamicin γ1,12 a potent antitumor antibiotic compound. Both Pfam13 and 
SCOP14 databases classify CalC as belonging to the AHSA1 family due to its 43-55% 
sequence similarity to other uncharacterized bacterial members of AHSA1. However, 
 201 
CalC contains a break in the C-terminal helix that is uncharacteristic of most Bet v 1-like 
proteins and would likely indicate a new CalC-like family within the Bet v 1-like 
superfamily. This leaves only the human Aha1 with a proposed function within the 
AHSA1 family. 
The Bacillus subtilis YndB protein is a protein of unknown biological function 
targeted for structural analysis by the Northeast Structural Genomics Consortium (NESG; 
http://www.nesg.org; NESG target: SR211). We previously reported the near complete 
nuclear magnetic resonance (NMR) assignments for B. subtilis YndB,15 where the protein 
was originally identified as being a member of the START domain15,16 due to the similar 
helix-grip fold found in the structure of two homologous proteins and based on CATH 
comparisons.17 The NMR structures reported for Bacillus cereus protein BC4709 (PDB 
ID: 1xn6) and Bacillus halodurans protein BH1534 (PDB ID: 1xn5) led to their START 
domain classification.16 These two proteins are 64% and 57% homologous to YndB, 
respectively, inferring a similar annotation for YndB. However, the SCOP and Pfam 
databases have suggested that YndB, BC4709, and BH1534 belong to the AHSA1 
family. Sequence similarity searches with YndB only identify proteins annotated as either 
AHSA1 or proteins of an unknown function. The primary difference between START 
domain and AHSA1 structures is that START domain proteins typically contain two 
additional N-terminal β-strands and an α-helix, which also makes the proteins larger. The 
structure of BC4709 and BH1534 do not have these additional structural components 
further supporting their AHSA1 classification. 
Assigning a function to an uncharacterized protein like YndB can be a daunting 
task that involves obtaining a high-resolution structure18 combined with detailed studies 
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that may include generating knockout libraries to analyze cell phenotypes, monitoring 
gene expression levels, or performing pull-down assays, all of which require in-depth 
bioinformatics analyses.19-23 As the biological function of a protein is, by definition, 
derived from its interactions with other biomolecules or small molecules, identifying 
interacting partners is an alternative route to obtaining a functional annotation. One such 
technique, FAST-NMR,24,25 utilizes a small biologically focused compound library 
combined with NMR high-throughput screening (HTS), rapid protein-ligand costructures 
using AutoDock26 and chemical shift perturbations (CSPs),27 and a comparison of protein 
active site structures28,29 to assist the functional annotation of proteins. However, the 
utility of FAST-NMR relies on structural analogs being found within the diverse 
functional chemical library. In the case of YndB, the known Bet v 1-like superfamily 
ligands combined with the expected hydrophobic cavity for YndB already suggests the 
protein is likely to bind lipid-like molecules. This eliminates the need for screening a 
diverse array of compounds found in the FAST-NMR compound library and instead 
requires an extensive screen against a focused lipid-like library. Because of the large 
number of biologically relevant lipid-like compounds30 and the corresponding limited 
commercial availability, an HTS assay is not practical or cost effective. Instead, an in 
silico screen31,32 provides an attractive alternative method to identify specific classes of 
compounds that may interact with YndB and to focus follow-up in vitro efforts. 
To better understand the general biological role of AHSA1 proteins, the structure 
and putative biological functions of the B. subtilis YndB protein was determined using 
NMR spectroscopy and the in silico ligand-binding screen. The three-dimensional 
solution structure of YndB (PDB ID: 2kte) is described herein and is consistent with 
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other AHSA1 proteins.†† As most Bet v 1-like and AHSA1 proteins contain a 
hydrophobic ligand-binding pocket, the in silico screen of a ~18,500 lipid compound 
library30 was performed to identify a particular class of lipids that preferentially bind 
YndB and to provide insight into its biological function. The B. subtilis YndB protein 
was shown to experimentally bind trans-chalcone, a member of an important class of 
antibiotics and an important plant metabolite produced by chalcone synthase (CHS).33 
Three other compounds similar in structure to chalcones (flavanone, flavone, and 
flavonol) and part of the same metabolic pathway were also shown to bind YndB, albeit 
weaker binders than trans-chalcone. These chalcone-like molecules are often found as 
precursors to flavonoids that play a key role in plant-microbe signaling and defense, 
where Bacillus strains have been shown to have a beneficial impact on plant health by 
protecting against fungal and bacterial pathogens.34 This suggests B. subtilis YndB may 
respond to a plant infection signal and induce a stress response. 
 
6.2 MATERIAL AND METHODS 
6.2.1 Solution structure of B. subtilis YndB. The three dimensional structure of 
Yndb is report as an 18 structure ensemble in the PDB (PDB ID: 2kte). [Figure 6.1A] The 
structure of the YndB protein was visualized and evaluated using the UCSF Chimera 
package from the Resource for Biocomputing, Visualization, and Informatics at the 
University of California, San Francisco (http://www.cgl.ucsf.edu/chimera).35 Putative 
binding sites of YndB and homologous proteins BC4709 and BH1534 were investigated 
and compared using CASTp,36 which attempts to identify protein ligand binding sites and 
active sites by defining the molecular surface and determining surface accessible pockets. 
                                                
†† Dr. Kelly Mercier was responsible for determining the solution structure of YndB. 
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Figure 6.1 The NMR solution structure of B. subtilis protein YndB: (A) a backbone trace 
of the 18 lowest energy conformation models and (B) a ribbon diagram where the α-
helices are colored red, the β-strands are colored yellow, and the loops are colored green. 
 
6.2.2 Sequence and structure similarity to YndB. To identify homologous 
proteins and elucidate a possible function, multiple similarity comparisons were 
performed. The pair-wise sequence alignment of YndB to protein sequences in a 
nonredundant database was performed using BLASTP37-39 and the default BLOSUM62 
scoring matrix. DaliLite v.340 was used to perform the structural similarity comparisons 
of YndB (model #10) with proteins from the RCSB PDB. ClustalW41 was used to align 
the sequences of YndB and the two homologous proteins, BC4709 and BH1534, for a 
detailed analysis of conserved amino acid residues that make up functionally relevant 
components of each protein. The ClustalW sequence alignments used the default settings. 
6.2.3 Virtual screening of a lipid compound library. The in silico screen of 
YndB against a lipid library was performed to identify classes of lipid molecules that are 
favored to bind the protein. The lipid library used in this study was obtained from the 
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Nature Lipidomics Gateway (www.lipidmaps.org), which contains two-dimensional 
structures of 21,824 lipid molecules (as of January 2010) found in mammalian 
species.30,42,43 Clearly, the lipid library is not exhaustive and many lipid molecules found 
in nonmammalian organisms are not represented, but the goal of the virtual screening 
effort is to identify a structural homolog to the natural ligand or to identify a particular 
class of lipid that preferentially binds YndB. Eight major categories of lipids are 
represented in the Nature Lipidomics Gateway library: fatty acyls (3,476 structures), 
glycerolipids (3,012 structures), glycerophospholipids (1,958 structures), sphingolipids 
(3,376 structures), sterol lipids (2,125 structures), prenol lipids (1,156 structures), 
saccharolipids (13 structures), and polyketides (6,708 structures). The eight major 
categories are further divided into a total of 538 distinct subclasses of lipid compounds. 
The two-dimensional structure files provided by the Nature Lipidomics Gateway were 
converted into three-dimensional conformers using the program OMEGA 2.3.244 
(OpenEye Scientific Software, Sante Fe, NM). OMEGA generates a database of multiple 
three-dimensional conformers for each ligand in the compound library using fragment 
assembly, ring conformation enumeration, and torsion driving. In this study, OMEGA 
was used to generate a maximum of 600 unique (> 0.5 Å rmsd) conformers for each lipid 
molecule for a total searchable database consisting o ~10,000,000 conformers. OMEGA 
failed to generate conformers for 3,306 of the lipid structure files, leaving a chemical 
library of 18,518 compounds for the in silico screen. Most of these failures occurred 
during the processing of the sphingolipid category of lipids (3,196 out of 3,376 failed) 
due largely to the large size and number of branches/rotatable bonds of the molecules in 
this category. 
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The docking program FRED 2.2.545,46 (OpenEye Scientific Software, Sante Fe, 
NM) was used for the virtual screen of YndB against the lipid library. FRED is a rigid 
docking program, which uses the multiple conformers of each ligand created in OMEGA 
and generates 100 docked poses within the defined binding site by rotating and 
translating the rigid molecule to optimize shape complementarity. The poses of each 
ligand conformer are then ranked using the built-in consensus scoring method, where 
only the top scoring pose is kept. As the conformers are rigid during this docking process, 
FRED has been shown to be very fast as compared with other docking programs that 
allow for ligand flexibility.47 This speed is necessary in order to screen the large lipid-like 
library in a reasonable amount of time. Although some accuracy may be lost due to rigid 
docking and a lack of a biologically relevant conformation for the ligand, FRED was 
primarily used to rapidly filter out compounds that could not fit into the YndB ligand-
binding pocket. Before initiation of the docking, model 10 from the YndB PDB file (PDB 
ID: 2kte) was prepared using FRED Receptor 2.2.5 (OpenEye Scientific Software, Sante 
Fe, NM), where a high-quality shape potential grid of 3403 Å3 was generated that 
encompassed the proposed binding cavity. Model 10 was selected as the target receptor 
for the virtual screen as it had the lowest violation energies during the solution structure 
calculations. The lipid library compounds were ranked using the default Chemgauss3 
scoring function that includes descriptors of shape and molecular chemical properties. 
Chemgauss3 incorporates steric and hydrogen bond interactions as well as protein and 
ligand desolvation parameters that are smoothed using a Gaussian function. The relative 
enrichment for each lipid class within the top 1000, the top 500, the top 200, the top 100, 
and the top 50 ranked compounds were calculated according to the following equation: 
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where %RE is percent relative enrichment, %AbLib is the percent abundance of a lipid 
class in the Nature Lipidomics Gateway library, and %AbFRED is the percent abundance 
of a lipid class observed in either the top 1000, 500, 200, 100, or 50 ranked compounds 
by FRED. 
6.2.4 NMR titration experiment. Based on the results of the virtual screen, three 
classes of lipid molecules were identified as possible binders: flavones/flavonols, 
flavanones, and chalcones/hydroxychalcones. Experimental validation of these possible 
binders was performed using chemical shift perturbations (CSPs) in 2D 1H-15N HSQC 
NMR spectra collected on a Bruker 500 MHz Avance spectrometer equipped with a 
triple-resonance, Z-axis gradient cryoprobe. The 2D 1H-15N HSQC NMR experiment was 
collected at 298 K with 32 scans, 1024 data points and a spectral width of 36 ppm in the 
indirect 15N-dimension. The ligands selected to represent each of the three potential 
binding lipid classes were trans-chalcone, flavanone, flavone, and flavonol (Sigma-
Aldrich, St. Louis, MO). Flavone and flavonol belong to the same class of lipids, but 
there was interest in how the binding would be affected with the addition of a polar 
functional group. The fatty acyl oleic acid (Sigma-Aldrich, St. Louis, MO) was also 
selected as a negative control. These compounds were selected based on availability, a 
simple scaffold that clearly represented the lipid class, and cost. Each compound was 
dissolved in “100%” deuterated DMSO-d6 (Sigma-Aldrich, St. Louis, MO) before 
titration. The titration analysis was performed with an 80 µM 15N-labeled YndB sample 
(20 mM MES buffer, pH 6.5 with 10% D2O, 0.02% NaN3, 10 mM DTT, 5 mM CaCl2, 
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100 mM NaCl, and 50 µM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS)) and 
increasing concentrations (ranging from 0 to 600 µM) of each ligand. The NMR data 
were processed with NMRpipe48 and the spectra viewed using NMRViewJ.49 
Kaleidagraph 3.5 (Synergy Software) was used to fit the NMR data to the following 
equation:50,51 
CSP!"# = CSP!"# 𝐾! + 𝐿 + 𝑃 − (𝐾! + 𝐿 + 𝑃 )! − 4( 𝐿 𝑃 )2 𝑃                         (6.2) 
 
where CSPobs is the 2D 1H-15N HSQC CSPs, [P] is the protein concentration, [L] is the 
ligand concentration, and KD is the dissociation constant. 
6.2.5 B. subtilis YndB-ligand costructures. Co-structures of YndB bound to 
each compound used in the NMR titration experiment (trans-chalcone, flavanone, 
flavone, and flavonol) were generated to analyze the ligand-binding pocket. Although a 
definitive identification of the binding pose of these ligands to YndB would require 
extensive NMR experiments and data analysis similar to the original effort to solve the 
apo-YndB structure, molecular docking can provide a rapid and reliable NMR-based 
model to examine the details of the binding interactions. 
AutoDock 4.0126,52 with the AutoDockTools 1.5.2 (http://mgltools.scripps.edu) 
graphical interface was used to simulate 100 different binding poses for each YndB-
ligand complex. AutoDock was used instead of FRED due to the accuracy gained from 
flexible ligand docking and because it is one of the most highly cited docking programs 
available.53 The grid map was generated with 0.375 Å spacing with xyz grid point 
dimensions of 50 x 58 x 48, which is of sufficient size to encompass the proposed 
binding pocket previously identified in CASTp and FRED. The docking calculations 
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were performed using the Lamarckian genetic algorithm default settings with a 
population size of 300 and 5,000,000 energy evaluations. 
  
6.3 RESULTS AND DISCUSSION 
6.3.1 Solution structure of B. subtilis YndB. The observed secondary structure 
and fold for B. subtilis YndB are characteristic of the helix-grip fold found in the Bet v 1-
like superfamily. The helix-grip fold consists of a β-sheet with two small and one long α-
helix. The β-sheet is comprised of five strands instead of the normal six. The missing 
short strand, which is normally β2, forms sheet like interactions in only two of the 18 
structures in the ensemble and appears to protect the edge of β3; unprotected edges can 
be adventitious interaction sites for aggregation.54 However, the strands are annotated 1, 
3, 4, 5, and 6 to facilitate comparisons with other family members: residues 12-18 (β1), 
63-69 (β3), 73-78 (β4), 83-91 (β5), and 96-104 (β6). The three α-helices are comprised of 
residues 22-28 (α1), 33-36 (α2), and 120-143 (α3) [Figure 6.1B]. There is significant 
variability in the loop regions of the protein corresponding to residues 37-63 and 105-
120. These loops appear to be important for the structure of the hydrophobic ligand-
binding cavity [Figure 6.1B]. 
Like other proteins with a helix-grip fold, YndB has an exposed hydrophobic 
core, likely used in the binding of lipid-like molecules. Analysis with CASTpÅ shows 
that the volume of this putative binding cavity is 790 Å3. The core of YndB consists 
primarily of aromatic side chains. One element of the YndB binding pocket is the long 
α3-helix. This helix is anchored to the β-sheet by residues W130, V134, and L138, which 
show NOE interactions to the sheet residues S15, T17, and L18. Helix α3 has previously 
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been identified as being crucial to the function of the structurally related START 
domains.55,56 In both of these earlier studies, the removal of part of the α3-helix 
eliminated ligand binding. Based on the NMR solution structure for YndB, removing the 
C-terminal residues would result in α3 no longer being associated with the β-sheet, and 
therefore, the protein would probably not be folded properly. Hence, we surmise that the 
previous results were likely due to protein instability and not the activity of specific 
residues to ligand binding. 
The Bet v 1-like superfamily classification for YndB and the reliability of the 
NMR structure is further supported by the structural similarities to two homologous 
proteins, BC4709 and BH1534 [Figure 6.2A,B]. The YndB protein exhibits a backbone 
rmsd of 1.1 Å and 1.2 Å to BC4709 and BH1534, respectively, when only secondary 
structural elements are included in the alignment. The main difference among the 
structures lies in the loop regions, where there appears to be a significant difference in the 
loop conformation of residues 37-63 and 105-120 for YndB. This difference affects the 
size of the hydrophobic cavity for YndB, where BC4709 and BH1534 have much smaller 
volumes (199 Å3 and 106 Å3, respectively) relative to YndB. 
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Figure 6.2 An overlay of the NMR solution structure of B. subtilis protein YndB 
(yellow), with (A) Bacillus cereus protein BC4709 (blue) (PDB ID: 1xn6) and (B) 
Bacillus halodurans protein BH1534 (red) (PDB ID: 1xn5). (C) The multiple sequence 
alignment from ClustalW of YndB, BC4709 and BH1534 with the 14 active site residues 
(< 5 Å from bound ligand) indicated in black rectangles. 
 
As expected from the high-sequence identity, the sequence compositions of the 
ligand binding sites are also similar [Figure 6.2C]. Nine of the 14 residues that line the 
cavity are identical and predominantly hydrophobic (V29, G34, F76, W78, W83, V85, 
F87, W130, and L138) and two others show high similarity. Although, none of these 
residues exist within the loop regions, the large loop from residues 37-63 is very well 
conserved with 16 residues being identical among the three proteins, once again 
indicating the importance of these loops for ligand binding. The loop regions 
corresponding to residues 37-63 and 15-120 are predicted to be conformationally flexible 
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based on the lack of NMR assignments.15 Of the 43 amino acids that comprise the two 
loop regions, a total of 21 residues are unassigned. Correspondingly, these loop regions 
have a limited number of structural constraints resulting in the observed conformational 
variability in the ensemble of calculated structures [Figure 6.1A]. Although the lack of 
NMR assignments and NOEs suggests conformational flexibility, these observations are 
not sufficient to define the loops as dynamic and requires further experimental evidence 
for verification.57 Nevertheless, it is anticipated that a bound substrate would restrict the 
loop conformation near the YndB ligand binding site. 
6.3.2 Sequence and structure similarity to YndB. The BLASTP search of 
YndB against a non-redundant protein sequence database identified 58 proteins with an 
E-value of 1.0 x 10-21 or lower that included BC4709 and BH1534. All of these proteins 
belong to the Gram-positive organisms of the order Bacillales and have sequence 
identities > 39% and sequence similarities > 58%. There is a clear division in sequence 
similarity between the 58 Bacillales proteins and other Gram-positive bacteria proteins 
homologous to YndB. The sequence similarity score drops significantly from E-values of 
10-21 for Bacillales proteins to E-values of ≥ 10-9 for other Gram-positive proteins. This 
sequence distinction may indicate a function specific to the Bacillales organism. 
The structural similarity search using DaliLite identified 590 proteins with a Z-
score over 2.0. Once again, the two proteins with the greatest structural similarity are 
BC4709 and BH1534 with Z-scores of 14.0 and 14.2, respectively. The top 100 proteins 
with the highest structural similarities have Z-scores ranging from 9.0 to 14.2 with 
sequence identities < 25%, except for BC4709 and BH1534. All of the proteins identified 
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in this range are either uncharacterized or members of the Bet v 1-like superfamily, 
which includes Bet v 1-like proteins in plants. 
6.3.3 Virtual screening of a lipid compound library. The in silico screen of 
YndB with the entire Nature Lipidomics Gateway lipid library took ~44 hours with the 
computation dispersed across 16 nodes of a Linux Beowulf cluster. Of the 18,518 
structures in the library, FRED successfully docked 17,475 compounds to YndB. The 
relative enrichment [Equation 6.2] of each lipid class from the FRED docking is plotted 
in [Figure 6.3A]. Only one lipid category, the polyketides, had a positive relative 
enrichment among the top 1000 docked lipid molecules. Polyketides represent 86.8% of 
the molecules in the top 1000, whereas they only make up 37.9% of the entire compound 
library for a relative enrichment of 129%. The polyketide representation increases 
significantly as the cutoff for the FRED scoring energy for molecules accepted in the top 
rankings is decreased. If only the top 50 docked compounds are considered, 98.0% of 
these compounds are polyketides, with only one hit being a member of the fatty acyl 
category. All of the polyketides identified as hits belong to the flavonoid class of lipids. 
Within the flavonoids, three subclasses emerge as favorable hits from the virtual screen: 
chalcones/hydroxychalcones, flavanones, and flavones/flavonols. 
The chalcone/hydroxychalcone subclass turns out to be the most significant hit as 
44.9% of the flavonoids in the top 50 hits were chalcones, whereas they only make up 
9.4% of the library of flavonoids. The remaining flavonoids in the top 50 hits belong to 
the flavanone (28.6%) and flavone/flavonol (14.3%) subclasses. The molecules from 
these three subclasses all have very similar chemical structures, which consist of at least 
two benzene rings and contain only a few rotatable bonds [Figure 6.3B]. 
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Figure 6.3 Summary of the FRED in silico screening results of the Nature Lipidomics 
Gateway lipid library and B. subtilis protein YndB. Approximately 18,500 lipid structures 
corresponding to ~10,000,000 conformers were docked into YndB. The compounds were 
ranked using the FRED Chemgauss3 scoring function. (A) A plot of the relative 
enrichment [Equation 6.1] for each of the eight major lipid categories within the top 
1,000 hits (red), the top 500 hits (green), the top 200 hits (purple), the top 100 hits (cyan), 
and the top 50 hits (orange). Only the polyketides were positively enriched in the virtual 
screen relative to their representation in the original lipid library. (B) The chemical 
structures of the four flavonoid compounds chosen to represent the three most enriched 
subclasses of lipids (chalcones/hydroxychalcones, flavanones, and flavones/flavonols) 
identified from the in silico screen. 
 
6.3.4 NMR titration experiment. Although virtual screening appears to be a 
useful tool for identifying particular classes of lipids that have structural and chemical 
properties amenable to binding to YndB, these results require validation by experimental 
methods. NMR is routinely used to evaluate protein-ligand interactions, to measure 
dissociation constants (KD) and to identify ligand-binding sites through the observation of 
CSPs.27,58,59 CSPs were calculated by comparing the average 1H and 15N resonance 
changes between ligand-free and ligand-bound YndB 2D 1H-15N HSQC NMR spectra. 
The advantage of this approach is the speed and minimal amount of protein and ligand 
required. Unfortunately, access to the specific lipid compounds predicted to bind YndB is 
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very limited due to low commercial availability and/or high cost. Based upon the in silico 
screening of YndB with a lipid library, chalcones/hydroxychalcones, flavanones, and 
flavones/flavonols were identified to be the most likely to bind YndB. Therefore, 
representative molecules were sought for each class containing the basic structural 
scaffold that would likely have characteristic binding properties. A member of the fatty 
acyl category of lipids was also sought for use as a negative control. 
For the chalcone/hydroxychalcone subclass of lipids, trans-chalcone was selected 
to represent the basic structural scaffold for this class. The titration of YndB with trans-
chalcone resulted in significant CSPs [Figure 6.4]. Nine YndB residues with the most 
significant CSPs (greater than two standard deviations from the mean) were identified: 
Thr80, Trp105, Val111, Ile112, Val122, Met126, Trp130, Thr131, and Ile133. These 
residues line the opening of the proposed binding pocket [Figure 6.6] identified by 
CASTp. Six more residues with significant perturbations (greater than one standard 
deviation from the mean) were also identified: Glu110, Val121, Arg123, Asp127, 
Gly128, and Asn135. These amino acids reside in the long α3-helix and contribute to a 
portion of the ligand binding pocket. Their perturbation may indicate a structural change 
in α3-helix upon binding. The remaining loop residues that define the binding pocket are 
unassigned in apo-YndB. 
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Figure 6.4 Overlay of the 2D 1H-15N HSQC spectra of B. subtilis protein YndB titrated 
with chalcone, where the chalcone concentration was increased from 0 µM (blue) to 160 
µM (cyan). The significant CSPs of the nine assigned amino acid residues used to 
determine the dissociation constant (KD) are highlighted with a black oval and labeled 
accordingly. Not all of the perturbed peaks were assigned; these residues are likely from 
the loop regions. 
 
The normalized CSPs for each of the nine amino acid residues were plotted as a 
function of protein-ligand concentration ratios and fit to a binding isotherm [Equation 
6.2] to determine a dissociation constant. trans-Chalcone binds tightly to YndB with a KD 
of ≤ 1 µM and a stoichiometry of 1:1. The binding stoichiometry is based on the 
observation that a two-site model does not fit the data as evidenced by the fact that the 
CSPs reaches a maximum at ~1:1 protein-chalcone concentration ratio [Figure 6.5]. 
Calculating an exact KD for trans-chalcone was not possible given the YndB 
concentration (80 µM) used for the 2D 1H-15N HSQC titration experiments, and 
significantly lowering the YndB concentrations was not feasible. Superimposed on the 
 217 
trans-chalcone NMR titration data [Figure 6.5] is a theoretical curve for a KD of 1 µM, 
implying an upper-limit for the trans-chalcone dissociation constant. 
 
 
Figure 6.5 NMR titration data for trans-chalcone (blue), flavanone (green), flavone 
(purple), and flavonol (orange). The normalized CSPs for the nine most perturbed 
residues are plotted versus the protein-ligand concentration ratios. The titration curves 
were fit to a binding isotherm [Equation 6.2] using Kaleidagraph 3.5 (Synergy Software). 
The best-fit curves are shown as a solid line. The theoretical curve displayed for trans-
chalcone corresponds to a KD of 1 µM and represents the upper-limit for the KD. The 
measured KD values are ≤ 1 µM (trans-chalcone), 32 ± 3 µM (flavanone), 62 ± 9 µM 
(flavone), and 86 ± 16 µM (flavonol). 
 
Representing the flavanone and flavone/flavonol subclasses, flavanone, flavone, 
and flavonol all showed CSPs of the same residues found to be perturbed in the trans-
chalcone titration, indicating that all the molecules bind in a similar manner. However, 
flavanone, flavone, and flavonol bound YndB significantly weaker than trans-chalcone 
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with dissociation constants of 32 ± 3 µM, 62 ± 9 µM, and 86 ± 16 µM, respectively 
[Figure 6.5]. The range of the dissociation constants mirrors the representation of each 
subclass in the virtual screen, where chalcones were the most abundantly ranked 
compounds, followed by flavanones and then the flavones/flavonols. Titration of oleic 
acid to YndB, which was used to represent the fatty acyl category of the lipids, showed 
no significant CSPs and therefore no evidence of binding (data not shown). 
6.3.5 B. subtilis YndB-ligand costructures. Using AutoDock, the three-
dimensional structures of trans-chalcone, flavanone, flavone, and flavonol were each 
docked into the YndB binding pocket identified by CASTp and supported by NMR CSPs. 
The docking of each compound did not result in much variation between the poses for 
each of the ligands. Out of 100 docked poses for each ligand, at least 80 were within a 2.0 
Å rmsd of each other. A comparison of the most energetically favorable poses for each 
ligand shows that the compounds essentially bind with the same orientation [Figure 6.6]. 
The docked structures are also consistent with the 1:1 binding stoichiometry predicted by 
the NMR titration experiments and CSPs. Binding two or more compounds in the YndB 
binding pocket is sterically prohibitive and the NMR CSPs do not identify a secondary 
ligand binding site. 
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Figure 6.6 A representation of the B. subtilis YndB protein surface using the NMR 
solution structure, where amino acid residues that exhibited NMR CSPs caused by the 
titration of trans-chalcone, flavanone, flavone, and flavonol are colored red (≥ 2 standard 
deviations from the mean) and blue (≥ 1 standard deviations from the mean). The 
residues with the largest CSPs can be found near the entrance to the ligand binding 
cavity, whereas the remaining residues are associated with helix α3. Shown within the 
ligand binding cavity are the docked conformations of the four ligands experimentally 
determined to bind YndB: chalcone (yellow), flavanone (green), flavone (purple), and 
flavonol (red). 
 
The free energy of binding predicted by AutoDock was essentially identical for 
each compound, averaging −7.2 kcal/mol which correlates to a dissociation constant of 
~5 µM. With the exception of trans-chalcone, this is a stronger binding affinity than 
observed for the three compounds in the NMR titration experiments. This is not 
surprising since predicting the actual free energy of binding using AutoDock has an 
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estimated error of 2.2 kcal/mol.60 In the YndB-chalcone modeled structure, there are 14 
residues that reside within 5 Å of the docked trans-chalcone, where five of these residues 
are aromatic [Figure 6.7]. These aromatic residues presumably have a strong influence on 
ligand binding and selectivity, consistent with the hydrophobic and aromatic nature of 
trans-chalcone and the other flavonoids. The binding of trans-chalcone to YndB does not 
appear to involve any hydrogen bonding interactions. 
 
 
Figure 6.7 The NMR solution structure of YndB docked with trans-chalcone (green). 
The sidechains for the 14 amino acid residues with 5 Å of the ligand are shown and 
labeled. Five aromatic sidechains surround the trans-chalcone molecule and form a 
hydrophobic pocket. 
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Most of the difficulty in generating an accurate protein-ligand co-structure for 
YndB stems from the suspected flexibility of the two loop regions that define the 
hydrophobic cavity. Any variation in the orientation of the loop sidechains directly 
results in changes in the binding site conformation that may be required to accommodate 
a ligand. This effect can be seen in some of the YndB structures found in the NMR 
ensemble. The YndB-chalcone model and the relative trans-chalcone orientation does 
correlate well with the binding site for the human phosphatidylcholine transfer protein 
(PC-TP) complexed with dilinoleoylphosphatidylcholine (PDB ID: 1ln1),61 a protein 
structure in the related START domain family [Figure 6.8]. Although the sequence 
identity between YndB and PC-TP is low (5%), both proteins have structural similarities 
(3.6 Å rmsd) with binding pockets located in the same region of the protein. However, 
the binding pocket of YndB is significantly smaller than the pocket found in PC-TP due 
to the tighter packing of the β-sheet with the loop regions and the long α3-helix. 
Nevertheless, the overlay of the YndB-chalcone model with the PC-TP complex indicates 
that chalcone and the other flavonoids bind within a pocket similar to the large 
dilinoleoylphosphatidylcholine-binding pocket. 
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Figure 6.8 A structural alignment of human PC-TP complexed with 
dilinoleoylphosphatidylcholine (PDB ID: 1ln1) with the B. subtilis YndB-chalcone 
NMR-based model. Only the trans-chalcone is shown from the YndB-chalcone structure. 
The structural alignment indicates the location of the docked trans-chalcone (red) relative 
to the PC-TP protein structure (blue) and a transparent molecular surface (cyan) 
representation of the bound dilinoleoylphosphatidylcholine. The binding pockets of the 
two proteins are in the same region, indicating a reasonable docking of trans-chalcone to 
YndB. 
 
6.4 CONCLUSIONS 
The NMR structure for B. subtilis protein YndB indicates that the protein adopts a 
helix-grip fold and is clearly a member of the Bet v 1-like superfamily. The YndB 
structure contains an apparent hydrophobic cavity between the long C-terminal α-helix 
and the antiparallel β-sheet. Like other members of the Bet v 1-like superfamily, the 
cavity suggests YndB binds to lipids, sterols, polyketide antibiotics, or other hydrophobic 
molecules as part of its biological function. The YndB protein was originally assigned as 
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a START domain protein based on the high-sequence similarity to B. cereus BC4709 and 
B. halodurans BH1534, which were assigned to START domains based on common 
structural features.15,16 Instead, SCOP and Pfam databases have suggested that YndB 
belongs to the closely related AHSA1 subfamily. Also, YndB, BC4709, and BH1534 do 
not have the additional N-terminal β-strands and the additional α-helix that are 
characteristics of a START domain structure.3 Likewise, a BLASTP sequence alignment 
search indicates YndB is more appropriately assigned as a member of AHSA1. The 
BLASTP search identified 58 proteins from organisms belonging to the Gram positive 
Bacillales order that are homologous to YndB with sequence identities > 39%. The 
functions for prokaryotic AHSA1 family members are typically classified as either a 
general stress protein or a conserved putative protein of unknown function. Likewise, the 
Dali search identified a large number of structural homologs to Bet v 1-like proteins, 
AHSA1 family members and an abundance of hypothetical proteins or proteins of 
unknown function. 
To further explore the potential functional annotation of YndB, the in silico 
screen against a ~18,500 lipid-like chemical library was conducted. The best binders 
identified from the in silico screen were from the three general lipid classes of 
flavones/flavonols, flavanones, and chalcones/hydroxychalcones. Representative 
compounds from all three classes were screened by NMR, where trans-chalcone, 
flavanone, flavone, and flavonol were all shown to bind in the YndB hydrophobic cavity 
with KD values of ≤ 1, 32, 63, and 86 µM, respectively. The fact that all four molecules 
chosen from the in silico screen were shown to bind YndB is rather remarkable and 
indicative of the inherent value of our approach. The typical hit rate for a high-throughput 
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screen is generally low (0.1-0.5%),62 where the in silico screens may result in improved 
hit rates of up to 35-90%.31,63,64 A model for the YndB-chalcone complex was shown to 
be consistent with the binding of dilinoleoylphosphatidylcholine to human PC-TP, a 
related START domain protein. 
The binding of chalcone and flavanone to a B. subtilis protein is an intriguing 
observation because these molecules are primarily found in plants as precursors to 
flavonoid molecules used for antimicrobial defense, flower pigmentation, absorption of 
harmful UV radiation, and signaling between plants and beneficial microbes.65-69 A 
number of structural homologs to YndB identified by Dali were Bet v1-like proteins in 
plants. In plants, chalcones are often synthesized from a cinnamoyl-CoA molecule 
followed by malonyl-CoA additions. The conversion of the resulting molecule into 
chalcone is catalyzed by the protein chalcone synthase (CHS).33 Thus, chalcone is a key 
substrate for antibiotics or other flavonoid-based compounds. After the synthesis of 
chalcone, the chalcone isomerase (CHI) enzyme converts chalcone to flavanone, which is 
another compound identified to bind YndB. The other two binding compounds, flavone, 
and flavonol, are products of the various flavonoid synthesis pathways that initiate with 
the chalcone scaffold.33 Bacteria do not possess CHS or CHI proteins and thus do not 
produce chalcone or flavanone. Some bacteria, including B. subtilis, do have proteins that 
appear to be homologous to the CHS proteins found in plants. These homologous 
proteins, known as type III polyketide synthases, appear to be pervasive in bacteria, 
indicating a possible mechanism for antimicrobial biosynthesis from chalcones, thus 
supporting the similarities of YndB to polyketide cyclases.7,70 Likewise, homologs of 
CHI have also been identified in bacteria.71 However, no Type III polyketide synthase 
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has been identified that is known to synthesize chalcones, and flavonoids have not been 
identified among the natural products of Bacillus. It seems unlikely that B. subtilis is 
producing chalcone-based antibiotics. These observations support the possibility of an 
exchange of genes between plants and bacteria, where these proteins are evolved for a 
unique bacterial function.72 
The chalcone-binding property of YndB may be related to stress response as 
originally indicated based on the relationship to the eukaryotic Aha1 protein. In addition, 
Bet v1-like proteins in plants, which were shown to be structural homologs of YndB, are 
also primarily related to a stress response caused by a pathogen infection. An evaluation 
of the genes found near YndB in B. subtilis supports the stress response explanation. 
Although there are numerous uncharacterized membrane proteins identified in this 
cluster, one of these genes codes for the membrane bound protein, amino acid permease, 
which is involved in spore germination. The gene for protein BH1534 from B. 
halodurans also contains sporulation factors upstream and nucleotide metabolism 
downstream along with numerous putative membrane proteins. Likewise, the BC4709 
gene for B. cereus has numerous membrane proteins in its cluster but also includes an 
ArsR transcriptional regulator and multidrug resistance proteins. The genes for all three 
of these proteins exist within regions containing stress response factors. Many other 
homologous proteins contain similar gene arrangements. These consistent gene 
arrangements hint at a likely stress-response mechanism, which is also supported by the 
similarities of these proteins to the eukaryotic Aha1 protein. Aha1 interacts with Hsp90, 
whereas prokaryotes have a homologous version of Hsp90 called HtpG, which has been 
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shown to be induced under high heat stress conditions. It should be noted, however, there 
is currently no direct correlation between HtpG and YndB or spore formation.73 
B. subtilis is a plant growth promoting rhizobacterium, which is often found on 
the surface of plant roots and provides protection against pathogens through biofilm 
formation.74,75 As chalcones are a key precursor to many antibiotics used by plants, it 
seems reasonable that B. subtilis has developed a mechanism of response toward 
chalcone-based compounds. Therefore, we hypothesize that the YndB protein, along with 
the homologous proteins BC4709 and BH1534, initiates a stress response-pathway when 
exposed to chalcone or chalcone-like compounds during the plant’s response to pathogen 
infection. Potentially, this stress response may either induce processes to help control 
plant pathogens76 and/or lead toward spore formation to protect B. subtilis from the 
impending release of antibiotics from the plant.77 As flavonoids are routinely used as 
signaling molecules between plants and microbes during pathogen infections,78 it is 
reasonable to consider chalcone binding as part of the symbiotic relationship between B. 
subtilis and plants. 
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CHAPTER 7 
VIRTUAL SCREENING OF A FUNCTION-BASED COMPOUND LIBRARY 
  
7.1 INTRODUCTION 
The vast majority of initial leads in drug discovery are identified from high-
throughput screens (HTS).1-3 Pharmaceutical companies have invested heavily in 
developing and maintaining large chemical libraries (>1,000,000 compounds), which are 
screened using automated, biological assays intended to monitor a specific response or 
biological effect.3 Unfortunately, HTS is extremely inefficient due to the high cost of 
developing, maintaining, and screening such large libraries of compounds. Furthermore, 
the random search for an effective drug in the vastness of chemical space (~1060 
compounds)4 is extremely challenging. Thus, HTS hit rates are typically very low, where 
<0.5% of compounds exhibit any inhibitor activity in an assay.5 Correspondingly, HTS 
assays are highly inefficient since most of the screening effort is spent on the analysis of 
negative data. HTS assays, by nature, are mechanistic “black boxes,” and a response does 
not provide any information on the mechanism of inhibition. This often leads to 
numerous false positives from undesirable interactions6-8 that may lead the drug 
discovery project astray. Improving the efficiency of drug discovery requires the 
implementation of advanced techniques that better guide the selection of lead candidates 
without sacrificing speed. 
Ideally, an entirely in silico approach to screening a large compound library 
would significantly improve efficiency and reduce costs.9,10 However, several 
assessments of virtual screens have concluded that, without prior in-depth analysis of the 
 232 
protein’s ligand binding site, only a marginal improvement in finding successful leads is 
observed relative to standard HTS.11 The inherent errors of a docking program to 
calculate the strength of interactions for each unique protein-ligand system makes it 
difficult to reliably rank the compound library from best binder to worst. 
Fragment-based drug discovery is an alternative method that focuses on a bottom-
up approach to finding a good binder. Low molecular weight compounds (< 250 amu) are 
used to find subpockets within the overall active site.12,13 Compounds that are found in 
nearby subpockets can be chemically linked to produce a theoretically stronger inhibitor 
or binder. This approach allows for a smaller library to be screened.12,13 However, 
experimental screens of fragment-based libraries are difficult due to the low affinity of 
the compounds.14,15 Unfortunately, using virtual screening to prioritize a fragment-based 
compound libraries is challenging since small compounds tend to be more promiscuous 
binders and any error in the calculation of an interaction has a greater effect on the 
overall rankings of the docked compounds.16 While fragment-based virtual screens are 
more efficient, they are not often used to prioritize a fragment-based compound library 
because of these challenges. 
In drug discovery, the large compound libraries and fragment-based compound 
libraries are intended to explore structural diversity in order to find a novel drug. 
Similarly, the FAST-NMR approach17,18 to the functional annotation of uncharacterized 
proteins uses a compound library of approximately 420 compounds that explores 
functional diversity by only including compounds that have been shown to have 
biological activity.19 This function-based compound library has a greater likelihood of 
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including compounds that are biologically relevant to the molecular function of the 
protein.19 
In FAST-NMR, the function-based compound library is initially screened against 
the protein of interest using a 1D 1H line-broadening NMR screen. The compounds that 
show line broadening are then followed by a 2D 1H, 15N-HSQC NMR screen to validate 
specific binding and locate the binding site. The 1D line-broadening screens require a 
significant amount of resources for preparation, execution, and analysis. Could virtual 
screening be used to prioritize the compounds in the function-based library instead of 
performing a 1D line-broadening screen?  
Two proteins, SAV1430 and PA1324, have been previously screened using the 
FAST-NMR approach. The results of the 1D line-broadening screens for these proteins 
are compared to the results of the virtual screens using the same function-based 
compound library. The ability of virtual screening to prioritize compounds shown to 
experimentally bind these proteins is then evaluated. 
 
7.2 MATERIALS AND METHODS 
Virtual screens using the function-based compound library were performed on 
two proteins previously screened by FAST-NMR: Staphylococcus aureus protein 
SAV1430 (PDB ID: 1PQX) and Pseudomonas aeruginosa protein PA1324 (PDB ID: 
1XPN).17,20 The function-based compound library used for the virtual screens consists of 
the same 420 compounds that were experimentally screened by FAST-NMR. The two-
dimensional structure for each compound in the library was converted into a three-
dimensional structure using MM2 energy minimization in Chem3D (CambridgeSoft; 
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http://www.cambridgesoft.com). All hydrogens were added to the protein and compounds 
using standard protonation states at a neutral pH. 
Docking was performed using AutoDock 4.0121-23 with the AutoDockTools 1.4.5 
(http://mgltools.scripps.edu)23,24 graphical interface, where 10 different binding 
conformations were simulated for each compound binding with the protein. Each protein 
was docked to the compound library twice, once with the grid encompassing the entire 
protein (blind docking) and again with the grid encompassing the experimental binding 
site identified during the FAST-NMR screens (guided docking). Grid maps were 
generated with 0.447 Å spacing in both cases with enough size to accommodate the 
largest compounds. The docking calculations were performed using the Lamarckian 
genetic algorithm default settings with a population size of 300 and 5,000,000 energy 
evaluations. The calculations were performed on an Intel Xeon 3.06 GHz dual processor 
Linux workstation and required approximately 10 days to complete. 
The docked conformer with the lowest binding energy for each protein-ligand pair 
was selected and then compared to the lowest energy conformers of the other protein-
ligand pairs. Receiver operating characteristics (ROC) curves (described in Chapter 1) 
were generated using the compounds identified as binders during the 1D line-broadening 
screen in FAST-NMR as true positives. From these prior experiments, 21 binders were 
identified for SAV143017 and 20 were identified for PA1324.20 The true positive rates 
were plotted against false positive rates over the full range of AutoDock binding energies 
for both the blind and guided docking. 
  
7.3 RESULTS AND DISCUSSION 
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The ideal goal of virtual screens is to enrich the compound library such that 
selecting a small fraction of highly ranked compounds leads to a greater likelihood of 
including true binders in the experimental screen. In the blind virtual screens of 
SAV1430 and PA1324, neither screen resulted in any significant enrichment of true 
binders [Figure 7.1A,B]. In fact, the true binders had a wide range of binding energies. 
Thus selecting the lowest energy protein-ligand complexes provided no benefit in 
selecting true binders. Of the 20 docked compounds with the lowest binding energies, 
SAV1430 had two true binders while PA1324 had one. None of these true binders for 
were the best binder. In fact, the two true binders for SAV1430 weren’t even docked into 
the experimentally determined binding site; indicating that the high ranking was 
erroneous. The best binder identified in FAST-NMR for both SAV1430 (O-phospho-L-
tyrosine) and PA1324 (suramin) ranked in the bottom 50% of the virtual screen (Table 
7.1). Additionally, neither of these best binders was properly docked into the 
experimentally-determined binding sites of their respective proteins. 
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Figure 7.1 ROC curves showing the true positive rate relative to the false positive rate of 
virtual screens for (A) SAV1430 and (B) PA1324. True positives are defined as the 
compounds that were shown to experimentally bind the proteins in the FAST-NMR 1D 
line-broadening screens. The red ROC curve indicates the results based on a blind virtual 
screen where the docking grid encompasses the entire protein. The blue ROC curve 
indicates the results for a guided virtual screen where the docking grid is focused on the 
experimental binding site. 
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Table 7.1 AutoDock binding energiesa for virtual screens of compound library 
 SAV1430 PA1324 
 Blind Guided Blind Guided 
Range -9.02 to -1.69 -7.21 to 0.25 -9.54 to -0.67 -7.35 to -1.41 
Average -5.51 -4.54 -5.23 -4.82 
Best experimental 
binderb -5.52 (214
th) -5.35 (92nd) -4.40 (331st) -7.35 (1st) 
a  Binding energies in kcal/mol 
b Binding energies and rank among docked compounds in library for best experimental 
binder identified in FAST-NMR screens. 
 
The results of the blind virtual screen are not surprising. Blind docking indicates 
no prior knowledge of the binding site, thus the docking process must spend time 
searching for an energetically favorable binding site as well as orienting the ligand into a 
more favorable conformation and pose.25,26 Despite using a greater number of energy 
evaluations (5,000,000) than the default, these additional resources still could not enrich 
the results of the virtual screens. Additionally, most of the lowest energy binders in these 
virtual screens did not dock into the experimental binding site identified by FAST-NMR. 
The results of the blind screen indicates a virtual screen is unlikely to replace the 
1D line-broadening screen of FAST-NMR as a means to prioritize the ligands for 
screening by 2D 1H, 15N-HSQC. But does the use of a focused function-based compound 
library provide any benefit towards virtual screening enrichment? When the virtual 
screen was run again with the grid set to encompass only the experimentally-determined 
binding site from FAST-NMR, the resulting enrichment did not significantly improve 
[Figure 7.1A,B]. Once again, selecting the lowest energy docked compounds did not 
improve the chances of identifying a true binder. Of the 20 docked compounds with the 
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lowest binding energies, only two of the SAV1430 and PA1324 true binders were 
identified in the virtual screen. Neither of these compounds was identified in the blind 
virtual screen.  
The best binder for SAV1430 (O-phospho-L-tyrosine) had very similar binding 
energies in both the blind virtual screen (-5.52 kcal/mol) and the guided virtual screen (-
5.35 kcal/mol) despite docking to completely different regions on the protein. 
Remarkably, the guided virtual screen did identify the best binder for PA1324 (suramin) 
as having the lowest binding energy. However, this is likely due to the size of suramin 
(1,291 amu), which would undergo a significant number of interactions compared to most 
molecules in the compound library. This is apparent from a comparison of the binding 
energies, where the energy terms defined by van der Waals forces, hydrogen bonding, 
and desolvation had the lowest values (-9.35 kcal/mol in blind screen; -7.80 kcal/mol in 
guided screen) for suramin compared to all the other compounds. On the other hand, the 
positive torsional energy (4.39 kcal/mol) for suramin offset these very low energies, 
which is why suramin was not identified as the lowest energy docked compound in the 
blind virtual screen. The docking energetics of suramin in the guided virtual screen was 
more favorable since the binding pocket contains a very positive electrostatic surface that 
interacts with several negative charges on suramin. This electrostatic interaction 
produced a low electrostatic energy (-3.14 kcal/mol) that contributed significantly to the 
total binding energy. This interaction was also previously determined as an important 
binding component during the functional annotation.20 In the blind screen, the suramin 
molecule was unable to find this positive electrostatic surface. 
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7.4 CONCLUSIONS 
In FAST-NMR, a typical 1D line-broadening screen of the compound library with 
a protein target identifies approximately 20 compounds that would be validated by a 2D 
1H, 15N-HSQC screen. For virtual screens to be a viable replacement, selecting the 20 
compounds with the lowest binding energies to be validated by 1H, 15N-HSQC screens 
should include a significant number of actual binders. Unfortunately, virtual screens of 
SAV1430 and PA1324 showed that no enrichment of actual binders occurred. Thus, 
replacing the experimental 1D line-broadening screen of FAST-NMR with a purely 
computational virtual screen of the same function-based compound library is not 
beneficial. The composition of the compound library does not appear to improve the 
enrichment process. 
Virtual screening does have some benefits for FAST-NMR beyond just replacing 
the 1D line-broadening screen. The guided virtual screens of SAV1430 and PA1324 
show that while the compound library was not enriched, it is still possible to identify tight 
binders. However, this is typically dependent upon the protein system being explored. 
PA1324 has a positive electrostatic surface in the binding pocket that interacts strongly 
with the negative charges of suramin, which made the interaction easier to score. In 
Chapter 6, the virtual screen of YndB was successful because the focused lipid library 
and well-defined hydrophobic pocket of the protein made steric hindrance and 
hydrophobic interactions the primary driving forces.27  
Should virtual screening be used for FAST-NMR? Because the resource cost for 
virtual screening is relatively low, there is some merit in utilizing it to supplement a 
FAST-NMR assay, because it may provide information on favorable binding regions and 
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predict dominant protein-ligand interactions. Virtual screening can also help investigate 
compounds that are not present in the function-based compound library with minimal 
additional effort. In the case of YndB (Chapter 6),27 virtual screening was used because 
experimentally screening a lipid library by NMR was not feasible, and there was 
significant prior evidence to suggest the location of the binding site the identity of likely 
ligands. 
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CHAPTER 8 
HUMAN DNAJA1: A POTENTIAL THERAPEUTIC TARGET FOR 
PANCREATIC CANCER 
  
8.1 INTRODUCTION 
Despite the decline of cancer-related mortality in the past decade, effective 
approaches to early diagnosis and treatment of pancreatic cancer remain elusive. 
Although it accounts for only 3% (43,000 new cases every year) of all cancers, pancreatic 
cancer is the fourth leading cause of cancer death in the United States (37,000 deaths 
annually) and has the highest mortality rate of any cancer.1,2 Those with an operable 
early-stage of the disease have a 5-year survival rate of about 20%.1,3 Unfortunately, 80% 
of all pancreatic cancer diagnoses indicate an advanced stage of the disease that is beyond 
the point of surgery.2-4 Inoperable forms of pancreatic cancer have a five-year survival 
rate of only 3%. The difficulty in detecting or diagnosing pancreatic cancer has several 
causes: the early stages of pancreatic cancer don’t typically exhibit symptoms; the 
symptoms that do occur are often similar to other illnesses; and the location of the 
pancreas behind other organs can hinder detection.2  
Most patients with advanced pancreatic cancer are treated with chemotherapy 
based on gemcitabine, which is a cytotoxic nucleoside drug that primarily inhibits DNA 
synthesis.5 However, this treatment is only mildly effective for patients with an advanced 
stage of pancreatic cancer and only provides a 5.91 month increase in the median survival 
rate.6 Also, gemcitabine-resistant forms of pancreatic cancer or acquired resistance during 
treatment are common problems.7 Correspondingly, there have been numerous attempts 
to combine gemcitabine with other cytotoxic agents, such as 5-fluorouracil or 
capecitabine, however these approaches have been mostly unsuccessful.8 It is apparent 
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that a cytotoxic approach to treating pancreatic cancer is not an effective therapy. 
Therefore, identifying novel, but druggable, protein targets for the treatment of pancreatic 
cancer and improving the quality of life for patients is an essential need. 
 This chapter reports the development of a pancreatic cancer ‘omics database 
(Borg) designed to identify potentially interesting protein targets for drug discovery. The 
human protein DnaJ homolog subfamily A member 1 (DNAJA1) was selected as a 
potentially interesting therapeutic target for the treatment of pancreatic cancer. The 
potential importance of DNAJA1 to pancreatic cancer is demonstrated with stress-
response cell-based assays using cell-lines overexpressing DNAJA1. Additionally, the 
structure of the J-domain of DNAJA1 (A1-JD) was determined by NMR spectroscopy 
followed by the identification of potential binding sites using a ligand-based NMR 
screen. 
  
8.2 MATERIALS AND METHODS 
 8.2.1 Selection of DNAJA1 from a pancreatic cancer ‘omics database. The 
scientific literature was searched to identify proteins potentially associated with 
pancreatic cancer. Five separate proteomic studies identified a total of 844 unique 
proteins that were differentially expressed in various pancreatic cancer cell lines.9-13 
Additionally, three separate genomics studies of mutation frequency or gene expression 
in 71 pancreatic cancer cell lines identified 4,492 genes that are significantly 
modulated.13-15 The resulting 5,336 proteins/genes were combined into a pancreatic 
cancer ‘omics database and evaluated with a simplistic, unsupervised method (Borg) to 
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bridge the gap between the large number of proteins/genes and human protein 
annotations. 
 In Borg, each protein or gene identified in the database was manually assigned a 
reviewed UniProtKB16,17 accession number in order to facilitate a uniform starting point 
for bioinformatics analysis. The UniProtKB accession numbers were used to cross-
reference the RCSB Protein Data Bank (PDB)18,19 to determine if an experimental 
structure exists for each protein. Additionally, homologous structures were identified 
with a BlastP20,21 sequence search against the RCSB PDB using an E-value of less than 1 
x 10-10. These protein sequences were also used to search the PSI: Knowledgebase22 to 
identify similar structures (structure count with E-value < 0.001) and targets (target count 
with E-value < 0.001). 
 Prioritization of potential therapeutic targets proceeded by generating a functional 
network of the proteins identified in the ‘omics database using protein function 
annotations from GO,23 OMA,24 BindingDB,25 DIP,26 eggNOG,27 Ensembl,28 KEGG,29,30 
PFAM,31 STRING,32 and RCSB PDB18,19 databases.‡‡ Each protein was given a binary 
score (“1” if the protein has the annotation or “0” if it does not) for each of the 7,795 
possible functional annotations identified from these databases. The dimension space of 
this dataset was reduced to three dimensions using principal component analysis (PCA), 
and then clustered into functionally distinct groups using Gaussian mixture models.  
Proteins in each cluster without experimental structures were then prioritized by 
assigning scores based on their annotation count, their neighboring nodes in STRING32 
                                                
‡‡ The functional clustering of the pancreatic cancer ‘omics database was developed and 
performed by Brad Worley using the in-house Borg software. 
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and DIP26 interaction networks, and the annotation counts of those neighboring nodes. 
The DIP (𝑊!,!) and STRING (𝑊!,!) scores were calculated as follows [Equation 8.1]: 
𝑊!,! = 1𝑙! 𝑙!!:!!∈!!                   and              𝑊!,! = 1𝑙! 𝑙!!:!!∈!!                                                                     (1) 
where the sum of the normalized lengths (l) from the set of all DIP/STRING interaction 
partners j with protein i, divided by the normalized length of protein i. Normalized length 
of a protein is the number of annotations divided by the maximum number of annotations 
in the database. 
8.2.2 Effect of DNAJA1 overexpression on pancreatic cell stress 
modulation.§§ MiaPaCa2 cells were obtained from the American Type Culture 
Collection (Rockville, MD). Cells were cultured as previously described.33 Briefly, 
MiaPaCa2 cells were maintained in Dulbecco's Modified Eagle's Medium (Life 
Technologies, Inc.) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 
nonessential amino acids, sodium pyruvate, and penicillin/streptomycin in 37°C 
incubator with 5% CO2. To stably express Full length His-tagged DNAJA1 construct, 
retroviral transductions were done essentially as described previously.34  
Cell lysates were prepared by scraping cells (80-90% confluent) into lysis buffer 
[50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 1% Triton x-100 (v/v), 1% sodium 
deoxycholate (w/v), and 0.1% SDS (w/v) 5 mM EDTA and 1 mM 
phenylmethylsulphonyl fluoride]. Lysates were incubated, on ice, for 30 min. and 
centrifuged at 4°C for 15 minutes at 13,000 rpm to remove cell debris. Supernatants were 
transferred to fresh tubes and protein content was determined using the Bradford protein 
                                                
§§ The evaluation of the effect of DNAJA1 overexpression on pancreatic cell stress modulation 
was performed by the lab of Dr. Pankaj Singh at the University of Nebraska Medical Center. 
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assay reagent (Bio-Rad) with various concentrations of bovine serum albumin as 
standards. Cell lysates were stored at -20 or -80°C. Cell lysate proteins were resolved on 
10% or 12% Tris-Glycine denaturing polyacrylamide gels in a 1x SDS-PAGE buffer 
(1g/liter SDS, 3g/liter Tris base, and 14.4g/liter glycine). Western blotting was performed 
as previously described.35,36  
Cell survival was evaluated by MTT assay as described elsewhere.37 Cells were 
plated in triplicate in 96-well plates at 5,000 cells per well and incubated at 37°C. 12 
hours later, cells were treated with anisomysin or solvent control and incubated for 24 
hours. At the end point, the culture medium was removed and 20 µl of MTT solution 
(5mg/ml, Sigma) was added per well, followed by a 2 hour incubation. MTT was 
removed and 200 µl of DMSO were added to each well to dissolve formazan. Formazan 
optical density was determined by utilizing a microplate reader at a wavelength of 
540nm. 
8.2.3 Solution structure of the DNAJA1 J-domain. The full human DNAJA1 
protein (397 amino acids) has been targeted by the Northeast Structural Genomics 
Consortium (NESG; http://www.nesg.org) for structural elucidation as HR3099 (UniProt 
ID: P31689) [Figure 8.1]. The J-domain of DNAJA1 (DNAJA1-JD; NESG ID: 
HR3099K) was selected for structural determination by NMR due to its high DIP and 
STRING scores, small size (67 amino acids) and proposed importance for binding to 
DnaK (Hsp70), an important heat shock protein involved in stress response and cancer.38-
42 
The NESG provided uniformly labeled 13C,15N-enriched DNAJA1-JD (77 amino 
acids with  10 non-native residues MGHHHHHHSH at the N-terminus for purification). 
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The protein construct containing the sequence for DNAJA1-JD was transformed into 
BL21 (DE3) + Magic cells. The soluble fraction of the lysed cells was collected and 
purified with a Ni-NTA affinity column (Qiagen) and gel filtration column (HiLoad 
26/60 Superdex 75 pg, Amersham Biosciences) chromatography. The NMR protein 
sample was stored in a sealed Shigemi tube with 20 mM 2-(4-morpholino)ethanesulfonic 
acid (MES; Sigma-Aldrich) buffer, pH 6.5 (uncorrected) with 10% D2O (Isotec), 0.02% 
NaN3 (Sigma-Aldrich), 10 mM dithiothreitol (DTT, Sigma-Aldrich), 5 mM CaCl2 
(Sigma-Aldrich), 100 mM NaCl (Sigma-Aldrich), and 50 µM 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS; Sigma-Aldrich). 
 
Figure 8.1 Protein sequence of DNAJA1 (UniProtKB ID: P31689). The red residues 
indicate the 67 amino acids of the J-domain (A1-JD). 
 
NMR experiments used for the protein backbone and sidechain assignments of 
DNAJA1-JD were collected at 298 K on a 600 MHz Bruker Avance spectrometer 
equipped with a 5 mm TXI probe. The backbone and sidechain assignments were 
completed using the standard and manual triple-resonance approach43-45 using the 
following NMR experiments: two-dimensional (2D)-1H,15N-HSQC; 2D-1H,13C-HSQC; 
MVKETTYYDVLGVKPNATQEELKKAYRKLALKYHPDKNPNEGEKFKQIS
QAYEVLSDAKKRELYDKGGEQAIKEGGAGGGFGSPMDIFDMFFGGGGRM
QRERRGKNVVHQLSVTLEDLYNGATRKLALQKNVICDKCEGRGGKKGAV
ECCPNCRGTGMQIRIHQIGPGMVQQIQSVCMECQGHGERISPKDRCKSC
NGRKIVREKKILEVHIDKGMKDGQKITFHGEGDQEPGLEPGDIIIVLDQ
KDHAVFTRRGEDLFMCMDIQLVEALCGFQKPISTLDNRTIVITSHPGQI
VKHGDIKCVLNEGMPIYRRPYEKGRLIIEFKVNFPENGFLSPDKLSLLE
KLLPERKEVEETDEMDQVELVDFDPNQERRRHYNGEAYEDDEHHPRGGV
QCQTS 
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and three-dimensional (3D) HNCO; HN(CA)CO; HNCA; HN(CO)CA; CBCA(CO)NH; 
CBCANH; HNHA; HBHA(CO)NH; CC(CO)NH; HCC(CO)NH; H(CC)H-COSY; and 
H(CC)H-TOCSY experiments. 15N-edited NOESY-HSQC and 13C-edited NOESY-
HSQC experiments were collected on a 500 MHz Bruker Avance spectrometer equipped 
with a triple-resonance, Z-axis gradient cryoprobe to identify nuclear Overhauser effects 
(NOEs). Amide hydrogen exchange rates were also evaluated on the 500 MHz Bruker 
Avance spectrometer using the (CLEANEX-PM)-FHSQC experiment. 
The NMR experimental data was processed using NMRPipe46 and evaluated in 
CCPNMR Analysis (http://www.ccpn.ac.uk).47 An initial homology model of DNAJA1-
JD was generated from the protein backbone resonances using CS-ROSETTA on the 
WeNMR GRID-enabled web portal (www.enmr.eu/webportal).48-50 
The initial model of DNAJA1-JD was refined with XPLOR-NIH 2.3151 using the 
following experimental restraints: NOE distance restraints (1,070 restraints), H-bond 
distance and angle restraints (50 restraints), 3JNHα coupling constant restraints (38 
restraints), 13Cα/13Cβ chemical shift restraints (127 restraints), and dihedral angle 
restraints (116 restraints) predicted from TALOS+.52 All peptide bonds were constrained 
to be planar and trans. A total of 400 structures were calculated with the 20 lowest 
energy structures being subjected to explicit water refinement based on the RECOORD 
protocols.53 An average DNAJA1-JD structure was calculated based on the average atom 
coordinates of the 20 water-refined structures and subsequently minimized using the 
same explicit water refinement above. 
The resulting structures were evaluated using the PSVS software suite,54 which 
includes Verify3D,55 ProsaII,56 PROCHECK,57 and Molprobity.58 The three-dimensional 
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structures of the proteins are represented here using the UCSF Chimera package from the 
Resource for Biocomputing, Visualization, and Informatics at the University of 
California, San Francisco (http://www.cgl.ucsf.edu/chimera). ClustalW59 was used (with 
default settings) to align the sequences of DNAJA1-JD with the J-domains of four 
homologous proteins: E. coli DnaJ J-domain (PDB ID: 1XBL);60 H. sapiens Hsp40 
(HDJ-1) J-domain (PDB ID: 1HDJ);61 H. sapiens HSJ1a (PDB ID: 2LGW);62 and H. 
sapiens DnaJ subfamily C member 12 (PDB ID: 2CTQ). Electrostatic surface potentials 
of the protein were calculated using Delphi.63 The identification of evolutionarily 
conserved residues using both sequence and structure was performed using the ConSurf 
server with default settings.64 
8.2.4 Identification of a ligand binding site on the DNAJA1 J-domain. To 
experimentally determine potential small molecule binding sites, a high-throughput NMR 
ligand affinity screen using the FAST-NMR compound library (described in Chapter 2 
and elsewhere)65,66 was performed. The 1D line broadening ligand-based screen and 2D 
1H,15N-HSQC protein-based screen follows the same procedure outlined in Chapter 2 
using 10 µM and 30 µM DNAJA1-JD (5% 13C, 100% 15N-labeled; provided by the 
NESG), respectively. The concentrations for the compounds were 100 µM in the 1D line-
broadening screen and 400 µM in the 2D 1H,15N-HSQC screen. 
The NMR spectra for the ligand affinity screens were collected on a 500 MHz 
Bruker Avance spectrometer equipped with a triple-resonance, Z-axis gradient cryoprobe 
with a Bruker BACS-120 sample changer. All 1D 1H NMR spectra were processed with 
the ACD/NMR Processor (ACD/Labs) and 2D 1H,15N-HSQC spectra were processed 
with NMRPipe46 and visualized in CCPNMR Analysis.47 
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The chemical shift perturbations (CSPs) between the resonances of the free 
protein and ligand-bound protein 2D 1H,15N-HSQC spectra were used to define the 
consensus binding site using CSP-Consensus (described in Chapter 4). AutoDock 4.2.367-
69 with AutoDockTools 1.5.469,70 (http://mgltools.scripps.edu) graphical interface was 
used to calculate 120 protein-ligand costructures, which were filtered using 
AutoDockFilter 2.0 (described in Chapter 3 and Chapter 4)71 to identify the costructures 
that best agree with the experimental CSPs. 
 
8.3 RESULTS AND DISCUSSION 
8.3.1 Selection of DNAJA1 from a pancreatic cancer ‘omics database. The 
goal of the pancreatic cancer ‘omics database is to focus the search for potentially 
interesting therapeutic targets. The ‘omics database contains 5,336 proteins/genes, which 
represents approximately 26% of the human genome. Clearly, not all of the proteins 
identified in these proteomics and genomics studies are related to pancreatic cancer or 
therapeutically important, thus additional efforts are required to prioritize the most 
relevant proteins. 
Within the ‘omics database, approximately 26% (1,194 proteins) have no known 
function and have been assigned as “putative”, “uncharacterized”, or “unknown” 
proteins. These uncharacterized proteins are potential therapeutic targets for pancreatic 
cancer, however determining the function of a protein is challenging. One approach to 
infer the function of these proteins is to leverage sequence and structural homology to 
proteins with known function. However, only 14% of the functionally uncharacterized 
proteins have a known structure, which hinders functional annotation by structural 
 251 
comparisons. Using sequence similarity of the uncharacterized proteins to find 
homologous proteins with a structure, the number of proteins with an experimental or 
homologous structure rises to 34%. Unfortunately, these structures, while important, do 
not provide enough information to functionally annotate the proteins, determine its 
potential role in pancreatic cancer, and develop a therapy based on that role. 
Instead of focusing on the uncharacterized proteins alone, another approach to 
prioritize the database would be to leverage the annotation and interaction information 
from several databases to develop a functional network. Functional pathways that are 
well represented in the ‘omics database hint at the importance of the proteins in that 
pathway towards pancreatic cancer. Additionally, uncharacterized proteins that have an 
association with many highly annotated proteins would make for potentially interesting 
protein targets. 
Based on the annotations from several databases (7,795 annotations), a functional 
network was generated that identified six broad functional classifications [Figure 8.2]: (1) 
DNA binding, transcription regulation, and transcription factors; (2) transmembrane 
signaling and transport activity; (3) chromatin, histone modification, and transcription 
regulation; (4) stress response and signaling; (5) translation and biosynthetic processes; 
and (6) mitosis and cytokinesis. Proteins within these clusters were then evaluated based 
on DIP (𝑊!,!) and STRING (𝑊!,!) scores, which identify those proteins that are 
associated with highly annotated functional pathways. Other factors, such as small size (< 
200 amino acids) and likely solubility, were evaluated for amenability to NMR structure 
determination. 
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Based on the above criteria, the human protein DnaJ-homolog A member 1 
(DNAJA1) was identified as having 25 annotations and DIP (𝑊!,!) and STRING (𝑊!,!) 
scores of 4.4 and 11.0, respectively. This indicates that DNAJA1 is associated with other 
well-annotated proteins in the 'omics database and is involved in a pathway that may be 
important in pancreatic cancer. In the pancreatic cancer 'omics database, DNAJA1 was 
shown to be down-regulated five-fold in pancreatic cancer cells relative to normal healthy 
cells and cells undergoing pancreatitis.12 
 
 
Figure 8.2 (Left) Functional network of the 5,336 proteins within the 'omics database. 
Proteins are color-coded based on functional clustering. Proteins involved in small 
isolated networks are shown below the primary network. (Right) Expanded view of the 
network for DNAJA1 (UniProtKB: P31689). Only the nearest neighbors are shown. 
Brown nodes indicate a general functional classification of mitosis and cytokinesis. Dark 
blue nodes indicate a general functional classification of chromatin, histone modification, 
and transcription regulation. Light blue nodes indicate a general functional classification 
of translation and biosynthetic processes. Grey nodes are proteins not present in the 
pancreatic cancer 'omics database, but have been shown to be associated with DNAJA1. 
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The protein DNAJA1 belongs to the family of proteins known as DnaJ proteins. 
The DnaJ proteins, also known as heat shock protein 40 (Hsp40 or Hsc40), are proteins 
originally identified in E. coli that act as co-chaperones to the molecular chaperone DnaK 
(Hsp70), which is responsible for several cellular processes such as rescuing misfolded 
proteins, folding polypeptide chains, transport of polypeptides through membranes, 
assembly and disassembly of protein complexes, and control of regulatory proteins.72-74 
DnaJ primarily facilitates the hydrolysis of ATP from DnaK which is necessary for the 
chaperone activity of DnaK.74-76  
There are over 41 members of the DnaJ family encoded in the human genome, 
where little is known about their specific biological functions.73 However, the specific 
DnaJ protein that binds DnaK appears to determine the activity of the complex.74 Each 
specific DnaJ protein can be classified into three subfamilies (A, B, C), with subfamily A 
closely resembling the DnaJ protein of E. coli.77 DnaJ subfamily A proteins typically 
consist of three distinct domains: (1) a highly conserved J-domain region of 
approximately 70 amino acids found near the N-terminus, which mediates the interaction 
with DnaK;76,78 (2) A G/F-rich region acting as a flexible linker; and (3) a cysteine-rich 
region containing 4 motifs resembling a zinc-finger domain. DnaJ subfamily B proteins 
do not typically have the cysteine-rich region, while DnaJ subfamily C proteins only have 
the J-domain.74 
In general, J-domain proteins modulate protein assembly, disassembly, and 
translocation.79 DnaJ subfamily A member 1 (DNAJA1) human protein has been shown 
to associate on its own with unfolded polypeptide chains and prevent their aggregation.80 
It has also been shown to regulate androgen receptor signaling and spermatogenosis in 
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mice.77 DNAJA1 has been reported to contribute to the resistance of glioblastomas to 
radiotherapy81 and has also been targeted as a biomarker for pancreatic cancer in order to 
evaluate the effects of FPTase inhibitors.82,83 Additionally, DNAJA1 appears to be 
involved in importing proteins into the mitochondria. 84,85 Of course, the mitochondrial 
pathway to apoptosis protects against cancer and requires importing apoptotic factors into 
the mitochondrial membrane.86-89 However, there have been no studies of whether the 
conserved J-domain of DnaJ alone has any role in cancer biology independent of DnaK.73 
Additionally, DNAJA1 is an interesting target based on its association with DnaK, which 
is expressed abundantly in various tumors and may even promote tumorigenesis by 
inhibiting cell death.40-42,90-92 
8.3.2 Effect of DNAJA1 overexpression on pancreatic cell stress modulation. 
The pancreatic cancer 'omics database and functional networking approaches identified 
DNAJA1 as a potentially interesting target for investigation. However, it is vital 
importance that experimental evidence is used to verify that DNAJA1 is a relevant target 
in pancreatic cancer. Cell-based functional assays were performed in order to identify any 
cancer related properties. MiaPaCa2 cells stably expressing DNAJA1 or vector control 
were subjected to a 1-hour incubation with anisomycin (370nM), a protein synthesis 
inhibitor, or UV treatment at 20 J/m2 or at 50 J/m2 doses to mimic stress. Activation of 
stress-induced JNK pathway was measured by evaluating the downstream 
phosphorylation of c-jun at 20 min post-treatment. The results indicate that 
overexpression of DNAJA1 diminishes anisomycin and UV-induced c-jun 
phosphorylation at S63 [Figure 8.3A]. Cell survival was also evaluated by performing an 
MTT assay 24 hours after treatment with anisomycin. The results indicate that DNAJA1 
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expression decreased cell survival under conditions of anisomycin treatment [Figure 
8.3B]. Expression of the DNAJA1 protein in MiaPaCa2 pancreatic cancer cell lines 
resulted in the cells being more susceptible to stress-induced (UV-induced DNA damage 
or anisomycin-induced inhibition of protein synthesis) apoptosis [Figure 8.3]. This 
effectively suppresses the phosphorylation-mediated activation of the oncogenic 
transcription factor, c-Jun, which is often found overexpressed and hyperphosphorylated 
in cancer93-95 and has an essential role in pancreatic cancer.96,97 c-Jun is a member of the 
JNK signaling pathway, and its transcriptional activity and expression is primarily 
regulated by the phosphorylation of two serines, Ser63 and Ser73.98-101 c-Jun regulates a 
range of cellular processes including apoptosis, tumorigenesis, and cell proliferation, 
which includes protecting cells from induced cell death.100,101 This makes c-Jun both a 
positive and negative regulator of cell death [Figure 8.4A]. However, in several cancers, 
c-Jun has been shown to inhibit apoptosis, leading to the uncontrolled growth typical of 
cancer.102-104 
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Figure 8.3 (A) The expression of His-tagged DNAJA1 in MiaPaCa2 pancreatic cancer 
cells suppresses the activation of c-Jun in response to anisomycin (370 nM) or UV 
treatement. 20 min-post treatment cells were subjected to lysis and the levels of phosphor 
c-jun (S63) and total c-jun were evaluated by western blotting. Expression levels of 
exogenously expressed DNAJA1 were evaluated by immunoblotting with anti-His 
antibody, while immunoblotting with anti-tubulin antibody was performed as a loading 
control (B) The expression of DNAJA1 in MiaPaCa2 pancreatic cancer cells decreases 
the survival in response to anisomycin treatment-induced stress. The cell survival was 
measured by MTT assay 24 hour post-treatment. (** indicates p < 0.01; *** indicates p < 
0.001) 
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Interestingly, heat-shock proteins have also been shown to be regulators of 
apoptosis, where DnaK (Hsp70) suppresses JNK activity.105-107 Thus our preliminary 
results suggest DNAJA1 stimulates the DnaK suppression of a JNK-induced anti-
apoptotic signaling pathway by forming a complex with DnaK [Figure 8.4B]. This 
hypothesis is consistent with the five-fold down-regulation of DNAJA1 in pancreatic 
cancer cells, the resulting suppression of c-Jun phosphorylation, and the corresponding 
susceptibility to stress-induced apoptosis by expressing DNAJA1. Obviously, protection 
from stress-induced apoptosis by down-regulating DNAJA1 would be beneficial since 
cancer cells, by definition, exist in a stressful environment. 
 
 
Figure 8.4 An illustration of the role of c-Jun in the JNK pathway under different 
phosphorylation states. 
 
8.3.3 Solution structure of the DNAJA1 J-domain. The backbone resonance 
assignments were completed using the 2D and 3D NMR experiments described above 
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(2D 1H, 15N-HSQC, HNCO, HN(CA)CO, HNCA, HN(CO)CA, CBCANH, 
CBCA(CO)NH, and HNHA). This resulted in 85.7% of the 77 amino acids in the protein 
unambiguously assigned in the 1H, 15N-HSQC. When excluding the non-native 10-
residue N-terminal His-tag used for purification and the prolines for which no amide 
exists, the assignment improves to 98.4% (63/64). The one amino acid for which the 
amide could not be assigned was Met11, which is the first residue following the His-tag. 
The side chain assignments were completed using a combination of the CC(CO)NH, 
HCC(CO)NH, H(CC)H-COSY, and H(CC)-TOCSY 3D NMR experiments. The 
backbone and sidechain assignments, not including 10-residue His-tag, were nearly 
complete with 63/67 N, 63/64 HN, 67/67 Cα, 70/70 Hα, 63/64 Cβ, 113/115 Cβ, 43/62 Cγ, 
66/74 Hγ, 26/48 Cδ, 40/54 Hδ, 11/21 Cε, 14/34 Hε, 0/9 Cζ, and 0/1 Hζ atoms assigned. 
Using the backbone resonance assignments, a homology structure of DNAJA1-JD 
was generated using CS-ROSETTA, which utilizes chemical shifts to select protein 
fragments from the PDB followed by Monte Carlo assembly and relaxation by Rosetta. 
This tool has been shown to be effective in predicting protein structures for small proteins 
up to 16 kDa. The homology model generated from CS-ROSETTA exhibited the same 
secondary structure as most DnaJ proteins and agreed with the secondary structure 
predicted from TALOS. All available backbone and side chain chemical shift 
assignments will be deposited into the Biological Magnetic Resonance Data Bank 
(BMRB; http://www.brmb.wisc.edu). 
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Figure 8.5 Complete backbone of 1H and 15N assignments of human DNAJA1-JD in a 
2D 1H, 15N-HSQC spectrum. 
  
The solution structure of DNAJA1-JD was calculated using 1,120 distance 
restraints, 116 dihedral restraints, 127 Cα/Cβ carbon chemical shift restraints, and 38 
3JNHα coupling constant restraints. The restraints used during the structure calculation are 
reported in [Table 8.1]. XPLOR-NIH was used to calculate 400 structures, and the 20 
lowest energy structures were selected for further refinement in water using the 
RECOORD protocol implemented in XPLOR-NIH. The resulting ensemble and average 
structures [Figure 8.6] agreed well with the NMR data, where the experimental restraints 
had low rms deviations [Table 8.1]. The water-refined average structure had no NOE 
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violations greater than 0.5 Å or dihedral violations greater than 5°. The water-refined 
ensemble of 20 structures had a backbone RMSD of 0.709 ± 0.119 Å to the unrefined 
average coordinates. This result improves to 0.399 ± 0.086 Å when only the residues 
involved in the more stable secondary structure elements are evaluated, which indicates 
the consistency of the structure calculation using the experimental restraints [Table 8.2]. 
In addition, comparing the original CS-ROSETTA homology model to the final water-
refined average structure showed a backbone RMSD of 1.803 Å (full protein) and 0.889 
Å (secondary structure). 
The PSVS software suite was used to verify the quality of the ensemble and 
average structures [Table 8.3]. Few unreasonable atom clashes were identified by the 
Molprobity module, and overall has very good Z-score (-1.59) compared to the average 
Z-score for NMR structures in the RCSB PDB (-10.74).54 This is actually comparable to 
the Z-scores of medium resolution protein structures found in the RCSB PDB (-1.39).54 
An evaluation of the probable dihedral angles expected for each residue using 
PROCHECK also shows impressive Z-scores (1.65 for Φ/ψ dihedrals and 1.48 for all 
dihedrals). Additionally, the 98.5% of the residues, for both the ensemble and average 
structures, fell within the most favored regions of Ramachandran space, where only one 
residue, Val12, existed in just the allowed region. Overall, the results indicate that the 
final ensemble and average models are good structures with little to no unreasonable 
structural features. The coordinates of the water-refined ensemble and the water-refined 
average structure will be deposited in the RCSB PDB. 
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Table 8.1 Structure calculation statisticsa 
 <SA> (SA)r 
RMSD distance restraints (experimental) (Å)   
    All (1120) 0.083 ± 0.001 0.082 
    Inter-residue sequential (|i-j| = 1) (269) 0.082 ± 0.003 0.086 
    Inter-residue short range (1 < |i-j| < 5) (221) 0.078 ± 0.005 0.073 
    Inter-residue long range (|i-j| ≥ 5) (80) 0.108 ± 0.008 0.098 
    Intra-residue (500) 0.084 ± 0.002 0.085 
    H-bonds (50) 0.038 ± 0.008 0.029 
RMSD Dihedral angle restraints (°) (116) 0.027 ± 0.044 0.00 
RMSD Cα and Cβ shifts restraints (ppm) (127) 0.873 ± 0.036 0.907 
RMSD 3JNHα restraints (Hz) (38) 0.536 ± 0.038 0.540 
RMSD (covalent geometry)   
    Bonds (Å) 0.007 ± 0.000 0.007 
    Angles (°) 0.649 ± 0.015 0.647 
    Impropers (°) 0.794 ± 0.037 0.778 
Energy (kcal/mol)   
    Total -2620.08 ± 70.18 -2834.43 
    Bond 37.44 ± 2.35 36.16 
    Angle 94.07 ± 4.69 95.65 
    Dihedral 0.02 ± 0.04 0.00 
    Impropers 33.44 ± 2.77 31.56 
    van der Waals -262.40 ± 10.76 -273.46 
    NOE 230.11 ± 7.09 226.01 
    3JNHα 10.99 ± 1.60 11.08 
    Cα and Cβ shifts 49.16 ± 4.30 52.92 
   
a  <SA> represents the final 20 water refined simulated annealing structures. (SA)r 
represents the water refined average structure of all 20 water-refined structures. 
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Table 8.2 Atomic rms differencesb 
 Full protein (residues 11-77) Secondary Structure 
 Backbone  atoms 
All heavy 
atoms 
Backbone  
atoms 
All heavy 
atoms 
<SA> vs SA 0.709 ± 0.119 1.417 ± 0.110 0.399 ± 0.086 1.232 ± 0.134 
<SA> vs (SA)r 0.888 ± 0.136 1.739 ± 0.139 0.639 ± 0.155 1.605 ± 0.131 
(SA)r vs SA 0.649 1.217 0.523 1.183 
b  <SA> represents the final 20 water-refined simulated annealing structures. SA 
represents the average structure of all 20 water-refined structures. (SA)r represents the 
water-refined average structure of all 20 water-refined structures. 
 
Table 8.3 Structure evaluationc 
 <SA> (SA)r 
PSVS Z-scoresd   
    Verify3D -0.80 -0.16 
    ProsaII (-ve) 2.40 2.52 
    Procheck (phi-psi) 1.65 1.46 
    Procheck (all) 1.48 1.54 
    MolProbity clash score -1.59 -1.56 
Ramachandran spacee   
    Most favored regions 98.5 % 98.5 % 
    Allowed regions 1.5 % 1.5 % 
    Disallowed regions 0.0 % 0.0 % 
   
c  <SA> represents the final 20 water-refined simulated annealing structures. (SA)r 
represents the water-refined average structure of all 20 water-refined structures. 
d Calculated with PSVS (more positive scores are better) 
e Calculated with Molprobity module in PSVS 
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The secondary structure and fold for DNAJA1-JD are characteristic for the other 
J-domains found in DnaJ homologs in most species. The structure consists of four α-
helices: residues 17-21 (α1); 29-42 (α2); 52-65 (α3); and 68-75 (α4) [Figure 8.6]. The 
loop between α2 and α3 (residues 43-51) contains the highly conserved His-Pro-Asp 
(HPD) motif (residues 44-46). 
 
 
Figure 8.6 (A) An overlay of the backbone trace of the 20 lowest energy, water-refined 
structures. (B) A ribbon representation of the average structure generated from the 
average atomic coordinates of the 20 lowest energy, water-refined structures, followed by 
water refinement of the average structure. Both structures are colored according to 
secondary structure: α-helix (red) and loop (white). 
 
When DNAJA1-JD was selected for structural work, there was no example of a 
DnaJ subfamily A member 1 protein in the RCSB PDB. However, since that time, a 
solution structure of the J-domain of human DnaJ subfamily A member 1 protein has 
been deposited in the PDB (PDB ID: 2LO1), which is the same protein (albeit with four 
more residues) as DNAJA1-JD. A comparison between 2LO1 and DNAJA1-JD show 
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significant agreement between the two structures, with a backbone RMSD of 1.751 Å (all 
residues) and 1.088 Å (secondary structure). While the two structures are fairly similar, 
evaluation of the structure of 2LO1 using PSVS indicates some differences from 
DNAJA1-JD. The Molprobity clash Z-score for 2LO1 (3.32) is significantly better than 
the score obtained from DNAJA1-JD (-1.56). Also, the Verify3D Z-score for 2LO1 
(0.40) is better than DNAJA1-JD (-0.80). However, the Z-score results of ProsaII (1.18), 
Procheck (phi-psi: -0.24), Procheck (all dihedral: -0.44), and Ramachandran space (6.9% 
allowed and 1.1% disallowed) for 2LO1 are significantly worse than that seen in 
DNAJA1-JD. These results indicate that 2LO1 has minimized the steric clashes, probably 
with a slightly more extended structure [Figure 8.7], at the expense of better 
stereochemistry and agreement with known protein folds. 
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Figure 8.7 Overlay of the ribbon structures for DNAJA1-JD (red) compared to the 
previously solved structure, 2LO1 (blue). 
 
The structures of 28 DnaJ proteins in various organisms have been solved. Most 
of these proteins (16 structures) are from humans, with the majority belonging to DnaJ 
subfamily B (6 structures) and DnaJ subfamily C (8 structures). The tertiary structure of 
DNAJA1-JD was compared to a few representative structures: E. coli DnaJ J-domain 
(PDB: 1XBL); human DnaJ homolog subfamily B member 1 J-domain (PDB: 1HDJ); 
human DnaJ homolog subfamily B member 2 J-domain (PDB: 2LGW); and human DnaJ 
homolog subfamily C member 12 J-domain (PDB: 2CTQ). All four proteins have 
essentially the same tertiary structure as DNAJA1-JD with PDBeFold Z-scores of 5.148 
(2.08 Å RMSD), 6.872 (1.65 Å RMSD), 4.541 (2.24 Å RMSD), and 6.904 (1.37 Å 
RMSD), respectively [Figure 8.8]. The different DnaJ homolog subfamilies do not appear 
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to have a significant difference in structure especially since the best matched structure to 
DNAJA1 belongs to DnaJ homolog subfamily C. The true difference in these subfamilies 
likely stems from differences in the other regions of the DnaJ proteins. 
 
 
Figure 8.8 Overlay of the ribbon structure for DNAJA1-JD (red) with (A) E. coli DnaJ J-
domain (PDB: 1XBL), (B) H. sapiens DnaJ homolog subfamily B member 1 J-domain 
(PDB:1HDJ), (C) H. sapiens DnaJ homolog subfamily B member 2 (PDB: 2LGW), and 
(D) H. sapiens DnaJ homolog subfamily C member 12 (PDB: 2CTQ). 
 
 267 
The sequence of human DNAJA1-JD is also very well conserved with J-domains 
from other organisms, with 56 proteins having ≥ 49% sequence identity. The sequences 
of the representative proteins 1XBL, 1HDJ, 2LGW, and 2CTQ have sequence identities 
of 51%, 56%, 47%, and 32%, respectively [Figure 8.9]. As expected, all five proteins 
have the highly conserved HPD motif present. Additionally, the α2-helix is highly 
conserved for all of the proteins except for 2CTQ. This is interesting as the α2-helix tends 
to be positively charged and represents a possible binding spot for DnaK (Hsp70) [Figure 
8.10].  
 
 
Figure 8.9 ClustalW comparison of DNAJA1-JD (HR3099K) with 1HDJ (blue), 1XBL 
(green), 2LGW (yellow), and 2CTQ (cyan). The highly conserved HPD sequence is 
outlined in a black box. The residues that make up the α2-helix are outlined with a red 
box. 
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Figure 8.10 An electrostatic surface representation of DNAJA1-JD (positively charged: 
blue and negatively charged: red). The large positively charged region corresponds to the 
residues of the α2-helix. 
 
8.3.4 Identification of a ligand binding site on the DNAJA1 J-domain. One of 
the primary functions for DnaJ is to stimulate the ATPase activity of DnaK. If DNAJA1 
were to act as a potential therapeutic target, understanding the binding interactions that 
can be influenced would help in the potential development of drug. The primary function 
of the J-domain of DnaJ is to bind to the ATPase domain on DnaK. As previously 
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mentioned, the main feature of the J-domain proteins is a highly conserved HPD motif 
[Figure 8.11], which may indicate its importance in binding to DnaK. 
 
 
Figure 8.11 (A) A ribbon representation of the conserved residues of DNAJA1-JD. (B) A 
surface representation of the conserved residues of DNAJA1-JD. (C) A 90° rotation of 
the surface representation of the conserved residues of DNAJA1-JD, which highlights the 
highly conserved HPD motif. The highly conserved residues (magenta) and poorly 
conserved residues (cyan) were calculated with Consurf. 
 
The RCSB PDB contains only one example of a J-domain in complex with DnaK. 
This example (PDB ID: 2QWN) is a crystal structure of the bovine auxilin (DnaJ 
homolog subfamily C) J-domain chemically cross-linked with bovine DnaK at the 
conserved HPD motif.72,108 A sequence alignment of the residues between the bovine 
auxilin J-domain and DNAJA1-JD allows for a prediction of the proposed DnaJ-DnaK 
interaction site [Figure 8.12A]. This proposed binding site includes the highly conserved 
HPD motif. However, there is some contention as to whether the cross-linked complex is 
biologically relevant or whether auxilin accurately represents most DnaJ interactions with 
DnaK.108-110 
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A previous analysis observed the chemical shift perturbations in 2D 1H,15N HSQC 
experiments when the E. coli DnaJ J-domain is bound to E. coli DnaK.111 The majority of 
the perturbed residues in E. coli DnaJ J-domain occurred along the α2-helix. An 
alignment of the sequence between E. coli DnaJ J-domain and human DNAJA1-JD 
allows for the mapping of those same perturbed residues [Figure 8.12B], which also 
indicates that the binding site is along the α2-helix, not the HPD motif. The α2-helix is 
intriguing as a binding site because of its positively charged surface [Figure 8.10]. 
Additionally, the proposed binding site on DnaK has a negatively charged surface, which 
supports the possibility of the α2-helix as the binding site for DnaK. Additionally, 
mutations of residues in the α2-helix inhibit the DnaJ-DnaK interaction.110,111 This 
supports the hypothesis that the α2-helix on DNAJA1 may represent the likely DnaK 
binding site. 
Another interaction site on DNAJA1-JD may be related to the inhibition of DnaJ 
activity. A related DnaJ protein, TIM14, is essential for the transport of proteins across 
the outer membrane of mitochondria by stimulating ATPase activity of mitochondrial 
Hsp70.112 Any mutation in the HPD motif of TIM14 effectively inhibits its activity, 
which indicates the importance of the HPD motif in the function of DnaJ proteins. 
Additionally, when TIM14 is complexed with TIM16, another J-domain like protein but 
without the HPD motif, TIM14 activity is inhibited. The location of the TIM14-TIM16 
interaction site partially overlaps with the proposed DnaK binding site that includes 
residues in the α2-helix.113 A sequence alignment of TIM14 with DNAJA1-JD indicates 
an essentially identical overlap [Figure 8.12C], where 4 of the 15 perturbed residues that 
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make up the α2-helix proposed binding site are also part of the inhibition site [Figure 
8.12D].  
 
 
Figure 8.12 (A) A surface representation of DNAJA1-JD highlighting another proposed 
DnaK binding site based upon the bovine auxilin-bovine Hsp70 complex (PDB ID: 
2QWN) colored in red and green (conserved HPD motif). (B) A surface representation of 
DNAJA1-JD (rotated ~90°) with the proposed DnaK binding site based upon NMR 
titration data colored in blue. (C) A surface representation of DNAJA1-JD (rotated ~90°) 
with the proposed inhibition site based upon the TIM14-TIM16 complex colored in 
purple. (D) The sequence of DNAJA1-JD with the proposed interaction sites indicated: 
DnaK binding site from titrations (blue circle); DnaK inhibition site (purple triangles); 
DnaK binding site from cross-linked auxilin-Hsp70 complex (red stars); highly conserved 
HPD motif (green box). 
 
 A high-throughput NMR ligand affinity screen was performed with the FAST-
NMR function-based compound library. The 1D line-broadening screen identified 27 
possible binders. A 2D 1H,15N-HSQC screen identified only 7 compounds that induced 
chemical shift perturbations (CSPs) upon binding with DNAJA1-JD [Figure 8.13]. The 
seven compounds induced CSPs in the same set of residues, inferring a consistent and 
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unique ligand binding site. Most of the compounds are small, but a common chemical 
motif or scaffold is not apparent. However, four of the compounds contain a phosphate 
group, two contain a carboxylic acid group, and hydroxyl groups are also very common, 
all these groups are likely to be deprotonated at pH 7.0, leaving negatively charged 
molecules. 
 
 
Figure 8.13 The structures of the compounds that induce significant chemical shift 
perturbations (CSPs) in a 2D 1H,15N-HSQC spectra of DNAJA1-JD. O-phospho-L-serine 
showed the greatest number of significant perturbations (9 significant CSPs). 
 
Of the 7 compounds, O-phospho-L-serine had the greatest number of 
perturbations (9) in the 2D 1H,15N-HSQC screen [Figure 8.14]. Using the size of O-
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phospho-L-serine and CSP-Consensus, every one of the perturbed residues was 
determined to be part of the consensus binding site. 
 
 
Figure 8.14 An overlay of 2D 1H,15N-HSQC spectra of free DNAJA1-JD (black) and 
DNAJA1-JD with O-phospho-L-serine (red). 
 
A DNAJA1-JD/O-phospho-L-serine costructure was determined using AutoDock 
and AutoDockFilter, which identifies the docked pose that best matches the chemical 
shift perturbation data. The costructure selected by AutoDockFilter [Figure 8.15] had an 
AutoDock binding energy of -2.66 kcal/mol, which fits with the average AutoDock 
binding energy of -2.54 ± 0.40 kcal/mol for all of the docked poses. The costructure has 9 
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residues within 6 Å of the docked ligand: Leu39, Leu41, Tyr43, His44, Lys47, Asn48, 
Glu 51, and Lys54 [Figure 8.15B]. Only four of these residues were perturbed in the 2D 
1H,15N-HSQC. However, the nearby residues identified in the costructure may be 
different due to the static nature of the protein during the docking calculation.  
 
Figure 8.15 (A) A surface representation of DNAJA1-JD with bound O-phospho-L-
serine where the residues showing a chemical shift perturbation are colored blue. The one 
residue, Glu51, which shows the greatest chemical shift perturbation with every binding 
ligand is colored red. (B) A ribbon representation of DNAJA1-JD bound to O-phospho-
L-serine where the sidechains of any residue within 6 Å of the ligand are displayed. 
 
Based on the protein-ligand costructure, the binding site coincides with the 
predicted inhibition site based on the TIM14-TIM16 complex [Figure 8.16A]. The O-
phospho-L-serine binding site is also consistent with the chemical shift perturbations for 
the other compounds shown to bind from the FAST-NMR assay. Surprisingly, the 
binding site is not particularly well conserved, evolutionarily [Figure 8.16B]. Since most 
of the binding ligands have negatively charged groups, it seems likely that the 
compounds have an electrostatic interaction with the positively charged region on the α2-
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helix [Figure 8.16C]. Additionally, most of the protein surface, including the binding site, 
consists of hydrophilic residues [Figure 8.16D] indicating that hydrophobic interactions 
are unlikely to be energetically favorable. These properties may explain why most of the 
ligands shown to bind to DNAJA1-JD were small and negatively charged. 
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Figure 8.16 A surface representation of DNAJA1-JD bound with O-phospho-L-serine 
with (A) the proposed inhibition site based on the TIM14-TIM16 interaction (purple), (B) 
the highly conserved (magenta) and poorly conserved (cyan) residues from Consurf, (C) 
the positively charged surface (blue) and negatively charged surface (red) from Delphi, 
and (D) the hydrophilic surface residues (light blue) and hydrophobic surface residues 
(orange-red). 
 
8.4 CONCLUSIONS 
Advances in the treatment of pancreatic cancer have been slow despite the urgent 
need for better therapies. The generation of a pancreatic cancer 'omics database identified 
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5,336 proteins which underwent significant changes in expression profiles or mutation 
frequency in pancreatic cancer cells, which represents nearly 25% of the human genome., 
An 'omics database was designed to find potential therapeutic targets using functional 
networks based on annotations and interaction information from several other databases. 
Our database identified the human protein DnaJ homolog subfamily A member 1 
(DNAJA1) as a promising therapeutic target. DNAJA1 is significantly down-regulated in 
pancreatic cancer cells. DNAJA1 is a cochaperone that facilities the hydrolysis of ATP 
from DnaK (Hsp70), a chaperone that assists protein folding, prevents aggregation of 
misfolded proteins, and transports proteins across membranes.  
Cell-based functional assays showed that the overexpression of DNAJA1 
suppresses the stress response capabilities of the oncogenic transcription factor, c-Jun, 
which is often overexpressed and hyperphosphorylated in cancer cells. c-Jun is part of the 
JNK signaling pathway, and its phosphorylation state can promote apoptosis or cell 
proliferation. DnaK has previously been shown to suppress the JNK pathway, which 
inhibits the hyperphosphorylated, anti-apoptosis state found in pancreatic cancer cells. 
The down-regulation of DNAJA1 in pancreatic cancer cells likely lowers the activity of 
DnaK, which allows for the hyperphosphorylation of c-Jun. 
The solution structure of the J-domain of DNAJA1 (DNAJA1-JD) was 
determined by NMR. The structure has the same features as other homologous J-
domains, including the conserved HPD motif in the loop between the α2 and α3 helices. 
A high-throughput ligand affinity screen by NMR identified 7 compounds that bound to 
the same region of the protein. The strongest binder, O-phospho-L-serine, appeared to 
bind in a region predicted to inhibit the binding of DnaJ proteins to DnaK.  
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The structure, bioinformatics analysis, cell-based assays and ligand affinity screen 
suggest that DNAJA1 has a role in pancreatic cancer. The J-domain of DNAJA1 appears 
to have overlapping protein-protein interfaces, where one interface activates DnaJ 
function and the other inhibits it. These interfaces on DNAJA1-JD may be interesting 
targets for future drug discovery efforts related to pancreatic cancer. 
 
 
Figure 8.17 An illustration of the proposed role P31689 (DNAJA1) and DnaK may have 
on the JNK pathway and c-Jun phosphorylation. The activation of DNAJA1 through the 
interaction with DnaK appears to suppress the JNK pathway, thus keeping c-Jun in the 
inactive state. However, inhibiting DNAJA1 binding to DnaK, as TIM16 does, would 
allow for the hyperphosphorylation of c-Jun which has an anti-apoptosis effect. 
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CHAPTER 9 
SUMMARY AND FUTURE WORK 
  
The number of proteins that are considered "uncharacterized" proteins with no 
known function is constantly growing. Pure biochemical approaches to determining 
protein function are too slow to address this growth, while using sequence and structure 
similarities for functional annotation is only reliable for globally similar proteins. 
Additionally, structural genomics has resulted in a large number of protein with 
structures for which nothing else is known. These uncharacterized proteins essentially 
become "orphaned" since it is unknown whether they present an interesting research 
target. New methodologies are necessary to address this problem.  
One alternative approach involves the comparison of the protein active sites 
instead of entire protein. Because the protein active site is responsible for the interactions 
of a protein with other biomolecules or small molecules, the properties of this localized 
functional epitope are typically more evolutionarily conserved.1,2 This dissertation 
demonstrates the application of this approach with Functional Annotation Screening 
Technology by NMR (FAST-NMR), which combines NMR ligand affinity screens and 
molecular docking in a high-throughput methodology to functionally annotate proteins.1,2  
Chapter 2 describes the application of FAST-NMR to propose functions for 20 
uncharacterized proteins from the Northeast Structural Genomics Consortium (NESG; 
http://www.nesg.org). A library of 460 functionally-relevant compounds3 was screened in 
a tiered approach with 1D 1H NMR line-broadening screens followed by 2D 1H, 15N-
HSQC screens to identify binders and a binding site.4 This was followed by molecular 
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docking with AutoDock, which generated a protein-ligand costructure.5,6 The 
experimental binding site defined by the costructure was then compared to a database of 
binding sites using the Comparison of Protein Active Site Structures (CPASS) 
program.7,8 Additionally, other bioinformatics tools combined with knowledge of the 
identity of the binding compounds were all used to propose functions for the 20 
uncharacterized proteins. The results of this approach are intended to guide future work 
on these "orphaned" proteins, thus minimizing time and effort. For example, using the 
weak binders identified during the FAST-NMR screen could guide future investigations 
of compounds with similar moieties. 
The FAST-NMR screen of the 20 NESG proteins represents the first time that the 
FAST-NMR process was implemented for multiple proteins at the same time. Overall, 
this resulted in improvements in the FAST-NMR protocol, as well as identifying any 
bottlenecks. Preparation of nearly 3,000 NMR samples requires a significant amount of 
time that could be alleviated with automated sample preparation, and should be one focus 
for improvement in the future. 
The other major bottleneck occurs during both the 1D and 2D NMR spectral 
analysis steps. Analysis of the 1D 1H line-broadening screen requires overlaying the 
spectra for the compound mixtures with and without protein. The spectra is then 
manually evaluated to identify any potentially decrease in peak height (line-broadening). 
Unfortunately, proteins have many hydrogen atoms that can be observed in the 1D 1H 
NMR spectra as well, and these hydrogen peaks can obfuscate the presence of peak line-
broadening for the ligands. Future efforts are investigating whether to use a 1D saturation 
transfer difference (STD)9 NMR screen instead of a 1D 1H line-broadening screen to 
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identify binding ligands. However, 1D STD NMR screens take significantly more NMR 
time and produce more hits that represent non-specific binders. Another approach 
currently under investigation would be to use mathematical techniques to subtract the 
protein peaks from the 1D 1H NMR spectra. This would effectively allow for an 
automated analysis of the spectra, which would increase throughput. 
For the 2D 1H, 15N-HSQC screens, the identification of chemical shift 
perturbations (CSPs) is straightforward. However, the challenge lies in identifying the 
amino acid resonance being perturbed. Each peak in a 2D 1H, 15N-HSQC experiment 
correlates to the amide of an amino acid residue. Since the proteins being investigated by 
FAST-NMR have had their backbones previously assigned by NMR, the resonances for 
each amino acid residue can be determined using the Biological Magnetic Resonance 
Data Bank (BMRB; http://bmrb.wisc.edu).10 However, in some cases during the FAST-
NMR analysis, the sample conditions of the protein are different enough to result in 
amino acid residue resonances that are not the same as those found in the BMRB. This 
can make it difficult to assign CSPs to amino acid residues, and thus determine a 
consensus binding site. Additionally, since CSPs, by definition, are the change in the 
residue resonance peaks of a protein with ligand compared to the protein without ligand, 
it is often difficult to determine the origin of each perturbed peak in a cluster of perturbed 
peaks. Both of these issues could be addressed by initially running a series of 2D 1H, 15N-
HSQC experiments that gradually change sample buffer conditions and/or ligand 
concentrations. This may generate smaller perturbations which could be easier track. 
The identity of the compounds that were shown to bind each protein during the 
FAST-NMR screens was extremely important in proposing a protein function. Currently, 
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there is no implemented protocol to evaluate the binding compounds as a whole in a 
systematic manner. There is significant value for functional annotation in identifying 
common physicochemical features, metabolic pathways, and other binding proteins. 
While these approaches were certainly used during the FAST-NMR analysis, they also 
required a significant amount of effort to evaluate individually. The BioScreen Ligands 
database (http://bionmr-c1.unl.edu/cgi-bin/ligands/index) is a great start to providing 
structural information on the compounds. However, implementing additional data into the 
database such as KEGG pathways,11 Tanimoto structural comparisons,12 the identity of 
binding proteins from the RCSB PDB,13 as well as the means to compare these features 
between a list of ligands would be an invaluable tool. 
The FAST-NMR process relies on the generation of protein-ligand costructures to 
identify an experimentally-determined binding site to be used for comparisons in CPASS. 
Experimental approaches to determine protein-ligand costructures with NMR 
spectroscopy or X-ray crystallography can take months.14,15 Chapters 3 and 4 describe the 
development of the programs AutoDockFilter (ADF) and CSP-Consensus (CSPC), which 
utilizes molecular docking and the CSPs from the 2D 1H, 15N-HSQC screens to quickly 
generate a protein-ligand costructure in approximately an hour.16 
ADF was shown to significantly improve the results of molecular docking with 
AutoDock by selecting the results that best agree with the experimental CSPs. However, 
as a filter, ADF still requires AutoDock to produce accurate results. Future versions of 
ADF could instead act to steer the docking process,17 which would require adding the 
ADF violation energy into the AutoDock calculations. Also, ADF does not currently 
allow for the filtering of AutoDock results if any protein sidechains are allowed to be 
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flexible during the AutoDock calculation. Addition of this feature would help remove any 
docking problems that occur due to the use of a protein apostructure. 
AutoDock accuracy is improved when the search grid is focused upon the binding 
site of the ligand.16,18,19 Normally, CSPs from the 2D 1H, 15N-HSQC screens are visually 
mapped onto the surface of the protein in order to subjectively identify a consensus 
binding site. CSPC was developed to make determining the consensus binding site more 
objective by using hierarchical clustering of the amide-amide distances between 
perturbed residues. When tested on 8 protein-ligand systems with experimental CSP 
values, it was able to reliably identify the binding site on each protein. Future work for 
CSPC involves setting up a web-based server for the program and creating a user 
interface to visually evaluate the clustering results. 
After generating the protein-ligand costructure with AutoDock and ADF, the 
ligand-defined binding site is then submitted to the CPASS program, where it is 
compared to a database of ligand-defined binding sites generated from the RCSB PDB.13 
The comparison involves the alignment of the binding sites structure and sequence. 
Recently, CPASS was updated to version 2,8 which includes additional comparisons that 
include Cβ position, surface accessibility, ligand alignment, and implementation on the 
Open Science Grid (OSG). Chapter 5 provided an evaluation of this new version of 
CPASS by using ROC comparisons to illustrate the enrichment of functionally similar 
proteins in CPASS. 
CPASS 2.0 has been shown to be very effective in selecting for proteins with high 
functional similarity. In general, a CPASS similarity score of 30% or greater indicates a 
greater likelihood of functional homology. However, the FAST-NMR screens of the 20 
 290 
uncharacterized proteins highlighted some potential problems that have made it 
challenging to use to functionally annotate proteins. However, the variability in defining 
a binding site using predictive or screening approaches can significantly influence 
CPASS similarity calculations, where differences in bound and unbound structures, errors 
in docking a ligand to the structure, and variations in ligand size all appear to decrease 
the CPASS similarity score for a well-characterized protein. Additionally, an evaluation 
of the CPASS results from a FAST-NMR screen of 20 proteins of unknown function 
highlights the impact of these issues. Specifically, these experimental problems hinder 
the ability of CPASS to reliably rank functional homologs as the top hit. 
While experimental and computational variability will always be an issue, one 
approach to minimize their effect would be to prioritize the matching process. As 
mentioned previously, the reason protein structural differences and ligand size/location 
affect the CPASS similarity score is due to the way CPASS defines the ligand binding 
site. Every residue within 6 Å of the ligand is defined by CPASS as the binding site. 
While residues at the edge of the 6 Å cutoff are scaled to minimize the impact of small 
structural variations, the majority of the residues in the binding site are essentially 
equivalent in terms of importance to the CPASS scoring function. Unfortunately, not 
every residue located within this binding site is necessary for the molecular function of 
the protein, and thus would not necessarily be conserved. Implementing a weighting 
function for each residue in the query based on predicted or known importance may help 
prioritize binding sites in the database that have similar sequence and structure between 
these important residues. Two factors could be considered as potential sources of 
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weighted scoring: distance of amino acid to ligand and/or evolutionary conservation 
among similar proteins such as that generated by ConSurf.20 
Additionally, CPASS scoring currently uses only the query active site to generate 
the reference score by which the similarity scores are generated. However, as illustrated 
during the FAST-NMR screens, proteins that bind to large compounds like suramin 
produce large binding sites, and thus large reference scores. Matching the entire binding 
site is difficult, and often results in a match in substructure but overall match less than 
30%. This could be addressed by using the smaller of the two active sites to generate the 
reference score or by generating a Q-score that implements alignment length into the 
comparison. 
The FAST-NMR screens also illustrated a potential update to CPASS that would 
be extremely useful to the end user. Since the uncharacterized proteins typically have 
lower CPASS scores, the relevant hits can often get mixed in with irrelevant hits. One 
potential approach would be to add KEGG pathways/reactions identifiers, compound 
name, source organism, and potential GO annotations for each active site in the CPASS 
database. This could allow for the immediate evaluation of common features found in the 
results, especially at lower similarity scores where it is more likely to see false positives. 
Unfortunately, the greatest problem facing the functional annotation of unknown 
proteins with CPASS is the size of functional space represented by the database. The 
number of protein structures represented in the PDB is still significantly smaller than the 
number of known protein sequences. Therefore, the query protein may represent the first 
member of a functional class of proteins present in the PDB. Structural genomics is 
attempting to address this problem by prioritizing experimental structure determination 
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efforts. This is leading to significant increase in the number of unique protein structures. 
But, unfortunately, the majority of structures deposited in the PDB lack a biologically 
relevant ligand. Since the CPASS database is generated from proteins with bound ligands 
in the PDB, a functional class that does not have a representative structure with a bound 
ligand would not appear in the results from a CPASS query. This is especially a concern 
for proteins that binds another biomolecule (protein, DNA, RNA) instead of a small 
molecular weight compound. These problems may be addressed by expanding the size of 
the CPASS database to potentially include predicted binding sites for unique proteins 
with no bound ligands using programs such as ConSurf20 or CASTp.21 The inclusion of 
protein-protein or protein-DNA binding sites would also expand the searchable functional 
space. However, introducing either of these approaches to expand the database does 
introduce its own challenges. 
Despite these issues, CPASS still provides valuable information based on the 
partial similarities that do exist, especially when combined with other bioinformatics 
approaches and experimental data. Additionally, CPASS can also be used to help 
understand the evolutionary relationships between proteins based on the changes that 
occur in the binding site. 
Recently, the structure of the YndB protein from Bacillus subtilis was 
determined.22,23 It featured a hydrophobic binding pocket that would likely bind a lipid 
molecule, which are not presently represented in the function-based compound library. In 
Chapter 6, the function of the YndB protein was determined using virtual screening of a 
lipid compound library followed by NMR titrations. Remarkably, the virtual screen 
identified chalcone molecules as likely binders, which was then verified by 2D 1H, 15N-
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HSQC titrations. Chalcone was determined to be a tight binder with a KD of less than 1 
µM. However, chalcone is not found as a natural product of Bacillus organisms. Instead, 
it is a precursor to antibiotics produced from plants. This hints at the potential symbiotic 
role between Bacillus and plants that uses chalcone as a signaling molecule to promote 
sporulation or antibiotic production in Bacillus. Current efforts are involved in verifying 
the effect of chalcone on Bacillus using a combination of cell growth analysis, 
proteomics, and metabolomics. 
Because virtual screening worked so well for the YndB protein, could it be used 
to supplant the 1D 1H NMR line-broadening screens in FAST-NMR? The work in 
Chapter 7 investigated this possibility and found that there are some significant 
drawbacks to using virtual screening as a complete replacement. Future efforts could 
explore the use of virtual screen to investigate compounds that are not in the function-
based compound library. It could also be used in cases where the binding site and a broad 
classification of the ligands are already known, as in the case of YndB. 
Another alternative approach within FAST-NMR to annotated proteins is to 
compare ligand binding profiles, which are a set of ligands experimentally shown to bind 
a specific protein. Proteins with the same function have been demonstrated to bind the 
same set of small molecules from a function-based chemical library.24 These ligand 
binding profiles can be used to identify functionally homologous proteins in a manner 
similar to sequence similarity techniques such as BLAST25,26 using only the results of 1D 
1H NMR line-broadening screen. This approach also has the added benefit of not 
requiring a protein structure or sequence. Virtual screening could potentially be used in a 
similar manner to identify a ligand binding profile, but on a large virtual library. 
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Pancreatic cancer is perhaps the deadliest cancer, yet it is not the most prevalent 
cancer and most of the current treatments for pancreatic cancer do not improve the 
prognosis. It's clear that discovery of a novel therapeutic target is important. Chapter 8 
discusses a bioinformatics approach (Borg) to prioritize the numerous proteins that have 
been shown to be involved in pancreatic cancer cells followed by the structural and 
functional characterization of DNAJA1, a potential therapeutic target for pancreatic 
cancer. The overexpression of DNAJA1 results in the suppression of an anti-apoptotic 
mechanism found in pancreatic cancer. The structure of the J-domain of DNAJA1 has 
identified two potential binding sites, one for activation and one for inhibition. Future 
work will continue to investigate the relationship between DNAJA1 and pancreatic 
cancer. This will involve identifying the factors that may inhibit DNAJA1 anti-apoptotic 
suppression. 
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